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Abstract 
The optimal treatment for acute myocardial infarction (AMI) requires the rapid 
restoration of flow in the infarct related artery and reperfusion of the myocardium at 
the tissue level through angioplasty. Coronary angioplasty, in the setting of AMI, is 
aimed at reducing myocardial infarct size, preserving left ventricular function and 
improving long term outcomes. Paradoxically, the opening of an occluded vessel 
following a period of ischaemia can result in further myocyte death. This is called 
lethal reperfusion injury. Current treatments for AMI have failed to attenuate 
reperfusion injury and combined morbidity and mortality rates remain high.  There is 
an urgent need for the development of novel cardioprotective therapies in the clinical 
arena. 
 
Remote ischaemic perconditioning describes the cardioprotective effect evoked by 
applying brief episodes of ischaemia and reperfusion applied to a limb with a blood 
pressure cuff prior to reperfusion but following the onset of ischaemia. Such 
strategies have been utilised in a number of proof of concept studies demonstrating 
the ability of remote ischaemic conditioning to attenuate reperfusion injury and 
reduce infarct size.  
 
As therapies for AMI improve, it has become increasingly difficult to demonstrate 
incremental improvements in currently used biomarkers. Cardiovascular magnetic 
resonance (CMR) imaging is an important imaging technique that is able to assess 
traditional imaging parameters with a high degree of accuracy and reproducibility. 
CMR is also provides supplementary information due to its unique ability to 
characterise the myocardium and identify the components of reperfusion injury. The 
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identification and quantification of these adverse elements of reperfusion offer further 
prognostic information beyond traditional imaging biomarkers and show promise as 
novel endpoints in clinical cardiovascular research. 
 
Data is presented on the use of remote ischaemic perconditioning in patients 
undergoing primary angioplasty. CMR endpoints have been utilised to assess the 
efficacy of this conditioning protocol in a high-risk patient group. 
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1. INTRODUCTION 
1.1 Ischaemic Heart Disease 
 
1.1.1 Epidemiology of Ischaemic Heart Disease 
 
Ischaemic heart disease (IHD) is the leading cause of morbidity and mortality 
worldwide, particularly in middle to high-income countries. Over seven million people 
every year die from coronary artery disease, accounting for 12.8% of all deaths.1 
Cardiovascular death rates in England have been falling but cardiovascular disease 
remains the main cause of death with up to 88,000 deaths attributable to IHD in 
2008.2 It also remains the most common cause of premature death (death before the 
age of 75) and heart failure in the UK with over 28,000 premature deaths in the UK in 
2008.2  
 
The decline in IHD mortality rates does not necessarily mean a decline in IHD 
absolute number of deaths and the absolute number of IHD deaths may continue to 
increase due to ageing of the population.3 At the same time, the decline in death 
rates does not translate into a decline in the global burden of disease caused by 
IHD, which remains extremely high. Looking at health care costs in isolation, IHD 
cost the UK £3.2 billion in 2006.2  
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Whilst there has been a reduction in the incidence of ST-elevation myocardial 
infarction (STEMI) over the last decade,4 there has been an associated increase in 
the incidence of non-ST elevation myocardial infarction (NSTEMI) as well as an 
increase in the number of patients with heart failure.5 The age- and sex-adjusted 
incidence of acute myocardial infarction (AMI) has decreased over the last decade.6 
Changes in the prevalence of emerging cardiovascular risk factors, such as diabetes 
and obesity, or changing demographic characteristics of patients hospitalised with 
acute myocardial infarction, may have differentially promoted the development of 
NSTEMI.7 At the same time the introduction of cardiac biomarkers to aid the 
diagnosis of myocardial necrosis will have increased the pick-up rate of infarction in 
patients with otherwise normal electrocardiograms.   
 
The mortality of STEMI is influenced by many factors, among them: age, Killip class, 
time delay to treatment, mode of treatment, history of prior myocardial infarction, 
diabetes mellitus, renal failure, number of diseased coronary arteries, ejection 
fraction, and treatment.8 Observational data suggests that this reduction in mortality 
in STEMI patients is due in part to a marked increase in interventional therapy 
(primary angioplasty) and changes in pharmacological therapy, including increases 
in use of β-blockers, statins, ACE inhibitors (or ARBs), and thienopyridines in 
patients with an acute coronary syndrome (ACS), and Glycoprotein IIb/IIIa 
inhibitors.9 These improvements will have been driven by increased use of evidence-
based treatments, better adherence to treatment guidelines, and reduced variation 
across hospitals.10  
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1.1.2 Definition of Acute Myocardial Infarction 
 
IHD is a manifestation of coronary artery disease or atherosclerosis. Atherosclerosis 
is a chronic and multifocal immune-inflammatory, fibro-proliferative disease of 
medium-sized and large arteries mainly driven by lipid accumulation.11 Build up of 
lipid in the coronary arteries over time leads to the development of a coronary 
atherosclerotic fibrolipid plaque. As plaques develop they can encroach into the 
arterial lumen. Plaques will often therefore disrupt blood flow in the coronary vessels 
by causing luminal obstruction leading to myocardial ischaemia - an imbalance 
between myocardial perfusion and demand. Pathological, imaging, and biological 
observations have demonstrated that atherosclerotic plaques rupture or erode, with 
differing degrees of superimposed thrombosis and distal embolisation, resulting in 
myocardial hypoperfusion, forming the basic pathophysiological mechanisms in most 
conditions of ACS.12  Thrombotic occlusion of an epicardial coronary artery causes 
ischaemia and subsequent myocardial cell death if epicardial patency is not promptly 
restored. Acute myocardial infarction is defined as a clinical (or pathologic) event 
caused by myocardial ischaemia in which there is evidence of myocardial injury or 
necrosis. ESC and AHA guidelines define criteria for acute myocardial infarction as a 
rise and/or fall of cardiac biomarkers, along with supportive evidence in the form of 
typical symptoms, suggestive electrocardiographic changes, or imaging evidence of 
new loss of viable myocardium or new regional wall motion abnormality.13 
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1.2 Ischaemia – Reperfusion Injury 
 
Despite an almost 50% reduction in the number of deaths from IHD in the UK over 
the last fifty years,14 the one year cardiovascular death rate is approximately 9% with 
hospitalisation for heart failure at 10%.   Reperfusion is essential to salvage viable 
myocardium but paradoxically reperfusion itself can lead to further damage to the 
myocardium, the so-called “double-edged sword” of reperfusion or lethal reperfusion 
injury.15 Protecting the heart against lethal reperfusion injury through the application 
of interventional strategies at the onset of reperfusion provides a novel approach to 
cardioprotection. It is necessary, therefore, to discover novel treatment strategies 
which will provide further protection to the myocardium from ischaemia-reperfusion 
injury, and can be used as adjunctive therapy to the current reperfusion strategies to 
further reduce morbidity and mortality. 
 
Although the prompt restoration of blood flow, by restoring epicardial patency, to the 
ischaemic myocardium is the optimal endpoint for patients suffering an STEMI, the 
onset of reperfusion itself is associated with myocardial injury itself. This injury, 
entitled ‘Reperfusion injury’, attenuates the benefits of reperfusion therapies such as 
primary angioplasty. 
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There are four types of reperfusion injury: 
a. Reperfusion-induced arrhythmias 
b. Myocardial Stunning 
c. Microvascular Obstruction (MVO) 
d. Lethal Reperfusion Injury 
 
1.2.1 Reperfusion induced arrhythmias 
 
Reperfusion induced arrhythmias are frequently seen in patients receiving 
reperfusion therapies, such as primary angioplasty. The most commonly associated 
arrhythmia seen is an accelerated idioventricular rhythm (AIVR). Ventricular 
tachycardia and fibrillation remain the most important causes of sudden death 
following restoration of antegrade coronary flow. AIVR was previously thought to be 
a marker of coronary artery patency following thrombolysis.16 However, although 
reperfusion arrhythmias are thought to be treatable and reversible, recent data 
suggests that their presence is a signal of adverse cellular response to infarct artery 
recanalisation, as indicated by larger infarct size.17 
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1.2.2 Myocardial Stunning 
 
Myocardial stunning is prolonged post ischaemic contractile dysfunction of the 
myocardium salvaged by reperfusion. This dysfunction can persist for several hours 
after transient non lethal ischaemia but eventually is followed by full functional 
recovery.18 
 
1.2.3 Microvascular obstruction 
 
Microvascular obstruction manifests in the catheter laboratory as coronary no-reflow. 
However the cause of coronary no reflow is microvascular obstruction - the inability 
to reperfuse a previously ischaemic region. The actual pathogenesis of this is 
unclear but has been attributed to a variety of factors such as capillary damage, 
endothelial and cardiomyocyte swelling, compression of capillaries, oxidative stress 
and inflammation.  
In 1966 Krug et al.19 noted a prolonged disturbance of blood supply following 
reperfusion of a region supplied by a temporarily ligated coronary artery. Using a 
feline heart they demonstrated abnormalities of the ‘deep’ myocardial circulation 
after episodes of ischaemia and reperfusion. The group showed interesting changes 
on histological sections with interstitial oedema and dilated capillaries, which were 
partially ruptured and packed with erythrocytes. The interstitial space was noted to 
be wider than normal with recognisable haemorrhage. 
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The ultrastructural features were further characterised in the canine model by Kloner 
and colleagues in 1974.20 The group used Thioflavin S which is a fluorescent vital 
stain for endothelium and allows for the measurement of the qualitative distribution of 
coronary flow following ischaemia-reperfusion. Intravenous Thioflavin S was injected 
simultaneously with the release of coronary occlusion or after reperfusion. After 40 
minutes of ischaemia and reperfusion, staining revealed a homogenous distribution 
of Thioflavin S indicating successful reperfusion into previously ischaemic tissue. 
However, after 90 minutes of circumflex occlusion and reperfusion, there were 
subendocardial areas noted which did not take up the stain indicating a lack of 
capillary perfusion or no-reflow.  Electron microscopy showed that the major features 
within the no-reflow areas were ultrastructural evidence of MVO postulated to be due 
to due to oedema and endothelial disruption.21 
 
Radioactive and fluorescent microspheres have also been used in the experimental 
setting to demonstrate the presence of MVO.22,23 Microsphere methods provide 
information on regional perfusion within organs and are an essential tool in 
cardiovascular research.24 Unfortunately, both the use of microspheres and 
Thioflavin S staining require post-mortem evaluation, therefore precluding the serial 
examination of MVO in the same animal and its application to humans. 
 
Essentially, multiple factors (Tissue oedema, endothelial disruption, plugging of 
capillaries by neutrophils and microthrombi, inflammation due to the generation of 
oxygen-free radicals and activation of complement components, and contracture of 
neighbouring myocytes)25,26 converge to reduce perfusion at a microvascular level. 
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Figure 1 Schematic Summarising different mechanisms of no-reflow and accompanying 
ultrastructural alterations of the microvascular bed (RBC, red blood cell) 
  
Reprinted with permission from Reffelmann T, Kloner RA Heart 2002;87:164. 
The consequences of coronary ligation of a non-atherosclerotic coronary artery, 
however, cannot be directly extrapolated to the human situation, where myocardial 
infarction is caused by occlusive coronary thrombosis superimposed onto an 
atherosclerotic unstable plaque.27 Angioplasty leads to distal coronary 
microembolisation of atherosclerotic debris or thrombotic material that is responsible 
for a substantial part of clinically observed MVO.28 Microemboli are composed of 
platelets, leukocytes, erythrocytes, and atherosclerotic material, including cholesterol 
crystals and; platelet-leukocyte aggregates that contribute to impaired 
microcirculation.29 The theory of microembolisation of friable material released from 
atherosclerotic plaques both at the point of plaque disruption prior to coronary 
occlusion and also following angioplasty would appear logical in humans. However in 
experimental models no-reflow occurs in the absence of atherosclerosis and thrombi; 
whereas human hearts with acute myocardial infarction are likely to have both. 
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Therefore human hearts that undergo reperfusion therapy for an acute myocardial 
infarction have the potential for microvascular obstruction due to a number of 
causes.30 
      
Figure 2 Histopathological slides showing a cross section through a coronary artery with 
evidence of microvascular obstruction 
Images Courtesy of Dr P Gallagher, Department of Pathology, University of Southampton. 
A number of techniques can be employed alone or in combination to demonstrate 
the presence of microvascular obstruction. It is clear that the presence of 
microvascular obstruction is a predictor of poorer outcomes. However, the ability to 
demonstrate a worse prognosis does not necessarily enable a quantitative approach.  
The ideal modality would not only identify the presence of MVO and therefore add to 
our knowledge of its incidence but also allow us to quantify the amount of MVO.  The 
ability to quantify MVO in turn enables its use as an endpoint in clinical trials for 
assessing the efficacy of novel cardioprotective therapies, reduce sample size 
necessary for such studies and will further aid risk stratification in patients following 
acute infarction. 
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1.2.3.1 Coronary Angiography and No Reflow 
 
Coronary angiography is often the first point in the evolution of a myocardial 
infarction that ‘no-reflow’ is identified and a number of indices are used to identify the 
‘no-reflow’ syndrome. The first, and most basic is TIMI (Thrombolysis in Myocardial 
Infarction) flow. This is a widely used scale from 0-3, referring to blood flow seen 
down a coronary artery on angiography during percutaneous coronary intervention. 
There are also limitations of using coronary angiography to assess for capillary 
reperfusion. Although TIMI grades 1 and 2 flow are known to indicate poor tissue 
perfusion, TIMI grade flow 3 has generally been thought to represent successful 
reperfusion. Studies have however shown that other markers of tissue perfusion 
have shown that 10-20% of patients with TIMI grade flow 3 have poor perfusion at a 
myocardial level despite epicardial patency.31 
 
For those patients who after primary angioplasty appear to have TIMI 3 flow, up to 
40% of these patients will still have microvascular obstruction that often remains 
undiagnosed unless different forms of imaging are used to delineate it. So up to 40% 
of patients with TIMI 3 flow on coronary angiography at the end of primary 
angioplasty procedure will still not be perfusing there myocardium and this patient 
group fares worse post STEMI.  
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There are other clinical indicators that we can use post STEMI including: 
1.2.3.2 The ECG and No Reflow 
 
The ECG is the most simple and commonly used diagnostic test for identifying 
ischaemia and infarction. ECGs are routinely performed before and after primary 
angioplasty for acute infarction. The resolution of ST-elevation has been taken as a 
marker of success of reperfusion in this setting. A number of methods exist to 
quantify the extent of ST-segment resolution (STR). The majority of studies use the 
sum of STR across a 12-lead ECG. The sum of ST segment deviation is calculated 
before and after fibrinolysis or angioplasty. STR has also been looked at in a single 
lead by examining the lead with the maximum ST segment deviation. The sum STR 
has been shown to correlate well with infarct related artery (IRA) patency and TIMI 
flow yet these do not necessarily translate into complete microvascular reperfusion. 
The interpretation of STR data suffers from variability between studies, in that 
methodology, definitions and time points of measurements differ between 
institutions.27 It is also important to note that differences exist between anterior and 
inferior MI with regard to ST segment resolution. Patients with anterior infarction 
develop significantly less ST resolution than those with inferior infarction, despite 
only small differences in epicardial blood flow, therefore suggesting that ST segment 
resolution is a less accurate predictor of epicardial reperfusion among patients with 
anterior than inferior MI.32 
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Just as the absence of ST-segment resolution does not always exclude the 
occurrence of reperfusion, albeit at a slower pace, ST-segment elevation also 
eventually resolves in acute infarction even in the absence of reperfusion.31 
 
1.2.3.3 Myocardial Contrast Echocardiography  (MCE) 
 
Contrast echocardiography has been recommended to assess the myocardium for 
the presence of no-reflow. There are many benefits to echocardiography including 
the availability, transportability and price. Contrast echocardiography utilises gas-
filled microbubbles that are very effective in scattering of ultrasound.33 Furthermore 
the microbubbles are generally small in size (< 5µm) and should not block capillaries 
whilst being retained in the vascular space, so can be can used to define 
microvascular perfusion.34 MCE likely underestimates the incidence and extent of 
MVO with studies using MCE suggesting the presence of no-reflow in 25-30% 
patients with AMI.35 Cardiovascular Magnetic Resonance (CMR) studies suggest 
that the incidence of no-reflow is a lot higher at 50%.36  Safety concerns exist with 
administration of contrast particularly in the setting of potentially unstable patients 
including acute coronary syndromes. Theoretically microbubbles bigger than the 
capillary may exacerbate no-reflow through mechanical obstruction of the vessel. 37 
 
1.2.3.4 Cardiac Magnetic Resonance Imaging (CMR) 
 
The use of CMR to assess microvascular obstruction will be discussed at length later 
further on in this thesis. 
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1.2.4 Lethal Myocardial Reperfusion Injury 
 
Lethal myocardial reperfusion injury is the most harmful form of reperfusion injury 
and is defined as the death of cardiomyocytes, which were viable at the end of the 
ischaemic phase.38 At the point of reperfusion where you have ischaemically 
damaged but viable cardiomyocytes, the process of reperfusion tips them into 
necrosis, irreversibly damaging them. The main evidence that reperfusion injury 
exists, in animal studies, is that by giving an intervention at reperfusion, you can 
reduce the infarct size by up to 40-50%. This suggests that 40-50% of the final 
infarct is determined by reperfusion itself. The existence of lethal reperfusion injury 
(particularly in man) as a separate entity distinct from cellular damage initiated by 
ischaemia and then exacerbated by reperfusion has caused controversy. Given the 
difficulty in predicting the onset of an ischaemic insult it was difficult to investigate the 
effect of reperfusion compared to that of ischaemia alone. Becker demonstrated 
larger numbers of irreversibly injured cells after reperfusion than before reperfusion 
in cardiac biopsy specimens.39 Further evidence and confirmation of the existence of 
reperfusion injury came from Zhao et al. Their group demonstrated in a canine model 
that applying an intervention at the point of reperfusion (three cycles of thirty second 
I/R) was as effective as pre-conditioning in reducing reperfusion injury in the form of 
myocardial oedema and infarct size.40 They were therefore able to show that 
reperfusion induced the death of myocytes that were viable (or reversibly damaged) 
at the transition point from ischaemia to reperfusion. The first demonstration that 
reperfusion injury existed in man was published by Staat et al. in 2005. The group 
showed how a postconditioning protocol (four balloon inflations of 60 seconds each, 
interrupted by 60 seconds of reperfusion) after direct stenting in STEMI patients 
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undergoing PPCI significantly reduced infarct size (measured by reduction in CK 
over 72 hours).41  
 
Effective therapies for treating reperfusion injury that have translated into mortality 
benefit are however lacking. 
 
A number of potential mechanisms have been postulated to act as mediators of 
lethal reperfusion injury. 
 
1.2.4.1 Reactive Oxygen Species (ROS) 
 
Reoxygenation of the myocardium following ischaemia causes production of ROS 
with a burst of oxidative stress. While low levels of oxygen radicals and oxidants are 
normally formed in cells and play important roles in cellular homeostasis, mitosis, 
differentiation, and signalling, following ischaemia and reperfusion radical formation 
is greatly increased triggering myocardial injury.42  
 
The main source of oxidative stress in the reperfused myocardium is inflammatory 
cells. At the same time the mitochondria also remain an important site of ROS 
formation. Active neutrophils can release significant amounts of superoxide and 
hypochlorous acid from their nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase and myeloperoxidase systems, respectively. The superoxide anion is broken 
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down to hydrogen peroxide (H2O2) by superoxide dismutase, and then to hydroxyl 
radical. In addition, the myeloperoxidase (MPO) system, converts H2O2 to 
hypochlorous acid (HOCl) in the presence of halides. HOCl oxidizes various amines 
to toxic chloramines.38 The accumulation of ROS in cells can lead to reversible and 
irreversible damage to cells and tissue through a number of actions including 
oxidative modifications of proteins (denaturation of proteins that form enzymes and 
ion channels), lipids (lipid peroxidation leading to membrane damage and calcium 
overload), DNA, Sarcoplasmic reticulum (leading to calcium dyshomeostasis and 
contractile dysfunction) along with impairment of metabolism and activation of 
adhesion molecules on the vascular endothelium. These actions eventually lead to 
loss of the cells molecular functions.43,44  
 
ROS have also been shown to have deleterious effects on the cell survival by 
reducing the bioavailability of nitric oxide (NO). The role of NO in cardioprotection is 
multifaceted although endogenous NO-synthase derived NO does not appear to be 
directly involved in triggering or mediating the early phase of ischaemic 
preconditioning protection.45 The overall role as to whether NO acts as a 
cardioprotective agent or promotes cell death remains unclear. Certain groups have 
demonstrated NO as a mediator of cardioprotection46 whereas others have shown it 
to induce apoptosis.47 Bell et al. have suggested a dose dependent effect where low 
dose NO can protect the myocardium through mitochondrial depolarisation and 
subsequent inhibition of mitochondrial Ca2+ overload.48 Higher concentrations of NO 
appear to lead to loss of protection and when combined with superoxide, contribute 
to cell death.49 
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Oxidative stress is also implicated in the opening of the mitochondrial permeability 
transition pore (mPTP), whose irreversible opening at the onset of myocardial 
reperfusion is a critical mediator of lethal myocardial reperfusion injury. Excessive 
ROS generation not only facilitates cell death through mPTP opening but prolonged 
pore opening also leads to an increase in mitochondrial ROS formation in cardiac 
myocytes50 creating a vicious cycle to promote lethal reperfusion injury.51  
 
1.2.4.2 Calcium Overload 
 
Following the advent of ischaemia, there is a shift to anaerobic glycolysis with the 
subsequent production of H+ ions secondary to the breakdown of ATP molecules. 
The lack of ATP leads to an intracellular build up of Na+ as the energy dependent 
Na+ / K+ -ATPase fails to export Na+ from the cell. At the same time the drop in 
intracellular pH leads to the activation of the Na+ / H+ exchanger with subsequent 
influx of Na+ ions. The ischaemia-induced inhibition of the Na/K ATPase and the 
failure of intracellular Na+ to recover completely on reperfusion have been shown to 
be important determinants of electrical and contractile dysfunction in the ischaemic 
/reperfused myocardium.52 The intracellular rise in Na+  is linked with the rise in Ca2+ 
as Na+ ions compete with calcium for extrusion via the Na+/Ca2+exchanger (NCX), 
resulting in a build up of intracellular calcium.53 The consequences of Ca2+ overload 
during ischaemia include cell-to-cell uncoupling, opening of connexin hemichannels 
and mitochondrial Ca2+ overload.54  
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Reperfusion of the ischaemic and already Ca2+ overloaded myocardium exacerbates 
cellular injury further with worsening of the intracellular Ca2+ load. The further influx 
of Ca2+ ions is mediated by the already present intracellular Na+ overload with 
reversal of the sarcolemmal Na+/Ca2+-exchanger. Restoration of the mitochondrial 
membrane potential at reperfusion also allows entry of Ca2+ into the mitochondria. 
Other mechanisms involve the rapid normalisation of pH, which enables the 
reactivation of proteins that were inhibited during the acidotic ischaemic phase which 
are involved in Ca2+ regulation. Excess of Ca2+ induces cardiomyocyte death by 
causing hypercontracture of the heart cells (representing a significant shortening of 
the cell, which is caused by strong contractile activation but becomes irreversible by 
disruption of cytoskeletal structures.),55 MPTP opening and caplain mediated 
proteolysis. 
 
1.2.4.3 Restoration of Physiological pH.  
 
As noted above, the onset of ischaemia is associated with a drop in intracellular pH 
due to a switch to anaerobic metabolism and the ensuing build-up of lactate and 
accumulation of H+ ions following the breakdown of ATP. The acidotic environment is 
not conducive to a number of noxious cellular activities which become inhibited at 
the abnormally low pH. These include the hypercontracture of myocytes, calpain 
mediated proteolysis and opening of the mPTP. Yet whilst acidosis has been shown 
to protect against cell death during ischaemia, the rapid normalisation of pH 
contributes significantly to reperfusion injury and loss viability of cardiac myocytes.56 
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Reperfusion of the myocardium prompts the activation of the Na+/H+ exchanger and 
the Na+/HCO3- symporter to restore physiological pH,57 with a reduced intracellular 
H+ load but increased Na+ load (favouring Ca2+ accumulation within the cell). 
Normalisation of pH contributes to reperfusion injury through hypercontracture and 
MPTP opening.42,58 
 
1.2.4.4 The Mitochondrial Permeability Transition Pore (mPTP).  
 
Whilst discussing different mediators of lethal reperfusion injury above it becomes 
clear that the mPTP plays a central role in facilitating cell death. Cardiac 
mitochondria play an important role in all three major pathways of cell death (which 
will be discussed later): apoptosis, necrosis and autophagy, with mPTP opening 
facilitating in particular necrotic and apoptotic cell death. The mPTP is a voltage 
dependent high conductance channel located in the mitochondrial inner membrane. 
The exact molecular composition of the pore remains to be elucidated. Three main 
proteins were previously thought to be involved including a mitochondrial peptidyl-
prolyl cis–trans isomerase known as cyclophilin-D, the adenine nucleotide 
translocase (ANT) and the mitochondrial phosphate carrier (PiC).59 It has since been 
shown that mPTP opening can occur without the involvement of cyclophilin-D or ANT 
and that cyclophilin-D is the mitochondrial receptor for cyclosporin and modulates 
the PTP rather than being a structural pore component.60 ANT is also likely a 
regulatory component of the pore whereas the role of PiC is less well understood.61 
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The mPTP was first described in 1979 by Haworth and Hunter who demonstrated 
how the permeability of mitochondria which have lost their endogenous protection 
could be modulated over a wide range by adjusting the level of Ca2+. They surmised 
that the ‘simplest molecular mechanism to account for the phenomena’ was the 
presence of a ‘trans-membrane hydrophilic channel’ where the response to Ca2+ was 
interpreted to be a gating effect at the internal end of hydrophilic channels. These 
channels spanned the inner mitochondrial membrane.62 A decade later it was shown 
that Ca2+ and oxidative stress synergistically promoted the reversible opening of the 
pore lending credence to its facilitation of ischaemia-reperfusion injury.63 The pore 
remains closed under ischaemic conditions with hypoxia de-energising the 
mitochondria which are therefore unable to accumulate large amounts of Ca2+, and 
the low intracellular pH, caused by the large increase in glycolytic lactic acid 
production, causes powerful inhibition of pore opening. 
Pore opening is therefore enhanced with reperfusion and the reversal of these 
conditions.64  
Pore opening results in a number of processes, the end point of which are usually 
cell death. Firstly the increased permeability to protons leads to dissipation of the two 
components of the proton motive force (pmf), the pH gradient and the membrane 
potential. In the absence of a pmf, mitochondria cannot synthesise ATP via oxidative 
phosphorylation and the ATPase goes into reverse and starts to breakdown the ATP 
produced by glycolysis. Therefore, myocytes cannot maintain ATP levels and the 
consequent disruption of metabolism and ionic homeostasis leads to uncoupling of 
the mitochondria and necrotic cell death.65 
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Secondly the opening of the pore also results in rapid exchange of solutes up to 1.5 
kDa in size, with redistribution of nicotinamide adenine dinucleotide (NADH) to the 
cytosol and an influx of cytosolic water. This is because the matrix protein 
concentration is very high,  exerting a colloidal osmotic pressure leading to swelling 
of the matrix compartment, causing matrix expansion. The inner mitochondrial 
membrane can accommodate this increase in volume since the cristae can unfold, 
whereas the outer mitochondrial membrane (which has a smaller surface area) 
cannot and following rupture releases the contents of the inter-membranous space. 
These contents include pro-apoptotic factors, such as cytochrome c and apoptosis-
inducing factor, which are released into the cytosol, where the process of apoptosis 
is initiated.65 The catastrophic mitochondrial swelling often leads to cell death before 
apoptosis can proceed, due to energetic collapse and uncontrolled enzymatic 
processes.53,66  
 
Whilst oxidative stress promotes mPTP opening and damage to the mitochondria, 
this can also lead to the generation of mitochondrial ROS, setting up a vicious cycle 
of impaired mitochondrial function and the exacerbation of ROS induced 
cardiomyocyte damage. This has been labelled ROS-induced ROS release (RIRR), 
and ROS generation in only small numbers of mitochondria can affect neighbouring 
mitochondria, eventually propagating the ROS surge to the whole cell through this 
positive feedback loop.67 
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1.3 Mechanisms of myocyte cell death 
 
Three main mechanisms of myocyte cell death are notable during ischaemia 
reperfusion injury including necrosis, apoptosis and autophagy. Parameters that 
indicate unequivocal cell death include loss of plasma membrane integrity, cellular 
fragmentation, and phagocytosis by neighbouring cells. Although necrosis and 
apoptosis are distinct forms of cell death with clearly distinguishing morphological 
and biochemical features, the two types of death can occur simultaneously in tissues 
or cell cultures exposed to the same stimulus with the intensity of the same initial 
insult deciding the prevalence of either apoptosis or necrosis.68  
 
1.3.1 Necrosis  
 
Necrosis was previously felt to be an unregulated process but more recent data has 
suggested that the events are actively regulated occurring in a programmed manner- 
termed necroptosis or programmed cell necrosis.69 The distinctive features of 
necrosis include loss of plasma membrane integrity, cellular and organelle swelling, 
and marked inflammation. ATP levels are markedly reduced in necrotic cells, due to 
severe mitochondrial damage that disables ATP generation as well as unrestrained 
energy expenditures.70  Apoptosis was first described in 1971 by Kerr as a form of 
‘shrinkage necrosis’ in an experimental model of hepatic ischaemia.71  
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1.3.2 Apoptosis  
 
Apoptosis is a structured form of cell death in which cells commit to a suicide 
program, which leads to the elimination of the cell without inducing an inﬂammatory 
response. It is characterised by cell shrinkage, chromatin condensation, DNA 
fragmentation, membrane blebbing, formation of membrane -enclosed apoptotic 
bodies and phagocytosis of these corpses by macrophages, or occasionally, 
neighbouring cells.72 ATP levels in apoptotic cells are well preserved due to 
continued production and decreased expenditures.70 Apoptosis therefore will result in 
the death of individual cells with little effect on surrounding, often healthy, tissue. In 
necrosis on the other hand, the dead cell expels its contents into the interstitial space 
causing damage to all the surrounding cells. Hence when cells die by necrosis in the 
context of myocardial ischaemia and reperfusion surviving cells are rarely found in 
the infarct zone with all cardiomyocytes being killed up until the border zone of the 
infarct.73 Programmed myocyte cell death is the major form of myocardial damage 
produced by occlusion of an epicardial coronary artery, whereas necrotic myocyte 
cell death follows apoptosis and contributes to the progressive loss of cells with time 
after infarction. Apoptosis representing the major independent form of myocyte cell 
death at 4.5 hours and myocyte necrosis peaking at one day.74 
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1.3.3 Autophagy 
 
Autophagy, or cellular self-digestion, is a cellular pathway involved in protein and 
organelle degradation. Although autophagy is primarily a protective process for the 
cell, it also plays a role in cell death. On a basic level, autophagy represents the cells 
own response to starvation75 with an intracellular recycling process in which 
organelles, proteins, and lipids are catabolised by lysosomal degradation providing 
cells deprived of nutrients with amino acids, free fatty acids, and energy.76 Although 
autophagy occurs at low levels in a normal heart, the process is enhanced in a 
number of pathophysiological conditions including ischaemia and reperfusion. 
Enhancing autophagy can also promote survival in response to brief hypoxia and 
lower levels of oxidative stress by removing damaged and harmful organelles and 
the recycling of macromolecules to maintain energy levels and protein synthesis. 
Concurrently severe stress (prolonged hypoxia and subsequent reperfusion), results 
in excessive and/or long-term up regulation of autophagy causing cell death by 
excessive self-digestion of essential organelles and proteins.77 
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1.4 Cardioprotection 
 
Kubler and Hass defined cardioprotection as encompassing ‘all mechanisms and 
means that contribute to the preservation of the heart by reducing or even preventing 
myocardial damage’.78 The definition has been refined further to take into account 
the specific pathophysiological process through which the myocardial injury is 
incurred. Focusing on acute ischaemia-reperfusion injury (IRI), Hausenloy uses the 
term ‘cardioprotection’ to refer to the endogenous mechanisms and therapeutic 
strategies that reduce or prevent myocardial damage incurred as a consequence of 
acute IRI.79 One strategy that has been shown to protect the heart against acute IRI 
is the utilisation of the endogenous mechanisms through which the heart protects 
itself from outside insult. The term used to describe these strategies 
(pharmacological or mechanical) is ischaemic conditioning. This is a broad heading 
given to the concept that brief episodes of non-lethal ischaemia and reperfusion 
applied to an organ or tissue bestow powerful protection against a subsequent 
episode of sustained, lethal IRI. The conditioning stimulus can be applied at a 
number of time points including (i) prior to the index myocardial ischaemic event 
(Ischaemic preconditioning or IPC), (ii) after the advent of ischaemia but before 
reperfusion (Ischaemic perconditioning or IPerC) and (iii) following reperfusion 
(Ischaemic postconditioning or IPost). At the same time the conditioning stimulus can 
be applied directly to the heart or to organs/tissue remote from the heart (remote 
ischaemic conditioning). 
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1.4.1 Ischaemic Preconditioning (IPC) 
 
IPC was first described by Murry et al.80 in a seminal paper in 1986. The group 
demonstrated that by subjecting the canine myocardium to four 5 minute cycles of 
ischaemia (induced by ligation of the circumflex artery) followed by reperfusion, 
infarct size was reduced by 75% when the heart was then subjected to a sustained 
episode of 40 minutes of ischaemia. This protection disappeared when the 
investigators extended the period of ischaemia from 40 minutes to 3 hours.63 
Following Murry’s work, ischaemic preconditioning has been reproducibly 
demonstrated in a number of animals including rabbits81, rats82, mice83, pigs84 and in 
man. 
 
IPC stimulates a biphasic pattern of cardioprotection with an early (classical or acute 
IPC) phase, which provides protection almost immediately lasting for approximately 
2-3 hours. This is followed by a delayed or late IPC phase. The delayed phase is 
often described as a second window of protection (SWOP) and provides protection 
after 12-24 hours, lasting up to 72 hours.85,86 The cardioprotection conferred by 
delayed IPC remains significant but is not as powerful as protection provided by 
early IPC.87  
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1.4.1.1 Triggers of IPC 
 
Cardioprotection induced by preconditioning is dependent on multiple complex 
intracellular signalling pathways. Triggers of cardioprotection exist that act before the 
onset of the index ischaemic episode and activate downstream signalling 
mechanisms which appear to display a ‘memory’ effect.88 In 1991 Liu et al.  
demonstrated in a rabbit model that the build up of adenosine (from hydrolysis of 
ATP) stimulated A1 adenosine receptors triggering the protection afforded by IPC. 
During the same study they also showed that preconditioning protection could be 
blocked by two dissimilar adenosine receptor blocking agents. Similarly a 5-minute 
intracoronary infusion of either adenosine or the A,-specific agonist was as effective 
in limiting infarct size as a 5-minute period of regional ischaemia.81 Similar studies 
were undertaken by looking at bradykinin and opioids which likewise demonstrated 
that an infusion of bradykinin limited infarct size in a rabbit model (similar to one 
cycle of ischaemic preconditioning) whereas pre-treatment with a bradykinin receptor 
antagonist or naloxone (opioid receptor antagonist) abolished the infarct size 
reduction achieved by IPC.89,90 These studies and others have shown that protection 
through IPC can be reproduced by pharmacological agents, acting as triggers of 
preconditioning , and that endogenous activation of a G-protein-coupled receptor 
(GPCR) is an essential component of IPC-induced protection in that IPC is a 
receptor-mediated phenomenon.91  Subsequent studies demonstrated that protection 
provided by the trigger substances could be abolished by inhibitors of protein kinase 
C (PKC).  Furthermore, ligands to other GPCR in the heart are able to mimic 
preconditioning through PKC.92 These studies therefore suggest the role of PKC as a 
common downstream mediator of IPC (with mediators referring to factors that act 
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following the onset of ischaemia and ‘mediate’ the protective effects of IPC.) GPCR 
ligands activate PKC via stimulation of phospholipase C, which breaks down 
membrane lipids to diacylglycerol, contributing to PKC activation.  
 
1.4.1.2 Mediators of IPC / Survival Kinases 
 
Multiple mediators of IPC have been identified in the form of pro-survival anti-
apoptotic protein kinases (coined ‘survival kinases’). There is significant interplay or 
‘cross talk’ between the survival kinases. ‘Cascades’ or pathways in which different 
kinases are dependent on the activation of others have been described. There is 
also considerable overlap in the end effect of the individual kinases and cascades. 
 
The main mediators of IPC include PKC, tyrosine kinase, PI3K - Akt cascade, 
mitogen activated protein kinases (MAPK) and the Janus kinase (JAK)-signal 
transducers and activators of transcription (STAT) pathway. 
 
Phosphatidylinositol 3-kinase (PI3K) is a key signalling enzyme implicated in cell 
survival and metabolic control with downstream targets including Akt, endothelial 
nitric oxide synthase (eNOS) and different isoforms of PKC. The PI3K-Akt pathway 
has been shown to act both prior to the ischaemic event following IPC93 and at the 
time of reperfusion with reactivation of the ischaemic kinase cascades (as part of the 
RISK pathway).94 Akt activates or inhibits downstream signalling molecules including 
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metabolic enzymes, apoptotic molecules and transcription factors resulting in the 
inhibition of MPTP opening. Key downstream signalling molecules of Akt are 
Glycogen synthase kinase-3β (GSK-3β) and Bcl-2-associated death promoter 
(BAD). Akt phosphorylates and inhibits both GSK-3β and BAD promoting cell 
survival by increasing glycogen synthesis, increasing the threshold for mPTP 
opening and inhibiting apoptosis.95  
 
Tyrosine kinases can be divided into: (1) receptor tyrosine kinases which may act as 
triggers of IPC by activating PKC and (2) cytosolic receptor tyrosine kinases which 
may act as mediators of IPC by acting downstream or in parallel with PKC.96 
 
The MAPK family includes four major serine/threonine protein kinase subfamilies. A 
number of these subfamilies are well described, including c-Jun NH2-terminal 
kinases (JNKs), extracellular signal-regulated kinase-1/2 (ERK1/2, also known as 
p42/p44 MAPK), p38 MAPKs, and the big MAPK-1 (BMK1/ERK5). They are 
activated by a diverse range of stimuli including ischaemia and reperfusion.97 MAPK 
activation therefore has been shown to take place during the trigger phase of IPC 
and also at reperfusion.98 The kinases convey their extracellular signals to their 
intracellular targets through the activation of various intracellular signalling pathways 
thereby controlling a diverse array of cellular processes. Activation ultimately leads 
to promotion of cell survival by reducing apoptosis, gap junction conduction, 
intracellular pH, calcium and oxidative stress and inhibition of mPTP opening.  
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JAK proteins are cytosolic tyrosine kinases associated with the intracellular domain 
of membrane-bound receptors, which transduce signals from extracellular ligands to 
the nucleus to orchestrate the appropriate cellular response. All four members of the 
JAK family (JAK1, JAK2, JAK3 and tyrosine kinase 2) transduce their signal through 
recruitment of STAT transcription factors. The STAT family consists of seven 
members are structurally similar proteins but functionally heterogeneous.99,100 IPC 
activates STAT1 and STAT3 leading to the up regulation of the inducible nitric oxide 
synthase (iNOS) gene.101 The JAK-STAT pathway is mainly implicated in delayed 
preconditioning.80 
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Figure 3 Overview of mediators/survival kinases in ischaemic preconditioning. 
Reprinted with permission from Hausenloy DJ , and Yellon DM Cardiovasc Res 2006;70:240-253 
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1.4.1.3 Effector Mechanisms of IPC 
 
The end point of the different cascades is to recruit the effector mechanisms of 
cardioprotection which are thought to be the mitochondria.75 The role of the 
mitochondria in IPC is multifaceted including; 
 
1. Opening of the mitochondrial KATP channel thereby preserving mitochondrial 
energy by increasing ATP synthesis and reducing ATP hydrolysis. 
2. Reduction in intracellular and mitochondrial Ca2+ accumulation 
3. Attenuation of mitochondrial production of ROS at reperfusion whilst at the same 
time generation of signalling ROS prior to ischaemia. 
4. Inhibition of mPTP opening. 
 
The major limitation of ischaemic preconditioning is the necessity of applying or 
introducing the preconditioning stimulus before the onset of the index ischaemic 
event. This, therefore, limits the potential clinical application to planned settings of 
myocardial ischaemia-reperfusion injury such as coronary artery bypass graft 
surgery, cardiac transplantation and elective percutaneous coronary intervention. 
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1.4.2 Ischaemic Postconditioning (IPost)  
 
IPost was first described in 2003 by Zhao et al40 who demonstrated in a canine 
model that interrupting reperfusion with short lived episodes of myocardial ischaemia 
could reduce infarct size comparable to that observed with preconditioning. By 
applying a conditioning stimulus at the point of reperfusion, one is therefore able to 
circumvent the problem of pre-empting the onset of ischaemia and apply the 
intervention of ‘conditioning’ to patients presenting following the onset of ischaemia 
e.g. acute myocardial infarction. As will become relevant later, the group also 
showed that the percentage of tissue oedema in both the pre- and postconditioning 
groups was significantly less when compared with the respective region in the 
control group, suggesting that both interventions will modify the degree of oedema 
as well as infarction.86 The ability of IPost to reduce infarct size has since been 
reproduced in multiple models including mouse,102 rat,103 rabbit,104 pig105 and 
humans. 
The mechanism of postconditioning-induced protection also comprises signal 
transduction pathways that involve the protein kinases described above. These two 
cardioprotective phenomena appear to recruit common signalling pathways at the 
time of myocardial reperfusion thereby offering a potentially common target for 
cardioprotection.80,88 The main trigger for cardioprotection invoked via IPost is 
thought to be intravascular adenosine with endogenous activation of adenosine 
receptors, in particular the A2A and A3AR subtypes.106 Survival kinases implicated in 
IPost include PKC,107 PKG (via NO - cGMP pathway),108 the activation of p70S6k 
and eNOS via the PI3K - Akt pathway87 and the MEK 1/2 - ERK 1/2 pathway.109 
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Two common pathways through which IPC and IPost mediate protection have been 
elucidated and are named the RISK (reperfusion injury salvage kinase) and SAFE 
(Survivor Activating Factor Enhancement) pathway.  
 
The RISK pathway describes a group of survival protein kinases [the PI3K-Akt 
pathway and Erk1/2 mitogen-activated protein kinase (MAPK)], which when 
activated at the time of myocardial reperfusion confers powerful cardioprotection.110 
The SAFE pathway involves Tumour necrosis factor alpha (TNFα) that activates the 
JAK-STAT pathway and thereby promoting cell survival.111 These two pathways 
relay the cardioprotective signal underlying IPC and IPost, from cell membrane 
receptors to the mitochondria where protective mechanisms subsequently occur 
such as mitochondrial permeability transition pore (MPTP) inhibition, mitochondrial 
connexin-43 channel activation, and mitochondrial ATP-dependent potassium 
channel opening.112 
 
Unsurprisingly given the shared pathways involved in IPC and IPost, IPost has been 
reported to target many of the proponents of lethal reperfusion injury, such as 
oxidative stress, calcium accumulation, inflammation, and mitochondrial permeability 
transition pore (mPTP) opening.113 
 
The widespread use of IPost in the clinical arena is limited by both its invasive nature 
and the fact that it is restricted to patients undergoing PCI. A more amenable 
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approach would be to mimic IPost, using pharmacological agents that target the 
RISK or SAFE pathways, thereby obviating the need for such an invasive IPost 
protocol.114 Another way to obviate the invasive nature of IPost is to harness the 
intriguing finding that cardioprotection can be elicited from applying the 
preconditioning or postconditioning stimulus to an organ or tissue remote from the 
heart offers an innovative treatment strategy for protecting the heart.115 
 
Figure 4 Overview of survival kinases in ischaemic postconditioning 
Reprinted with permission from Hausenloy DJ , and Yellon DM Cardiovasc Res 2006;70:240-253 
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In the case of AMI, it has been difficult to utilise cardioprotective strategies firstly 
given the inability to predict the onset of ischaemia and secondly concerns over 
further invasive balloon inflations in an already unstable patient. The application of 
remote ischaemic conditioning has obviated these issues providing a 
cardioprotective strategy that can be applied following the onset of ischaemia and is 
delivered in a non-invasive manner. 
 
1.4.3 Remote Ischaemic Conditioning (RIC)  
 
RIC describes the cardioprotective effect elicited from applying one or more cycles of 
non-lethal ischaemia-reperfusion to an organ or tissue remote from the heart. It was 
originally described by Przyklenk116 who showed that brief episodes of ischaemia in 
one vascular  bed (Circumflex territory) protects remote, virgin myocardium from 
subsequent sustained coronary artery occlusion (Left anterior descending artery) in a 
canine model reducing infarct size. This form of intramyocardial cardioprotection 
across coronary territories was then extended beyond the heart such that the latter 
could be protected by applying the RIC stimulus to organs and tissues remote from 
the heart.117  
Soon after the discovery by Przyklenk et al. it was demonstrated that the heart could 
be protected by a RIC stimulus applied to organs remote from the heart including 
kidney,118 small intestine,119 brain120 and lower limb.121 The aim of moving the 
conditioning stimulus outside of the heart was to alleviate the need for an 
interventional approach which is not the case if one needs to apply an ischaemic 
stimulus to these remote organs.  
Page 47 of 261 
 
The breakthrough away from an interventional approach (and therefore enabling its 
clinical application) was started by Oxman122 who induced ten minutes of lower limb 
ischaemia by applying a thin elastic tourniquet around the upper third of the rats’ 
hind extremity in a tight position, closed by a clamp to stop the arterial blood supply 
in the leg. This was followed by ten minutes of reperfusion prior to thirty minutes of 
ischaemia in the LAD territory. The group demonstrated a significant reduction in the 
frequency of reperfusion ventricular arrhythmias between the control group and the 
group treated with RIC via limb ischaemia. The frequency of arrhythmias was similar 
between the groups treated with ‘classical preconditioning’ and the group treated 
with RIC.122 
RIC by limb ischaemia can be achieved by either tourniquet application to the limb or 
direct occlusion of the femoral artery, and has been shown to be effective and 
reproducible in reducing injury of other organs in both animals and humans.117 
Kharbanda et al.123 subsequently demonstrated that transient limb ischaemia  
[Remote IPC before the ischaemic insult was induced by 3 cycles of ischaemia (5 
minutes of cuff inflation and deflation) of the contralateral arm] in humans could 
protect against endothelial IRI of an opposite limb. The ability to induce remote 
ischaemic conditioning (RIC) using limb ischaemia and reperfusion has facilitated the 
translation of RIC into the clinical setting. Importantly, the timing of the RIC stimulus 
can accommodate most clinical settings of acute IRI, as it has been reported to 
protect the organ or tissue whether applied prior to (termed remote ischaemic 
preconditioning, RIPC),116 after the onset of ischaemia (termed remote ischaemic 
perconditioning, RIPerC),124 or even at the time of reperfusion (termed remote 
ischaemic postconditioning, RIPost).117,125 
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1.4.3.1 Mechanisms of RIPC 
 
The actual mechanism through which an episode of brief ischaemia and reperfusion 
in an organ or tissue exerts protection against a subsequent sustained insult of IRI in 
a remote organ is unclear. Although signal transduction pathways recruited within 
the protected organ are thought to be similar to those in IPC and IPost, the 
mechanistic pathway linking the remote organ / tissue to the heart is yet to be fully 
elucidated.91 There appears to be an intervening communication or transfer step 
between these triggers from the remote site to the target organ that is not required 
by either direct IPC or IPost.126 In general, the mechanisms underlying RIC are 
thought of as three inter-related events (1) the initial events occurring in the remote 
organ or tissue in response to the RIC stimulus. The application of brief episodes of 
IR to the remote organ or tissue generates endogenous factors which protect the 
target organ or tissue from injury.127 (2) The protective signal is conveyed from the 
remote organ or tissue to the target organ or tissue. The transmission of the 
protective signal is multifactorial comprising blood-borne factor(s), neuronal 
mechanisms, and/or systemic responses.128 (3) The events occurring in the target 
organ or tissue which confer the protective effect.129 It is hypothesised that Step two / 
conveying of the signal from the remote organ to its intended target takes place 
either by a humoral or neuronal process.  
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1.4.3.2 Humoral Hypothesis 
 
It has been shown that RIPC requires a period of reperfusion of the remote organ or 
tissue suggesting that cardioprotection requires wash-out of cardioprotective 
factor(s) into the circulation.129 The humoral hypothesis proposes that the 
endogenous substance or some other as yet unidentified humoral factor generated 
in the remote organ or tissue enters the bloodstream activating its respective 
myocardial receptor thereby stimulating the various intracellular pathways implicated 
in ischaemic preconditioning.130 McClanahan et al. showed that ischaemic 
preconditioning of non-cardiac tissue (by intermittent left renal artery occlusion) was 
as protective of the myocardium as classical myocardial preconditioning.118 Dickson 
et al. postulated that if the trigger signal responsible for preconditioning at a distance 
is humoral in nature, then it should be transferable from one animal to another of 
similar species. The group then demonstrated through a number of studies that the 
effect of ischaemic preconditioning  was transferable from a preconditioned donor 
heart to a ‘virgin non-preconditioned acceptor heart’ either through blood transfusion 
into an untreated animal131 or through perfusion of coronary effluent into an 
untreated isolated rabbit heart.132 Both studies demonstrated a significant reduction 
in infarct size of 77% and 69% respectively suggesting the presence of a humoral 
trigger signal for distant preconditioning.133 In order to exclude an ongoing afferent 
neurogenic mechanism, Kostantinov et al. showed that RIPC by lower limb 
ischaemia reduced infarct size in a pig donor (denervated) heart following orthotopic 
heart transplantation from a brain dead donor.134 The study could not however rule 
out the possibility of a humoral effect on local, intramyocardial, neurones.134 A 
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number of endogenous substances have been investigated for their role in humoral 
pathways of RIC. These include adenosine, bradykinin, opioids, calcitonin gene-
related peptide and endocannabinoids.131 There is, however, no consensus 
regarding the identities of the trigger/triggers and cardiac signalling components 
required to reduce infarct size with RIC.135 
 
1.4.3.3 Neural Hypothesis 
 
The neural theory proposes that preconditioning the remote organ or tissue 
generates an endogenous substance such as adenosine, bradykinin or calcitonin 
gene-related peptide (CGRP), which then activates a local afferent neural pathway. 
This in turn recruits an efferent neural pathway terminating at the heart and 
mediating cardioprotection.136 Gho et al. presented evidence for a neurally mediated 
pathway in rats when they demonstrated that the reduction in MI size induced by 
brief ischaemia and reperfusion of the anterior mesenteric artery could be abolished 
in the presence of a ganglion blocker, hexamethonium. Interestingly ganglion 
blockade abolished protection by mesenteric artery ischaemia but not by coronary 
artery ischaemia.137 The same group postulated that bradykinin released locally 
during ischaemia-reperfusion in the mesenteric bed stimulates sensory nerves 
projecting on efferent nerves to the heart and demonstrated cardioprotection 
conferred by local administration of bradykinin to the mesenteric artery could be 
abolished by hexamethonium.138  
A recent human healthy volunteer study, however, demonstrated that the bradykinin-
2 inhibitor HOE-140 had no effect on RIPC. Although this human study investigated 
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the ability of RIPC to abolish the reduction in acetylcholine-mediated, endothelium-
dependent vasodilatation induced by IRI it does raise the possibility of a different 
mechanism in humans and animals.139 
The role of adenosine released from a remotely preconditioned organ to stimulate 
afferent nerve fibres has also been extensively investigated. Pell et al. used the non-
specific adenosine receptor antagonist, 8-sulphophenyltheophylline (8-SPT) 
delivered before the conditioning stimulus to successfully block the cardioprotective 
effects of RIPC induced by renal ischaemia.140 A similar study by Takao et al. 
showed that when 8-SPT was given following the RIPC stimulus (induced by renal 
artery ischaemia and reperfusion), infarct size reduction could again be abolished in 
rabbits.141 Evidence for the role of the neuronal pathway has also been presented in 
a number of studies  that have demonstrated the loss of RIC protection in animals 
subjected to resection of different nerves.114,142,143 
Evidence also exists for the role of a systemic response in the cardioprotective effect 
of RIC. RIC is thought to induce profound changes in gene expression and cellular 
function, including mitochondrial adaptation to metabolic stress and leukocyte 
activation.144 
 
Given proof for the role of both a neuronal and humoral pathway it is likely that there 
is interplay/cross over between both pathways in order to mediate cardioprotection. 
Indeed in a study by Lim et al. using limb ischaemia in a mouse model required both 
the neural and humoral pathways to limit myocardial infarct size. 129   
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After the cardioprotective signal has been relayed from the remote preconditioned 
organ to the heart intracellular signal transduction mechanisms are recruited within 
cardiomyocytes which are similar to those that participate in IPC and IPost.91 These 
include the ligand binding to G-protein cell surface coupled receptors including 
adenosine, bradykinin, opioids, angiotensin, and endocannabinoids. The binding to 
these cell surface receptors activates intracellular kinases such as PKC, and other 
signalling components such as reactive oxygen species, nitric oxide and the 
mitochondrial KATP channel.145 
 
1.4.4 Clinical Applications of Cardioprotective Strategies 
 
From what we have written above it is clear that the cardioprotective strategies of 
IPC, IPost and RIC lend themselves not just to the arena of bench-side laboratory 
work but belong crucially in the realm of clinical medicine where there is a real need 
to translate these effects into reductions in peri-procedural injury (whether it be PCI 
or cardiothoracic surgery) and infarct size, thereby improving outcomes in patients 
with coronary artery disease. 
 
1.4.4.1 Cardioprotection in Cardiac Surgery 
 
In 1993, Yellon’s group were the first to show that IPC could be used as a 
therapeutic intervention for cardioprotection in the clinical setting. Fourteen patients 
were randomised prior to coronary artery bypass surgery (CABG) to either a 
Page 53 of 261 
 
preconditioning protocol or placebo. The preconditioning protocol involved two 3 
minute periods of cross-clamping the aorta interspersed with 2 minutes of 
reperfusion prior to 10 minutes of cross-clamping with electrical ventricular fibrillation 
(causing acute global ischaemic injury) while the distal aorto-coronary anastomoses 
were done (and subsequent acute global reperfusion injury). The group were able to 
show a slowing of the rate of ATP depletion, measured from myocardial biopsy, in 
patients treated with IPC.146 In order to evaluate the effect of IPC throughout the 
whole course of the operation as opposed to just metabolic changes occurring at a 
single time point, Yellon’s group went on to use the same preconditioning protocol in 
patients undergoing CABG and measured serum Troponin-T (TnT) as a marker of 
ischaemic injury. They found that patients in the IPC group had less perioperative 
myocardial injury (PMI) as evidenced by lower serum TnT concentrations.147 A meta-
analysis of IPC in cardiac surgery was compiled by Walsh in which the majority of 
trials used a similar IPC protocol to that of Yellon’s group. Other protocols included 
the use of different stimuli, such as a single cross-clamp application of 5 minutes 
duration, or simultaneous aortic and caval clamping and one group used a single 1 
minute period of aortic cross-clamping followed by 5 minutes of reperfusion. These 
various protocols of intermittent aortic cross clamping showed benefit in the form of 
fewer ventricular arrhythmias , less inotropic requirements and a shorter intensive 
care unit stay (by three hours).148 
However, due to the invasive nature of this particular IPC protocol and the risk of 
arterial thrombo-embolism from cross-clamping and declamping an atherosclerotic 
aorta, it has been difficult to warrant performing larger prospective clinical studies 
that would be necessary to determine definitively whether IPC induced by 
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intermittent aortic cross-clamping can improve clinical outcomes in patients 
undergoing CABG surgery.149  
 
1.4.4.2 RIC in Cardiac Surgery 
 
The phenomenon of RIC obviates the need for such an invasive approach to 
cardioprotection. Gunaydin et al. were the first to utilise RIPC in the clinical setting of 
CABG in a small trial of only eight patients with half being randomised to RIPC. Their 
protocol involved a tourniquet wrapped around the right upper extremity of the 
patient (right upper limb ischaemia) that was inflated to 300mmHg and deflated twice 
to perform 3 minutes of ischaemia separated with 2 minutes of reperfusion in the 
preconditioning group.150 This protocol failed to demonstrate a difference in cardiac 
enzymes (CPK, CK-MB and LDH) between the two groups when they were 
measured 5 minutes after declamping the aorta. Given that the study size is so small 
and also the failure to measure cardiac enzymes at any other time points beyond 5 
minutes of aortic declamping makes the data difficult to interpret.149 Six years later 
Cheung et al. were the first to demonstrate positive results with the use of RIC in 
cardiac surgery. 37 children undergoing surgical repair of congenital heart defects 
were randomised to RIPC induced by four 5 minute cycles of lower limb ischaemia 
and reperfusion using a blood pressure cuff inflated to 15mmHg above systolic 
pressure or control. The group showed that this RIPC protocol was effective in 
reducing Troponin I, postoperative inotropic requirements and airway resistance at 
six hours.151 In adults, undergoing CABG, Hausenloy et al. randomised 57 patients 
undergoing elective surgery to RIPC induced by three 5-min cycles of right upper 
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limb ischaemia, using a blood pressure cuff inflated to 200 mmHg, with an 
intervening 5 minutes of reperfusion.152 RIPC reduced Troponin-T release at multiple 
time points postoperatively and the total area under the curve for concentration was 
reduced by 43% in the RIPC group. Given that cross-clamp fibrillation was the 
predominant method used to protect the heart in this trial, the group repeated the 
study with a new cohort of patients undergoing elective CABG receiving cold-blood 
cardioplegia alone in order to determine whether RIPC using the same protocol 
conferred cardioprotection in a setting that is was clinically applicable with cold-blood 
cardioplegia having become the standard of care. This study confirmed the results of 
its forerunner demonstrating a 42% reduction in Troponin-T release over a 72 hour 
postoperative period,153 confirming the use of RIPC to reduce PMI in man. A 
secondary analysis of these two studies showed beneficial effects of RIPC outside 
the heart with a reduction in the incidence of acute kidney injury (AKI) in the 
preconditioned group.154  
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Trial N Clinical Setting Intervention Outcome 
Gunaydin 
(2000)155 
8 Elective  
CABG +/- Valve 
Upper Limb 
2 x 3min 
↓LDH 
Cheung  
(2006)152 
37 Paediatric 
Congenital 
Heart Defect 
Repair 
Lower Limb 
4 x 5min 
↓TnI 
↓Ionotropic req. 
↓ Airway resistance 
Hausenloy 
(2007)153 
57 Elective 
CABG 
Upper Limb 
3 x 5min 
↓TnT (AUC/72hrs) 
↓ AKI155 
Frassdorf 
(2009)156 
30 Elective 
CABG 
Sevoflurane ↓TnI 
 
Venugopal 
(2009)154 
45 Elective  
CABG +/- Valve 
Upper Limb 
3 x 5min 
↓TnT (AUC/72hrs) 
↓AKI155 
Zhou 
(2010)157 
60 Paediatric 
Congenital 
Heart Defect 
Repair 
Upper Limb 
3 x 5min 
 
 
Pre-Op (1 & 24hrs) 
↓Respiratory Index 
↓Ionotropic req. 
↓TnT 
↓CK-MB 
Thielman 
(2010)158 
53 Elective 
CABG 
Upper Limb 
3 x 5min 
↓Peak/Mean TnI 
↓TnI (AUC/72hrs) 
Rahman 
(2010)159 
162 Elective/Urgent 
CABG 
Upper Limb 
3 x 5min 
No reduction in TnT 
Wagner 
(2010)160 
101 Elective  
CABG 
Upper Limb 
3 x 5min 
Pre-Op (18hrs) 
↓TnI 
Hong 
(2010)161 
130 Off Pump 
CABG 
Upper Limb 
4 x 5min 
No significant 
reduction 
(↓TnI AUC by 26%) 
Ali 
(2010)162 
100 CABG Upper Limb 
3 x 5min 
↓CK-MB 
Karuppasamy 
(2011)163 
 
 
CABG Upper Limb 
3 x 5min 
No significant 
reduction TnI 
Hong 
(2012)164 
70 Off Pump 
CABG 
Upper Limb 
4 x 5min 
(RIPC & RIPost) 
↓TnI AUC 
Table 1 Table showing Clinical studies investigating therapeutic interventions which have 
shown benefit in the setting of cardiac bypass 
Adapted from Hausenloy and Yellon. Preconditioning in the Heart. J.M. Gidday et al. (eds.), 
Innate Tolerance in the CNS: Translational Neuroprotection by Pre- and Post-Conditioning. 
2013. DOI 10.1007/978-1-4419-9695-4_4. 91 
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1.4.4.3 RIC in Coronary Intervention 
 
Angioplasty is also an appealing target in which to attempt to ameliorate IRI. PMI has 
been noted during PCI with raised cardiac enzymes including CK-MB and troponin 
elevations but also by the presence of late gadolinium enhancement on cardiac MRI 
(CMR).165 PMI in this setting can be caused by a number of factors including 
myocardial ischaemia-reperfusion injury arising from the angioplasty balloon 
inﬂations, coronary embolisation and distal branch occlusions.166 The initial study 
looking at the role of IPC in angioplasty was disappointing. Illiodromitis et al. reported 
that no myocardial protection was conferred when forty one patients with stable 
angina and single vessel coronary artery disease underwent elective PCI. RIPC was 
induced by three 5 minute cycles of bilateral upper-limb ischaemia (cuffs inflated to 
200mmHg) immediately before PCI but in contrast to what would be expected the 
group observed that RIPC appeared to exacerbate cardiac enzyme release after 
angioplasty.167 The study is small and the failure to demonstrate protection by RIPC 
could be explained by the inclusion of a large proportion of patients with diabetes 
mellitus, a group where IPC is thought to be less effective168 and the high incidence 
of nitrate use in the control arm which has been shown to have preconditioning-
mimetic properties.169 The study also fails to state the actual number of patients who 
had lesions predilated before stenting or the number of patients with the presence of 
collateral supply. If predilatation (or post-dilatation) did take place it would be helpful 
to know the number of times the lesion was predilated, to what pressure and for what 
duration, all factors which are likely to contribute to PMI or paradoxically effect IPC. 
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Hoole et al. randomised 202 patients awaiting elective PCI to either RIPC induced by 
upper limb ischaemia with three cycles of cuff inflations to 200mmHg for 5 minutes or 
control. Interestingly they excluded patients taking preconditioning-mimetic and 
preconditioning-blocking medication. In the same vein participants were instructed to 
avoid any strenuous activity that could provoke angina (which could also act as a 
preconditioning mimetic) before their procedure. The group showed that RIPC 
attenuated PCI-related troponin-I (TnI) release at 24 hours with a significantly lower 
median troponin in the RIPC group and no detectable troponin release in 48% of 
patients in the RIPC group compared with 29% of patients in the control group. 
Patients in the RIPC group also reported less chest pain during the procedure, 
demonstrated fewer ST-segment changes on ECG during balloon inflation, and, 
above all, appeared to show fewer major adverse cardiac and cerebral events at 6 
months (mostly driven by repeat admission for an acute coronary syndrome).170 Six 
year follow up showed a reduction in the rate of major adverse cardiac and cerebral 
events.171 
 
 A smaller study by Ghaemian et al. was able to confirm the findings of Hoole’s study 
albeit with a different RIPC protocol. In this study of 80 patients, RIPC was induced 
by 2 cycles of lower-limb ischaemia and reperfusion with cuff pressure being 
elevated to above systolic pressure. The group showed that significantly fewer 
patients in the RIPC group had biochemical evidence of myocardial injury (as 
measured by TnT) at 12 and 24 hours compared to the control group.172 The use of 
the lower limb / thigh deserves a mention given that the majority of modern day RIC 
trials have used the upper limb in view of its accessibility and the fact that upper limb 
arteries are less prone to atherosclerotic disease than the lower limb thereby 
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avoiding potential complications of distal arterial embolisation or venous 
thromboembolism. The use of the lower limb, given the significantly larger bulk of 
skeletal muscle to deliver the RIC stimulus, may confer greater cardiac protection if 
the phenomenon is dose dependent.172 It is interesting then that Ghaemian et al. 
were able to see a significant reduction in TnT with just two cycles of RIPC when 
using lower limb ischaemia with the cuff being inflated to lower pressures when 
compared with other studies, which have used three or four cycles. The time 
advantage of two cycles over the usual three becomes crucial in the setting of acute 
myocardial infarction where longer door-to-balloon or call-to-balloon times are 
thought to be strong predictors of infarct size and outcome. 
Prasad et al. also investigated the use of RIC in a seemingly similar trial but failed to 
demonstrate a cardioprotective effect with no difference noted in peak TnT or CK-
MB.173The group used three cycles of RIC induced by three minutes of upper limb 
ischaemia (Cuff to 200mmHg) and three minutes of reperfusion. The authors point 
out a number of differences between their study that failed to show protection and 
that of Hoole et al., which did demonstrate a cardioprotective effect. The study by 
Prasad et al. (a) had a smaller sample size making it possible that the negative result 
is a false negative, (b) used a shorter RIC cycle (cycles of 3 minutes as opposed to 5 
minutes) meaning the stimulus may not have been enough to induce 
cardioprotection with the protocol being applied immediately before angioplasty as 
opposed to an hour by before angioplasty (c) 33-36% presented with an acute 
coronary syndrome requiring ‘urgent’ revascularisation and over 50% were noted to 
have unstable angina as opposed to the CRISP Stent study in which all cases were 
elective and would therefore be labelled as having stable angina (d) TnT was used 
as opposed to TnI (e) patients were older and had a higher frequency of diabetes 
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mellitus, these both being characteristics in which RIC is more difficult to 
induce,43,;173 and (f) no exclusion of patients with recent preceding angina as a 
possible preconditioning mimetic or patients on oral hypoglycaemic agents 
(particularly glibenclamide) which can block preconditioning. 
In a recent study more closely matching that of Hoole et al. of 205 patients, Lou et 
al.confirmed the findings that an RIPC protocol of three cycles of 5 minutes of 
ischaemia (Cuff to 200mmHg) and 5 minutes of reperfusion significantly reduced 
PMI as measured by high sensitivity TnI.174  
With the studies above in cardiac surgery and elective PCI, one is able to pre-empt 
the episode of index ischaemia, yet this is obviously not the case with an STEMI. For 
this reason the conditioning stimulus can only be applied either after the onset of 
ischaemia but before reperfusion (per-conditioning) or following reperfusion with 
IPost.   A number of mechanical and pharmacological strategies have been shown to 
be of benefit in patients presenting with an acute myocardial infarction who undergo 
PPCI. Yet at the same time, a number of strategies that have shown promise in 
animal models have not translated into positive clinical studies in humans. 
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Trial N Setting Intervention Outcome 
Illiodromitis1
67 
(2006) 
41 Elective 
Angioplasty 
Bilateral 
Upper Limb 
3 x 5min 
↑CK-MB 
↑ TnI 
Hoole/Davie
s 
(2009/2013) 
170,171 
242 Elective 
Angioplasty 
Upper Limb 
3 x 5min 
↓TnI 
↓Chest pain 
↓ST segment deviation 
↓MACCE at 6 yrs 
Prasad173 
(2010) 
95 Elective 
Angioplasty 
Upper Limb 
3 x 5min 
No difference 
in  
periprocedural 
myonecrosis (TnT) 
Ghaemian172 
(2012) 
80 Elective 
Angioplasty 
Upper Limb 
2 x 5min 
↓TnT 
↓Chest pain 
↓ST segment deviation 
Lou174 
(2013) 
205 Elective 
Angioplasty 
Upper Limb 
3 x 5min 
↓hscTnI 
↓type4a MI 
Table 2 Table of the use of RIC in the setting of elective angioplasty 
 
1.4.4.4 Pharmacological Conditioning in STEMI 
 
Pharmacological agents are appealing in the setting of an STEMI as they can be 
administered quickly prior to reperfusion via a number of different access routes 
including the intracoronary route allowing rapid perfusion into the myocardium. 
A large Japanese study (J-Wind) by Kitakaze et al. assessed the administration of a 
three-day infusion of atrial natriuretic peptide (ANP) in patients with an STEMI. The 
infusion was started following reperfusion. In this study of 569 patients, ANP 
significantly reduced biochemical infarct size as measured by CK but did not 
significantly reduce troponin levels.  The authors also noted a significant 
improvement in ejection fraction at 6 months, and decreased the incidence of cardiac 
death and admission to hospital because of heart failure in the ANP group.175 
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Although not commented on in the paper, it is important to note the large number of 
patients in the control group who were labelled as ‘Rescue’ in whom one may expect 
a poorer outcome whilst paradoxically a more judicious use of intra-aortic balloon 
pumps in the treatment arm. 
Piot et al.176 randomised 58 patients to an intravenous bolus of cyclosporine (which 
has been shown to be an inhibitor of mPTP opening) or placebo to patients prior to 
PPCI with direct stenting and demonstrated a significant reduction in CK. In a sub-
group of 27 patients, a reduction in infarct size measured by CMR within the first 
week was demonstrated. As with any clinical trial it is difficult to control for all 
variables and it was noted that more patients (although not significant) in the control 
group underwent facilitated or rescue PCI having failed thrombolysis. Further CMR 
studies at six months in 28 showed to assess post infarct remodeling showed a 
sustained reduction in infarct size detrimental effect on LV remodeling. The study 
was a proof on concept study, which was not powered to address remodelling. A 
larger multi-centre study (looking to recruit over 900 patients) is underway to address 
whether cyclosporine can improve clinical outcomes in STEMI patients.177 
Our own group administered erythropoietin (which has shown promise in preclinical 
studies) to patients prior to PPCI, which failed to reduce infarct size as measured by 
CMR. Interestingly this study, through the use of CMR, noted a significant increase 
in the incidence of MVO. This finding turned the trial from a neutral trial to a negative 
trial. Whereas traditional biomarkers did not show any difference between the two 
groups, imaging biomarkers assessed by CMR were able to note the increase in 
MVO.178 
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Lønborg et al. showed how exenatide increased myocardial salvage (Measured by 
CMR using T2 weighted STIR imaging) when administered prior to PPCI.179 A post 
hoc analysis showed that exenatide treatment was associated with a 30% decrease 
in final infarct size only in patients with an ischaemic time of < 132 minutes.180 
 
1.4.4.5 RIC in STEMI 
 
Rentoukas et al. were the first to study the role of RIC in STEMI. 96 patients were 
randomised to either a protocol that would seem to be a mixture of per-conditioning 
and IPost in that it was a twenty-minute protocol that started ten minutes before the 
first balloon inflation/reperfusion.181 RIC was induced by inflating a blood pressure 
cuff placed on the upper limb to 20mmHg above systolic pressure for 4 minutes and 
4 minutes of reperfusion for three cycles. Two other groups were randomised 
including the control group and a third group, which were treated with the per-
conditioning protocol as well as the initiation of a morphine infusion at the onset of 
reperfusion.  In the RIPC groups, a significantly higher proportion of patients 
achieved full ST-segment resolution but this did not translate into a significant 
reduction in TnI. A post-hoc analysis of the data only showed significance when the 
two RIPC groups were aggregated and compared to the control. These findings do 
however suggest a potential role of morphine as a mediator of cardioprotection, 
which is supported by recent observations, indicating that pre-treatment with the 
opiate receptor antagonist naloxone can interfere with cardioprotection.182,183 
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A recent study by Bøtker et al. randomised 333 patients presenting with a STEMI to 
a per-conditioning protocol of four cycles of alternating 5-min inflation and 5-min 
deflation of a standard upper-arm blood-pressure cuff to 200mmHg or control prior to 
primary angioplasty. The protocol was started by ambulance staff on route to 
hospital. Analysis of 251 patients in the ‘intention to treat analysis’ showed that 
myocardial salvage (assessed by myocardial nuclear scanning) as a percentage of 
left ventricle was significantly higher in the intervention group. Comparison of mean 
salvage index did not however reach significance. No difference was noted either in 
final infarct size, LV function or troponin release. Per-protocol analysis of the 142 
patients who completed follow up demonstrated, that the primary endpoint of salvage 
index and percentage salvage was significantly higher in the remote conditioning 
group than in the control group.184 The difference appeared to be driven by those 
patients presenting with anterior myocardial infarctions with the largest areas at risk 
therefore having the greatest proportion of potentially salvageable myocardium. This 
confirms previous cardioprotection studies in STEMI patients, which suggest that the 
patients most likely to benefit from cardioprotective strategies are those with the 
largest area at risk (AAR). Therefore, in studies in which all patients were included, 
any cardioprotective effect may be diluted accounting for some of the negative 
clinical cardioprotection studies.112 For this reason, some studies will only recruit 
patients with occluded LAD arteries, yet this moves our work away from real world 
scenarios in which patients present with occlusions of any of the three major 
coronary arteries.  
 
In Bøtker’s study,184 the treatment protocol was completed before arrival at the 
cardiac centre in all but 16 patients which is likely a reflection of the long transfer 
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times in Denmark. Mean symptom to balloon times was 190 minutes although call to 
balloon time is not recorded. For those 16 patients the protocol was continued in 
tandem with the angioplasty i.e. following the advent of reperfusion. In the same vein 
reperfusion had also begun prior to arrival at the hospital in a significant proportion of 
patients with 40% of patients having a patent coronary artery on initial angiography 
(>TIMI 0 flow), indicating that at least for some patients the protective arm ischaemia 
was applied after the recommended time-window, possibly lowering the expected 
benefit of the RIPC. This would explain the subgroup analysis findings of higher 
levels of myocardial salvage in patients with a fully occluded artery on arrival (TIMI 0 
flow).185 At the same time this also likely represents a real world analysis of patients 
presenting with acute myocardial infarction as vessel occlusion is a dynamic and 
multifactorial process and efficient anti-platelet and antithrombotic therapies 
instituted early can lead to spontaneous reperfusion prior to PPCI.112 TIMI 0 flow on 
admission does not exclude the possibility of stuttering reperfusion and reocclusion 
having taken place prior to angiography or visa-versa where a patent artery on 
admission does not exclude a significant period of complete occlusion prior to 
angiography. Stuttering reperfusion and occlusion is likely to have a conditioning 
effect but leaves us unable to accurately assess whether we are giving our 
intervention as an IPC, IPost or as a per conditioning strategy. 
 
Page 66 of 261 
 
1.4.5 Limitations of Conditioning 
 
There are a number of limitations that have impeded the translation of 
cardioprotective strategies from preclinical research into mainstream clinical practice. 
 
One of the main limitations of a conditioning strategy, as mentioned above, was the 
need to directly condition the heart. The advent of RIC, obviated the need to directly 
condition the myocardium although techniques used often remained invasive in 
nature. The move to use limb ischaemia with a blood pressure cuff or tourniquet as 
well as investigation of pharmacological agents has further facilitated the translation 
of ischaemic conditioning into various clinical settings involving IRI. The protocol of 
inflating a blood pressure cuff on a human limb is safe, cheap and involves a 
protocol that can be initiated in a pre-hospital setting without significant technical 
ability. It is interesting to note however, that although concerns exist with regard to 
conditioning the heart directly, there have been no reported adverse events in 
humans that are directly attributable to an IPost strategy.186 
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Another of the limitations of cardioprotection has been the failure of clinical 
cardioprotective studies to replicate the findings of their preclinical predecessors. 
This has been the focus of much interest and a number of reasons appear to exist.  
 
(i) The majority of clinical trials have been small proof of concept studies, which may 
allow for type II statistical errors. The need to demonstrate actual clinical benefit in 
larger scale multicentre, randomised, double-blind, controlled studies has been taken 
on board by a number of working groups and larger human cardioprotective studies 
are now underway.187 
 
(ii) There appears to be little consensus as to which protocol is best used for RIC 
and hence different groups are applying stimuli to different limbs for differing lengths 
of time.  
The question of whether RIC is an all-or-none stimulus or is dose dependent is yet to 
be elucidated but will be essential in helping to standardise protocols across clinical 
studies in an aim to gain reproducible results. 
 
(iii) There are major differences between animal models used in conditioning studies 
and the typical patient undergoing PPCI for an acute myocardial infarction. Some of 
these differences will be difficult to overcome but others need to be adjusted for in 
future preclinical studies.  
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(a) Age and health of the animal - Animal models will likely involve the use of 
young, healthy animals without the co-morbidities that a patient may be expected to 
have such as diabetes mellitus or hypertension. Patients with co-morbid conditions 
are chronically treated with multiple different medications, which may mimic or block 
conditioning effects whereas animal models will be treatment naive.  
 
(b) Animal vs. Human models of IRI - Animal models of myocardial ischaemia 
differ from that of the human in that they involve the ligation of a non-atherosclerotic 
vessel and are therefore unlikely to stimulate the inflammatory settings of acute 
infarction. At the same time, removal of the ligature, to restore flow will not mimic the 
conditions of reperfusion induced by angioplasty with the subsequent embolisation 
and MVO. Patients undergoing PPCI are likely to have residual disease at first 
presentation that may not be ‘dealt’ with when focus is placed on the culprit lesion in 
the setting of acute infarction. Experimentally induced IRI will be fixed, continuous 
and often, particularly in small animals, relatively short whereas in humans 
ischaemia and reperfusion is a dynamic and possibly intermittent / stuttering process 
with varying but often prolonged periods of ischaemia and reperfusion. 
(iv) Study endpoints – Major differences exist in how groups design their studies 
including how they assess their chosen endpoints. A wide range of endpoints exist 
that are utilised within cardiovascular research including both biochemical and 
imaging biomarkers.  Our study focuses on the use of CMR as a novel non-invasive 
imaging strategy to assess the efficacy of cardioprotective strategies. The use of 
CMR will be discussed in detail in the coming sections. 
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1.5 Cardiac MRI 
 
The role of imaging within acute infarction is multifaceted. It helps to accurately 
establish the diagnosis, can aid in risk stratification and therapeutic decision making 
and can also be used to monitor response to different therapies. In the setting of 
acute myocardial infarction CMR is able to provide a host of information including 
assessment of global and regional wall motion, calculation of left (and right) 
ventricular volumes, calculation of stroke volume and hence ejection fraction. The 
ability to perform tissue characterisation is a key feature that makes CMR unique 
when compared to other imaging modalities. It enables accurate definition of 
abnormal myocardium thereby advancing myocardial phenotyping from a binary 
quantitative approach (how much myocardium is either alive dead), to a more 
sophisticated assessment of myocardial quality with a multi-parametric assessment. 
This approach promises both clinical utility and new insights into the fundamental 
biological mechanisms of cardioprotective interventions. CMR allows assessment of 
myocardium at risk either by T2-weighted imaging or infarct endocardial surface area 
(Infarct-ESA), imaging of microvascular damage (MVO or haemorrhage) and 
accurate assessment of the transmurality of infarction as well as the amount of 
myocardial necrosis. 
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1.5.1 Cardiac Volumes 
 
Accurate assessment of cardiac volumes, mass and function has important 
prognostic and therapeutic implications; hence the accuracy of the data can 
significantly affect the appropriateness of certain diagnostic or therapeutic 
approaches in an individual patient. Serial measurements are important to evaluate 
treatment and changes in volumes and function over time. Cardiac volumes and 
function are therefore intrinsic to cardiovascular research and are used as surrogate 
endpoints in a large proportion of cardiovascular studies. Most imaging modalities 
can measure cardiac volumes. CMR is considered the gold standard188 for the 
measurement of cardiac volumes and function. The ability of CMR to delineate 
between blood pool and myocardium allows measurements to be made with a high 
degree of accuracy and reproducibility.189 Other imaging modalities that can be used 
to assess cardiac volumes include echocardiography and ventriculography 
(angiography or radionuclide).  
 
Echocardiography is widely used post myocardial infarction to assess LV function, as 
it is cheap, easily available, portable and non-invasive. M-mode and 2-D 
echocardiography are acoustic window and operator dependent and rely on 
geometric assumptions that do not hold true in patients with dilated, remodelled 
ventricles190 IHD is a regional or segmental process, so that volume measurement is 
more important than assessing LV end-diastolic diameter (LVEDD), which is readily 
measured by transthoracic or transoesophageal echocardiogram but only rises 
following global ventricular stretch. Echocardiography is thereby less useful in 
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ischaemic disease for measuring ventricular volumes because of its inaccuracy 
when regional asynergy is present.191 
 
Ventriculography only allows for a single two-dimensional assessment of volumes. 
Imaging is reliant on heart rhythm and ectopy (or patient movement) can often 
render non-diagnostic images. Should the images be non-diagnostic there is little 
scope for repeating the cine run given the risk of contrast nephropathy with 
increasing contrast load. 
 
Radionuclide ventriculography is used to assess cardiac function yet suffers from 
similar limitations to echocardiography including poor acoustic windows or spatial 
resolution and geometric assumptions. At the same time it lacks the accessibility of 
echocardiography and involves exposure to ionising radiation.  Radionuclide 
angiography has been shown to underestimate left ventricular function 
 
A significant advantage of CMR for evaluation of cardiac indices is its reproducibility 
and accuracy compared with 2D planar or projection techniques that depend on 
geometric assumptions in order to define mass and volume determinations. This 
allows small changes in myocardial mass and/or volume to be detected over time or 
as a result of therapy. This is particularly useful for determining the impact of therapy 
or for research purposes in clinical trials.192 The high reproducibility of CMR suggests 
that a smaller sample size is required to detect a change in volumes, mass193, and 
function in comparison with published values for techniques using LV geometric 
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assumptions.194 CMR LV size and systolic function are precisely determined with 
standard errors of about 5%.194 
 
1.5.2 Infarct Size 
 
Myocardial infarct size is a major determinant of prognosis following an acute 
myocardial infarction (AMI). Infarct size has been correlated with malignant 
arrhythmias,195 heart failure and mortality196 hence the need for therapeutic 
strategies to limit the amount of infarcted myocardium. 
Infarct size, as a direct measure of damage in myocardial infarction, has long been 
used as a surrogate measure in cardiovascular trials. A number of imaging and non-
imaging biomarkers have been used to express infarct size including ECG 
measurements, cardiac enzymes (CK, CK-MB and Troponin) measured as an ‘area 
under the curve’ or peak enzyme release in serial measurements, Technetium-
sestamibi SPECT and Cardiac MRI. 
These markers are ‘surrogate’ or ‘replacement’ measures used in trials of 
cardiovascular disease. The real endpoint relevant for definitive evaluation of a 
treatment typically is survival. For this reason a significant number of trials will use 
primary endpoints in clinical cardiovascular studies of death, reinfarction or heart 
failure. The use of these so called hard endpoints can prove difficult given that 
incidence of the event is often low during short - or medium - term follow-up. 
Furthermore, some events might not be linked to atherosclerosis resulting in low 
sensitivity. As a consequence, large sample sizes and long follow-up periods are 
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required absorbing time and financial resources. Missing data and noncompliance 
are also more likely in longer-lasting studies.197,198 
The use of surrogate endpoints was initially based on an established association 
between the presumed surrogate and the corresponding true endpoint. However, the 
mere existence of an association between a possible surrogate endpoint and the 
true endpoint is not sufficient for using the former as a surrogate. What is required is 
that the effect of the treatment on the surrogate endpoint reliably predicts the effect 
on the true endpoint.187 
 
1.5.2.1 Determinants of Infarct size 
 
There are multiple determinants of final infarct size. The main determinants include; 
       
(i) Duration of coronary occlusion 
 
Reimer and Jennings identified the wavefront phenomenon of ischaemic cell death 
as a function of the duration of ischaemia.199 Their seminal papers demonstrated that 
necrosis occurs first in the subendocardial myocardium and with longer durations of 
coronary occlusion involves progressively more of the transmural thickness of the 
ischaemic zone (area of myocardium subtended by the occluded coronary artery 
which we will describe as the ‘area at risk’).  Microvascular injury, evidenced by 
interstitial haemorrhage, also progresses from subendocardial to subepicardial 
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zones but the time scale is slower than that for myocyte necrosis.199 Hence the 
maxim of “time is muscle” and the drive to constantly improve on pain-to-balloon and 
door-to-balloon times to halt the ‘wavefront’/progression of necrosis in a bid to 
salvage myocardium. The time between symptom onset and the provision of 
reperfusion therapy (ideally by PPCI) reflects total ischaemic time and minimising 
delays is associated with improved outcomes.8 Longer ischaemic times mean less 
salvageable myocardium and delay is linked with larger infarct size and increased 
mortality.200 In this regard little has changed in 35 years as Reimer and Jennings 
concluded in 1977 that since the amount of potentially salvageable myocardium 
progressively decreases as the period of ischaemia is prolonged, time is the most 
critical variable involved in delaying or preventing ischaemic myocardial cell death.199 
 
Figure 5 Wavefront Phenomenon - CMR short axis image demonstrating anteroseptal LGE 
 
The infarction can be seen to be spreading out from the endocardium to epicardium. 
The progression of spread having been halted by PPCI demonstrating myocardial 
salvage. 
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(ii) Area at risk (AAR) 
 
The area at risk (AAR) refers to the myocardium subtended by a particular coronary 
artery that once occluded is at risk of infarction. The size of the AAR is a major 
determinant of the final infarct size. Reimer and Jennings again showed that the 
quantity of myocardium made ischaemic by occluding a particular coronary artery 
varied from dog to dog and that the AAR correlated with the amount of necrosis.201 
Given that the amount of necrosis can only ever be as large as the AAR then the 
comparison of infarct size from a particular coronary bed cannot be made between 
subjects. Small differences in the AAR may result in a significant variation of infarct 
size, underscoring the fact that most of the infarct size variability is due to the extent 
of the myocardium at risk.202 In order to standardise measures infarct size can be 
expressed as a percentage of the AAR. This also enables the quantification of 
myocardial salvage which is the potential infarct size (AAR) minus the actual infarct 
size. The assessment of myocardial salvage may be a more important measure of 
outcome than traditional measures including biomarker release or EF.203 
 
The ability to measure the AAR is particularly ideal in STEMI patients, where the size 
of the AAR can differ (from 10 to 50% of the LV) depending on which the coronary 
territory is affected. 112  
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The AAR can be estimated from a number of different methods including: 
 
(a) The extent of ST-segment elevation on presenting 12-lead ECG. Although 
theoretically a 12-lead ECG is easy to perform and allows estimation of the AAR 
prior to reperfusion, in the era of PPCI the diagnosis of STEMI is often made from a 
limited Paramedic ECG prior to the angioplasty. A routine 12-lead ECG, in the 
presence of a diagnostic, would unnecessarily increase door-to-balloon times. The 
ECG only allows for estimation of the AAR and not infarct size so, cannot be used to 
assess myocardial salvage.204 
 
(b) The number of regional wall motion abnormalities present on echocardiography 
or LV angiography. The circumferential extent of the abnormally contracting 
segments are calculated and expressed as a percentage of the internal 
circumference of the LV in end-diastole. This offers an indirect and often inaccurate 
measure of the AAR.97  
(c) Coronary angiography using the BARI or APPROACH scores.  
 
These markers, however, do not very accurately or even quantitatively reflect 
myocardial salvage. Therefore, research on reperfusion strategies, although highly 
sought, has been debilitated by a requirement for large sample sizes and prolonged 
follow-up periods.205 
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The current gold-standard non-invasive imaging technique for measuring the AAR is 
myocardial perfusion imaging (single-photon emission computerized tomography - 
SPECT) where an intravenous injection of technetium is given to the STEMI patient 
prior to PPCI.  The patient then has a perfusion scan within 6-8 hours and the 
radioisotope is not taken up by the myocardium in the territory of the infarct-related 
coronary artery - this is the AAR. The patient then has a repeat scan 7-10 days later 
which delineates the resultant infarction.  
 
Despite the need for two separate studies, SPECT has the advantage of offering the 
assessment of AAR and infarct size using the same modality. Myocardial salvage as 
assessed by SPECT has been shown to correlate with mortality.206 SPECT suffers 
from a number of limitations including the need to image the patient within six hours 
of reperfusion (with ideally a 24 hour nuclear imaging service to enable to 
administration of the isotope - 99Tc-sestamibi), which is usually impractical. The 
patient will have to undergo two studies with exposure to ionising radiation (which 
would need to be added to the patients exposure for PPCI) to provide relatively 
limited spatial resolution. SPECT scans have been shown to have difficulty in 
evaluating the inferior wall of the left ventricle adjacent to the diaphragm, and also 
lack penetration in obese patients.207 The poor spatial resolution of SPECT is 
reflected in the fact that CMR systematically detects subendocardial infarcts that are 
missed by SPECT.208 In those patients enrolled in trials with a patent coronary artery 
at admission, 99Tc-sestamibi may escape into the ischaemic bed therefore 
underestimating the AAR.184 
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CMR, with high temporal and spatial resolution, allows for the quantification of AAR 
and infarct size therefore allowing for the assessment of myocardial salvage in a 
single scan which can safely be performed early following PPCI. The use of CMR to 
assess infarct size and AAR will be discussed below. 
 
(iii) Residual flow in the territory at risk (Collaterals and Antegrade flow in the IRA). 
As mentioned earlier, acute infarction can often be a stuttering process with dynamic 
changes in flow ranging from TIMI 0 to TIMI III flow. In a number of studies between 
40 - 50% of STEMI patients presented to the hospital already having significant 
coronary flow (TIMI flow >1) within the infarct related artery.183,209 
 
The presence of antegrade flow makes it difficult to retrospectively assess the area 
at risk. For example, using 99Tc-sestamibi in those patients with a patent coronary 
artery at admission, may lead to an underestimation of the AAR in view of the 
chance that the trace may escape into the ischaemic bed.184 It is also important to 
note that antegrade flow down the IRA will confound conditioning studies as 
mechanical or pharmacological mimetics need to be applied prior to the opening of 
the occluded artery. Once the artery is open (TIMI flow >1) and the cascade of 
reperfusion injury begun, it is too late to apply pre- or perconditioning strategies. 
Similarly the presence of the coronary collateral circulation has been noted to be a 
confounding factor in such studies for identical reasons.  Collateral arteries are 
usually only evident in 10–40% of MI patients undergoing PCI, yet most MI studies 
have suggested that myocardial perfusion may be maintained and LV function 
preserved in patients with an adequate coronary collateral circulation.210 Hence, with 
Page 79 of 261 
 
continuous flow to the AAR, through the collateral circulation the degree of IRI will be 
diminished. Collateral flow supplying the myocardium (that likely develop as an 
adaptation to ischaemia) will thereby reduce the AAR and infarct size.211 Depending 
on the exact amount of collateral flow recruitable during a brief coronary occlusion, 
long-term cardiac mortality has been shown to be reduced by up to one fourth 
compared with the same situation without collateral supply.212  
In the presence of collateral blood supply the precise timing of IRI will not be easy to 
establish and therefore one cannot reliably apply a conditioning strategy. Studies in 
cardioprotection will often therefore either exclude patients with collateral flow on 
initial angiography or attempt to measure it. The assessment of coronary collateral 
blood flow is very difficult. It can only be assessed during the occlusion of the 
collateral-receiving artery by the measurement of intracoronary occlusive pressure or 
velocity derived collateral flow index, expressed as a fraction of flow during vessel 
patency.213 The majority of collateral vessels in humans may not be angiographically 
detectable;214 therefore any grading system provides only an estimate of collateral 
flow.215 
The presence of collateral flow has caused difficulty in translating cardioprotective 
studies from animals to humans. The collateral circulation in humans differs from that 
of animals with a wide spectrum of collateral flow exists between various mammalian 
species.216 The canine coronary circulation contains a well-developed native system 
of functional, preformed epicardial collaterals, which results in the persistence of 15–
30% of baseline blood flow during coronary occlusion. In the normal human heart, a 
native system of preformed collaterals is also present, but is much less developed, 
located primarily in the subendocardium.217 It has been suggested that significant 
coronary collateralisation to the AAR may in part explain the negative findings of the 
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clinical cardioprotection studies112 and that patients with collateral flow should be 
excluded from such studies.218 
 
(iv) Hemodynamic factors: Haemodynamic factors including blood pressure and 
heart rate at the time of coronary artery occlusion also impact on infarct size. 
Tachycardia and/or hypotension occurring in a STEMI patient will likely increase 
infarct size through increased myocardial oxygen consumption.219 Preclinical studies 
have demonstrated that augmenting coronary flow and therefore reducing 
myocardial oxygen demand prior to reperfusion reduces infarct size and increases 
myocardial salvage.220 Disappointingly clinical studies have failed to demonstrate 
benefit in human studies with the use of intra-aortic balloon counterpulsation (IABC) 
as an adjunct to revascularization in STEMI patients.221Interestingly for a study 
(CRISP-AMI) setup to examine one of the determinants of infarct size, it failed to 
take coronary collateralisation (not recorded) or evidence of anterograde flow (TIMI > 
0 = 30% patients) on initial angiography into account. In the same vein, the patients 
in the study had ischaemic times of longer than 3 hours which will likely limit the 
amount of salvageable myocardium. 
 
1.5.2.2 Cytoplasmic Markers (CK and CK-MB) of Myocardial Necrosis 
 
Measurement of cardiac biomarker levels is routinely performed in clinical practice, 
as well as in clinical trials after myocardial infarction to estimate the extent of 
myocardial necrosis. Venous sampling of creatine kinase (CK) and CK-MB 
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concentrations have been shown to correlate with histopathological measures of 
infarct size222 as well as with functional and clinical outcomes in the setting of 
STEMI.223  Concerns with regard to relying on cytoplasmic markers to predict infarct 
size include (i) uncertainty as to which method (peak concentrations, area under 
time-concentration curve [AUC], or single time-point measurements) is most reliable, 
(ii) the fact that both CK and CK-MB are not cardiospecific, being found in both 
skeletal and myocardial tissue224 and (iii) reperfusion therapy is thought to alter the 
kinetics of these enzymes leading to a higher peak value at an earlier time point.225 
Troponins are more sensitive and specific for detection of myocardial necrosis and 
are currently the gold standard for the diagnosis of myocardial infarction. Troponin 
measurements at differing time points have been shown to correlate with myocardial 
function measured by echocardiography226 and function and infarct size measured 
by SPECT227 imaging and CMR.228  
 
1.5.2.3 Late Gadolinium Enhancement (LGE) Imaging 
 
Late gadolinium enhancement (LGE) imaging by CMR is a highly sensitive and 
specific technique for imaging infarct size post myocardial infarction offering high 
resolution images which have only previously been achievable by the 
histopathological analysis of postmortem specimens.  
Contrast enhancement using gadolinium (Gd) agents is based on T1-shortening and 
the distribution of contrast agent within the tissue. The mechanism of early and late 
enhancement relates to the different wash-in and wash-out kinetics of normal 
myocardium and tissue with myocardial infarction or fibrosis.229 Gadolinium-based 
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contrast agents rapidly diffuse into the extracellular space but, because of chemical 
charge and molecular size, contrast is unable to cross intact cell membranes. In 
essence, these agents cannot normally enter the intracellular space in the presence 
of intact myocytes and the volume of distribution is small. In the acute phase 
following infarction, myocyte cell membranes rupture with loss of sarcomere integrity 
(88% of myocytes in infarcted regions have sarcolemmal tears, compared with 0% in 
normal regions)230, allowing the extracellular tracers to be passively distributed into 
the intracellular spaces of irreversibly injured myocardial cells. Hence the volume of 
distribution of Gd-DTPA is increased in the setting of acute infarctions in humans.231 
Additionally to an increased volume of distribution, an altered wash-in and wash-out 
kinetic, where Gd-DTPA becomes “trapped” in the infarcted tissue due to the 
severely reduced wash-out is a contributory factor to an increased concentration and 
hyperenhancement.232 Changes in kinetics could be due to a number of factors, 
including changes in coronary flow rates, capillary permeability, or functional 
capillary density.229 
 
The principles in chronic infarction are similar in that the distribution of Gd-DTPA is 
dependent on the degree of architectural disruption of the myocardium. Within the 
infarcted zone, myocytes are replaced by collagenous scar. Fibrosis (scar) has a 
larger extracellular space (hence larger concentration and volume of distribution) 
than does normal myocardium. Multiple studies analysing myocardial histology 
showed a significantly elevated proportion of fibrosis in scar compared to viable 
myocardium (25–49% vs. 9–25%, respectively). Therefore, the elevated signal 
intensity on LGE imaging in scar tissue can be explained by an increased volume of 
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distribution due to the higher degree of fibrosis secondary to myocyte loss and 
fibrous reorganisation.233 
 
Following the administration of Gd-DTPA (which shortens the T1 relaxation time) an 
inversion recovery sequence is applied which suppresses the normal myocardium 
resulting in the infarcted myocardium appearing bright.  
 
 
Figure 6 Mechanism of Late enhancement imaging and distribution of Gd-DTPA in normal 
myocardium, acute and chronic infarction 
 
Reprinted with permission from Kim RJ et al. Assessment of myocardial viability by contrast 
enhancement. In: Higgins CB, de Roos A, eds. Cardiovascular MRI and MRA. Philadelphia, PA: 
Lippincott Williams and Wilkins; 2003; 209– 237..234  
 
Kim et al.235 demonstrated in a canine model that late enhancement is seen with 
both (reperfused and non-reperfused) acute and chronic infarction with the location 
and spatial extent of necrosis showing excellent correlation with macroscopic slices 
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stained with TTC. However severe, transient ischaemia was not shown to lead to 
hyperenhancement despite the presence of myocardial stunning. Other important 
findings from their study included infarct shrinkage over time (8 days to 3 weeks) and 
partial volume effect of infarct imaging in the use of late enhancement technique. 
 
 
Figure 7 The comparison of ex-vivo MR images with TTC-stained slices in 1 animal at 3 days 
after infarct 
Reprinted with permission from Kim R J et al. Circulation 1999;100:1992-2002  
 
From a clinical perspective the results demonstrated the ability of CMR to distinguish 
between acute myocardial infarction (hyperenhancement and evidence of regional 
wall motion abnormality), injured but viable myocardium (no hyperenhancement but 
evidence of regional or global contractile dysfunction), and normal myocardium (no 
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hyperenhancement with normal function). In the setting of chronic myocardial 
infarction, late enhancement imaging and cine MRI may also distinguish between 
myocardial necrosis, hibernating myocardium, and normal myocardium.187 
Mahrholdt et al.236 further demonstrated the high sensitivity and specificity of 
detection of infarction by CMR as compared to the previous gold standard of SPECT 
imaging. Whereas transmural infarction was picked up at similar rates by both 
modalities, SPECT imaging missed subendocardial infarction that was picked up by 
CMR and confirmed histologically on TTC staining. This confirmed the findings of 
Kim et al. above that subendocardial infarcts detected by CMR corresponded to 
infarcts defined histologically.235 
Wu et al. showed that initial infarct burden as delineated by infarct size (measured 
on delayed enhancement images on CMR done at day 2 post PPCI) was the 
strongest predictor of persistent LV enlargement (ESVi) and future cardiac events 
(cardiac death, non-fatal re-infarction and symptomatic congestive heart failure 
requiring hospitalisation.).237 Infarct size was more predictive of adverse 
cardiovascular events than ejection fraction (EF) or ESVi measured in the acute 
phase post MI. ESVI and EF calculated within 7 days of a STEMI can be inaccurate 
measures of the extent of irreversible myocardial injury because of ischaemic 
stunning or previous areas of chronic hibernation.238 Unlike LVEF and left ventricular 
volumes, infarct size is not dependent on preload / afterload or stunning. Wu’s group 
showed that patients with an infarct size measured at 18.5% were unlikely to develop 
adverse events with a negative predictive value of over 90%.237 This high negative 
predictive value demonstrates the importance of quantifying the amount of infarcted 
myocardium suggesting that CMR is able to identify patients who are at higher risk of 
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adverse LV remodelling and MACE and therefore may warrant more aggressive 
treatment.236,237 
The additive value of quantifying the amount of LGE was more recently shown by 
Larose et al. who demonstrated that the occurrence of LV dysfunction at 6 months 
invariably increased with greater LGE: a cut-off of ≥23% LGE measured on CMR 
very early following PPCI (within 12 hours) showed the best accuracy for late LV 
dysfunction (sensitivity 89%, specificity 74%) beyond traditional risk factors such as 
infarct territory, maximum CK-MB rise, pain-to-balloon time, presence of Q waves, 
and LVEF during STEMI. LGE volume incurred the strongest association to LV 
function change, beyond infarct transmurality, MVO, and salvaged myocardium 
(measured using T2-weighted STIR imaging).239 
 
The study by Larose also addresses the question of when should infarct size be 
measured in order to best risk stratify patients. Infarct healing occurs early after 
reperfused infarction and is characterised by infarct shrinkage, infarct and adjacent 
wall thinning and loss in the myocardial mass. Most infarct healing is finished at 4 
months post-MI suggesting that this is a reasonable time point to study the 
morphological consequences of infarct repair.240 Early studies by Pfeffer et al. 
suggested that although left ventricular volumes were increased in relation to infarct 
size measured at four months, no such relationship existed early (24 hours) after 
infarction.241 A small study of 22 patients demonstrated a reduction in infarct size (as 
measured by LGE imaging) in patients treated with PPCI of 31% between week one 
and five months post infarction. Infarct size decreased relatively to the same extent 
in small and large infarctions and shrinkage appeared to be independent of the 
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territory affected.242 The follow-up measurements by Larose’s group averaged 27% 
less than those made within 12 hours after reperfusion and match the follow 
measurements of other studies using CMR.243 These reductions in infarct size likely 
reflect resolution of acute inflammatory changes and replacement of resorbed tissue 
by scar. The relative magnitude of any changes is apparently insufficient to negate 
the value of measurements during the early post infarction period.244 Ganame et al. 
showed that although LV remodelling continued up to 1 year after the acute event, 
infarct size when measured at baseline (median 72 hours post PPCI) remained a 
powerful predictor powerful predictor of late LV remodelling.240 Therefore LGE 
imaging early after PPCI may overestimate myocardial necrosis when the volume of 
the infarcted tissue tends to increase due phenomena such as hyperaemia, oedema 
and inflammatory cells infiltration.245 Despite this early measurement of infarction 
remains a strong independent predictor of adverse outcomes. 
 
Engblom et al. reported a rapid initial reduction in the degree of LGE during the first 
week following reperfusion for AMI. The group explained their findings firstly based 
on the original studies of Reimer and Jennings suggesting that resorption of 
oedema, haemorrhage, and irreversibly injured myocytes within the region of 
infarction lead to the reduction in LGE at one week. The group also postulated that 
the loss of hyperenhancement of a viable peri-infarction zone surrounding the 
irreversibly injured core of myocytes early after infarction contributed to the early 
reduction in LGE.246 
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Multi centre data now exists both for the assessment of CMR to detect infarction and 
also to link CMR endpoints with mortality. One international multi centre double 
blinded randomised control trial looked at the performance of delayed enhancement 
imaging for the detection and assessment of infarction using CMR. 566 patient scans 
were done across 26 centres. The sensitivity of detecting MI in the acute setting was 
99% and 96% in the setting of chronic MI. The accuracy was also extremely high 
when assessing for the presence of hyperenhancement in the correct infarct related 
artery territory, as determined by coronary angiography247 (Interestingly this in itself 
has limitations as the possibility of infarction with angiographically normal coronary 
arteries exists in which CMR will determine the presence of infarction). 
Importantly, this study represented the first multicenter trial designed to evaluate an 
imaging approach for detecting infarction. Although several multicenter trials had 
previously used infarct size measurements by SPECT as a surrogate endpoint to 
assess the efficacy of an investigative therapy, these trials were not designed to 
evaluate SPECT, and limited multicenter data on the sensitivity or accuracy of 
radionuclide imaging for detecting or localizing infarction have been reported.248 With 
regard to SPECT, there is minimal data on chronic MI and NSTEMI as the majority of 
the data with SPECT comes from STEMI.249 Yet even in patients with STEMI up to 
25% of patients with clinically defined infarction appear to have no evidence of 
infarction of SPECT imaging in that SPECT appears to miss the infarct.  For example 
the EMERALD trial investigated distal embolus protection in acute MI using MIBI. 
The data showed that the inter quartile range of infarct size in the control arm was 0 - 
23%.250 The results therefore suggest that at least a quarter of patients had infarction 
missed by SPECT in that particular trial. 
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In a further multi centre trial Kim et al. showed that both LV volumes and extent of 
infarct (number of segments with evidence of scar) measured by CMR in a non-
selected (n=1561) population, demonstrated incremental prognostic value over a 
clinical model.  Survival curves showed that the extent of scar predicted outcome not 
only in all patients but also in patients with preserved ejection fraction.251  
 
Given that the presence and extent of infarction measured by CMR predicts adverse 
cardiovascular events, the ability to accurately and reproducibly measure LGE 
becomes important. A number of methods have been have been used to measure 
the amount of LGE in acute infarction as well as other cardiovascular pathologies 
that manifest focal fibrosis. The different techniques will be discussed later within this 
thesis. The techniques include; 
(i) Visual Assessment 
(ii) Planimetry  
(iii) Semi-automated methods 
(iv) Full Width Half maximum 
 
Controversy exists as to when is the most appropriate time to image and measure 
infarct size. Reimer and Jennings talk of the changing anatomic reference base of 
the evolving myocardial infarction252 and timing of infarct imaging should therefore be 
viewed under the prism of the underlying pathophysiology of infarction.248 The infarct 
zone is heterogeneous and the extent of infarction is dynamic due to oedema, 
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haemorrhage and inflammation. The infarct zone may therefore appear to extend 
without any further myocyte death. What follows is subsequent reduction in the 
extent of infarction as oedema subsides, haemorrhage is reabsorbed and dead 
myocytes are removed and replaced by scar.253 There are advantages to both 
scanning patients early after AMI and also opting to wait a number of weeks. In 
scanning patients early, one is able to assess multiple components of infarction 
including oedema, haemorrhage and MVO, which not be present at a later date. 
Leaving CMR to a later stage means that resolution of regional wall motion 
abnormalities or stunning may have resolved giving an accurate assessment of 
overall LV function. This enables assessment of patients for devices such as 
implantable cardiac defibrillators.  Assessment of IS by CMR as an inpatient soon 
after PPCI is safe and obviates the need for the patient to return at a later stage. In 
terms of clinical trials, given that measurement of CMR indices early after PPCI 
offers prognostic information, it would seem reasonable to use this data as a clinical 
endpoint.  
 
1.5.3 Area at Risk assessed by CMR 
 
CMR has been used to delineate the AAR on standard LGE imaging with: 
(i) Infarct Endocardial Surface Area (Infarct-ESA) measurement on LGE imaging 
The measurement of the lateral boundaries of the endocardial surface area of 
infarction is based on the wavefront phenomenon. The Infarct-ESA technique relies 
on two principles; 
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(a) The subendocardial lateral boundaries of the infarct are established within the 
first forty minutes of coronary occlusion. Infarction then spreads out towards the 
epicardium. 254 Subsequent increases in infarct size are dependent on the transmural 
wave-front progression of necrosis from endocardium to epicardium, modulated by 
the presence of collateral flow and time-to-reperfusion.255 Taking a short-axis stack 
through the LV both the endocardial surface area and the endocardial surface area 
of the hyperenhanced region (infarct-ESA) are traced. The infarct-ESA from all slices 
is summed and divided by the total endocardial surface area. This is expressed as a 
percentage of the LV to define the area at risk: 
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Figure 8 Illustration of the Infarct ESA technique 
 
 
Note is made of how this technique will underestimate the AAR in situations of small 
degrees of infarction. 
(b) LGE imaging by CMR can detect even very small subendocardial infarction. 
In a study of 78 patients, Versteylen et al. compared the performance of 
angiographic, electrocardiographic and CMR techniques to assess the AAR. The 
group demonstrated that CMR techniques agreed best with the physiological 
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concepts, followed by the angiographic methods, with the electrocardiographic 
scores showing the worse agreement. Between both CMR techniques, the ESA 
method demonstrated a better degree of agreement than T2-weighted imaging.256 
Unfortunately the study did not compare this technique with the current reference 
standard of SPECT. The group sensibly point out the risks inherent in using different 
techniques to quantify the infarct size and AAR. Even though measuring infarct size 
and AAR on CMR (whether with T2-weighted images or Infarct-ESA) may use 
different measurements, less variation is likely to occur when comparing one CMR 
measurement with another CMR measurement than with a non-CMR measurement.  
Two different techniques may be highly correlated but one may always be 
consistently underestimating or overestimating the other.255 
In another small study, looking at only CMR techniques, Ubachs et al. compared 
Infarct-ESA to T2-weighted imaging (used as a ‘reference standard’). The group 
demonstrated Infarct-ESA technique underestimated AAR in comparison to T2-
weighted imaging.257 The use of T2-weighted imaging as a reference standard for 
AAR assessment may be slightly premature. At the same time the fact that one 
technique may underestimate a variable does not preclude the comparator from 
overestimating the same variable. The limitations of T2-weighted imaging will be 
discussed below. The group do however point out a significant limitation of the 
infarct-ESA technique whereby it does underestimate the AAR. When ischaemic 
time is very short or in essence a STEMI is aborted, the absence of any necrosis or 
late enhancement makes it difficult to define the AAR on LGE images. The result of 
this is twofold - one will be unable to normalise groups with regards to the AAR, yet 
the calculation of myocardial salvage can proceed unimpeded. If there is no 
identifiable necrosis, then irrelevant of the size of the AAR, the amount of myocardial 
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salvage will approach 100% (MSI=1). Yet when the degree of necrosis does not 
appear to reach the lateral borders of the risk zone both the AAR and the resultant 
degree of salvage will be underestimated. 
 
(ii) Oedema imaging using T2 weighted CMR 
Oedema is a basic element of tissue response to acute injury. In this sense the 
myocardium is no different to other tissues and organs in the body, in that 
myocardial oedema occurs in reaction to many cardiovascular conditions (both acute 
and chronic) and following clinical interventions to address these disease processes.  
The term myocardial oedema refers to both fluid accumulation in the cardiac 
interstitium (vasogenic) and to myocyte swelling (cytogenic). Usually there is only a 
very small interstitial fluid component, contained within a gel of collagen, elastic 
fibres and glucosamine glycans, which drains from the subendocardium to 
subepicardium via the lymphatic system.258 Myocardial fluid balance is determined 
by fluid filtration rate out of the coronary microvascular exchange vessels into the 
cardiac interstitium and its removal rate from the interstitium via myocardial 
lymphatic vessels.259 Under normal conditions, however, the rate at which fluid 
enters the cardiac interstitium is equal to the myocardial lymph flow rate, and, thus, 
myocardial water content remains relatively constant. 
 
Experimental studies in canine and pig hearts suggest that myocardial oedema 
which develops in the AAR following a reperfused infarct can be visualised and 
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measured using a T2-weighted imaging sequence which detects oedema as an 
increased signal intensity. 
 
In 1983 Higgins et al. showed that T2 weighted nuclear magnetic imaging techniques 
were sensitive to myocardial oedema that had formed as a result of acute myocardial 
infarction in a dog.260 Signal intensity on T2-weighted images was noted to be 
increased in the infarcted segment.  The same group used a similar model but 
imaged canine hearts earlier and in-vivo demonstrating that the increased signal 
intensity was noted as early as 30 minutes following reperfusion and uniformly 
increased at three hours. The suggestion therefore was that the area of increased 
signal intensity identified not just infarcted myocardium but also the 
AAR.261,262McNamara et al. brought T2-weighted imaging in acute infarction into the 
clinical arena in a small study demonstrating similar results to earlier animal 
experiments by detecting myocardial infarction as a region of high signal intensity 
relative to that of adjacent normal myocardium.263 
The ability to detect infarcted myocardium does not necessarily imply the ability to 
detect acutely infarcted myocardium.  Yet the capability to determine acutely 
ischaemic or infarcted myocardium represents a significant step in characterising the 
metabolic condition of the myocardium beyond simple indices of regional strain or 
contractile function.264 Most imaging techniques that are used to image the 
myocardium are unable to differentiate acute from chronically infarcted tissue. 
Echocardiography and cine MRI will show a regional wall motion abnormality both in 
the acute and chronic setting. Wall thinning although mostly pathognomonic for 
chronic remodelled infarcted myocardium, will not necessarily be present in a non-
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transmural infarction. Necrotic tissue will show up as bright on late enhancement 
MRI imaging in both acute and chronic setting (although literature exists that 
suggests that the signal intensity in acutely infarcted tissue is greater than that of 
chronic infarction).  
 
A small canine study by Aletras et al. demonstrated that regional hyperintense areas 
on T2-weighted images obtained two days post infarction accurately define the AAR 
in both reperfused and non-reperfused infarctions when compared with microsphere 
area at risk measurements.265 An elegant study by Mewton et al. assessed the ‘post 
reperfusional’ AAR with two T2-weighted techniques (STIR and ACUTE2) and 
infarct-ESA against the reference pathological AAR (Uniperse blue dye) in an in vivo 
pig model of acute reperfused myocardial infarction. Arterial enhanced CT was also 
used to assess AAR prior to reperfusion. The group demonstrated that both T2-
weighted techniques and Infarct-ESA correlated well with pathology yet 
overestimated the AAR. At the same time the best correlation was obtained with pre-
reperfusion CT.266 The authors hypothesise that the overestimation in size of AAR 
compared to other studies may be an issue of timing. Abdel-Aty et al. reported that 
transmural increased signal on T2-weighted images were noted within 30 minutes 
following experimental occlusion in open-chest dogs. Increased T2 signal preceded 
necrosis (LGE or troponin release) and was augmented by reperfusion.267 Abdel-Aty 
et al. studied 73 patients with acute or chronic infarction and found that T2-weighted 
imaging had a high specificity (96%) to distinguish one from the other.268 The finding 
of a transmural area of oedema that was larger than the actual area of infarction 
helped reawaken interest in the use of T2-weighted imaging to delineate the AAR.  
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A number of studies have since attempted to validate the use of T2-weighted 
oedema imaging for measuring the area at risk in humans. These are listed below: 
Study Author N Day Sequence Comparator 
Oritz-Perez255 83  N/A BARI vs Infarct ESA   (r = 0.90, p<0.001) 
APPROACH vs Infarct ESA  
                                    (r = 0.87, p<0.001) 
Wright209 108  STIR  
(8mm) 
BARI vs Infarct ESA   (r = 0.42, p<0.001) 
Infarct ESA vs T2W    (r = 0.77, p<0.001) 
Carlson269  16 7 STIR 
(8-10mm) 
SPECT vs T2W           (r = 0.70, p<0.001) 
Sörensson260 16 7 CE SSFP 
cines 
(8mm) 
SPECT vs T2W           (r = 0.78, p<0.001) 
Hadamitzky 261 207 4 TSE 
(8mm) 
SPECT vs T2W          (r = 0.80, p<0.0001) 
Ubachs248 37 4 TSE 
(8-10mm) 
Infarct ESA vs T2W     (r = 0.17, p=0.002) 
Berry270 50 4 T2-SSFP 
(6mm) 
APPROACH               (r = 0.74, p<0.0001) 
DUKE                         (r = 0.54, p=0.0001) 
Payne271 54 2 STIR 
ACUTE2 
APPROACH vs STIR (r = 0.44, p<0.01) 
APPROACH vs ACUTE2 
                                   (r = 0.68, p<0.01) 
Fuernau271 197 3 STIR 
(N/A) 
APPROACH               (r = 0.87, p<0.001) 
Infarct ESA vs T2W   (r = 0.56, p<0.001) 
APPROACH vs Infarct ESA                                      
                                   (r = 0.44, p<0.001) 
Lønborg272 91 2 STIR 
(8-15mm) 
T2W vs T2W 
(TE 65msec; slice thickness 15 mm vs 
TE 100 msec; slice thickness 8 mm) 
Moral273 75 4 STIR  
(8mm) 
APPROACH                (r = 0.69, p<0.001) 
BARI                            (r = 0.72, p<0.001) 
Infarct ESA vs T2W     (r = 0.87, p<0.001) 
APPROACH vs BARI  (r=0.91,  p<0.001) 
BARI vs Infarct ESA    (r=0.70,  p<0.001) 
APPROACH vs Infarct ESA 
                                     (r = 0.72, p<0.001) 
Table 3 Table showing studies attempting to validate the use of T2-weighted oedema imaging 
for measuring the area at risk in humans 
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Figure 9 CMR Long axis images of a study patient two days post PPCI 
 
Image 1 is an IR sequence demonstrating a long segment of subendocardial LGE. 
Image 2 is a T2-weighted (TIRM) sequence demonstrating increased signal 
(myocardial oedema) throughout the anterior wall. Images are consistent with 
significant myocardial salvage. 
 
 
Figure 10 CMR Long axis images of a study patient three days post PPCI 
 
Image 1 is an IR sequence demonstrating extensive/transmural anterior LGE with 
the presence of MVO. Image 2 is a T2-weighted sequence showing as in the 
previous patient in the figure above increased signal (myocardial oedema) 
throughout the anterior wall. There is however no evidence of myocardial salvage. 
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Carlsson et al. showed in a small series that the AAR measured by T2-weighted 
imaging correlated well with SPECT. The group also showed that the AAR when 
measured by CMR was similar between day one and day seven with the area of 
oedema disappearing by six weeks.269 The study limitations include its small sample 
size and the fact that the scans were done across two different platforms (Siemens 
and Philips) with varying sequences. Another small study by Sörensson et al. 
achieved similar results using a different T2-weighted (post-contrast) sequence. The 
CMR studies were again performed across two different CMR platforms (GE and 
Philips) yet enrolment was limited to patients with TIMI 0 flow on initial 
angiography.274 A study by Hadamitzky et al., although showing a good correlation 
between SPECT and T2-weighted CMR for AAR assessment is hampered by a 
number of limitations.275 Over 50% of patients included in the trial had TIMI flow ≥ 1 
meaning that SPECT will likely underestimate the AAR given that  99Tc-sestamibi 
may escape into the ischaemic bed. Despite the overall good correlation between 
CMR and SPECT, the authors note substantial differences in individual cases. These 
include (i) patients in whom the calculated infarct size was larger than the AAR for 
both modalities and (ii) patients with a short ischaemic time demonstrating a signal 
intensity too low to be completely detected automatically. It is also important to note 
that over 10% of patients were excluded due to poor image quality on T2-weighted 
images. Bland-Altman plots for this study showed wide limits of agreement for 
measurement of AAR (as well as scar, and salvage area) suggesting that these 
modalities should not be used interchangeably on serial testing.276  
In summary studies that have attempted to validate the use of T2-weighted imaging 
for the assessment of the myocardium of risk are varied and suffer from a number of 
limitations including; 
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(i) Sample sizes are often small 
(ii) Patients scanned on multiple platforms within single studies 
(iii) No inter-study reproducibility data 
(iv) Variation exists in the time from reperfusion to CMR imaging 
(v) Failure to compare risk zones to reference standard 
(vi) No consensus exists on the most suitable T2-weighted sequence (or 
parameters) to use with multiple sequences being harnessed within a single study. 
(vii) No consensus on most appropriate threshold to define abnormal (oedematous) 
myocardium. By using a lower threshold for quantifying oedema, one increases the 
likelihood that the measured AAR will be substantially larger than infarct size simply 
from partial volume arguments.277 
 
Aside from the lack of consensus on the use of T2-weighted sequences, controversy 
exists as to whether the T2-weighted imaging can be appropriately used to measure 
the AAR. These concerns include; 
(a) T2-weighted imaging delineates the area of infarction rather than the AAR - A 
number of small pre-clinical studies have suggested that T2-weighted imaging 
highlights the area of acute infarction as opposed the area at risk.278,279,280  
(b) Delineation of reversible vs. irreversible myocardial injury - In theory T2-weighted 
imaging will delineate the AAR including the area of infarction but will not be able to 
Page 101 of 261 
 
delineate between the two. Croisille et al. point to the dramatic changes in the 
myocardium of patients with irreversible injury vs. irreversible injury. This includes 
significant differences in wall thickness, electrolytes, ultrastructural changes and in 
total water content (88% vs 0-10%). The significant difference in total water content 
between reversibly injured myocardium and irreversibly injured myocardium, lead 
Croisille et al. to question the oft cited finding of transmural increase in signal 
intensity.281 
(c) The effect of cardioprotective strategies on myocardial oedema - the greatest 
challenge over the use of T2-weighted CMR to assess the AAR is the suggestion 
that a cardioprotective strategy may be able to reduce the amount of myocardial 
oedema and hence reduce the measured AAR as delineated by the oedematous 
region. The underlying principle of the AAR is that it is a fixed amount of myocardium 
subtended by a particular artery that would not be affected by any particular 
intervention. As mentioned earlier, Zhao et al. demonstrated in a canine model that 
both pre- and post-conditioning protocols were able to significantly reduce the 
percentage of tissue oedema (as assessed by the ex vivo measurement of water 
content in a tissue sample of the area at risk).40 Thuny et al. were also able to show 
in humans that ischaemic post-conditioning reduces the extent myocardial oedema 
(as assessed by T2 weighted imaging - STIR, slice thickness 7mm) in STEMI 
patients undergoing PPCI.282  
Studies using T2-weighted imaging have been hampered by technical difficulties. 
Dark-blood methods are subject to artefacts such as posterior wall signal loss due to 
cardiac motion, and bright subendocardial rims due to stagnant blood.283 Sequences 
and image quality are also limited by arrhythmias and difficulty breath holding. Newer 
sequences such as the T2-prepared SSFP bright blood approach,283 ACUT2E TSE-
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SSFP  (a hybrid between steady state free precession (SSFP) and turbo spin echo 
(TSE) for bright-blood T2-weighted imaging)284 go someway towards addressing 
these issues with a higher diagnostic accuracy than dark-blood T2-weighted MRI.285 
T2-mapping offers a quantitative approach increased accuracy in the detection of 
myocardial oedema whilst at the same time addressing the technical issues of 
previous sequences. 
T2-weighted imaging clearly advances our understanding of the complex 
pathophysiology of AMI, yet is associated with many unanswered questions. The use 
of these sequences in the assessment of the AAR needs to be undertaken with 
caution. Such a caveat should not limit research into the attenuation of (and hence 
imaging of) myocardial oedema as a modifiable component of reperfusion injury. 
Newer techniques such as T2 mapping offer advantages over standard T2 weighted 
images both in terms of their diagnostic accuracy but also in the ability of the 
technique to quantify the T2 signal of the myocardium.286 T1 mapping techniques are 
also being utilised to image myocardial oedema.287 
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1.5.4 Microvascular Obstruction (MVO) assessed by CMR 
 
Anatomic no-reflow was first recognised in a canine model of reperfused myocardial 
infarction and was described as the failure to restore normal myocardial blood flow 
despite the removal of the coronary obstruction.20 Therefore restoration of coronary 
flow by PPCI to remove the epicardial obstruction does not guarantee adequate 
perfusion at a myocardial level. Given that the presence of MVO is associated with a 
larger infarct size, impaired (LV) ejection fraction, adverse LV remodelling and 
poorer clinical outcomes, the ability to identify MVO is crucial. CMR is currently the 
best technique to identify microvascular obstruction.  João et al. demonstrated the 
ability of CMR to identify MVO in humans and described how large infarcts, 
associated with prolonged obstruction of the infarct-related artery, were 
characterised by central dark zones surrounded by hyperenhanced regions.288 
Microsphere blood flow in areas of hypoenhancement, following reperfused 
infarction, are significantly reduced (>50%) when compared with myocardium remote 
from infarcted tissue.289 This helps explain the regional differences in signal intensity 
within infarcted tissue (hypo- and hyperenhancement) which are secondary to 
impaired wash-in (secondary to impaired perfusion) and wash-out kinetics of Gd-
DTPA.  Slow wash-in of gadolinium in reperfused, infarcted regions leads to early, 
low tissue contrast concentrations, whereas slow washout eventually leads to higher 
contrast concentrations compared with normal tissue.290  Gadolinium is not a pure 
intravascular agent and extravasates into the interstitium within minutes following 
administration, it will gradually diffuse into the initially hypoenhanced zone. 
Therefore, the size of MVO will decrease over time from contrast administration. 
Given that MVO is often imaged using three different techniques (post-contrast), the 
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earliest technique used will demonstrate a larger area of MVO than the last 
technique used in a particular study which may underestimate the extent of MVO.291  
 
MVO can be imaged by a number of techniques using CMR. These include: 
 
1.  Gadolinium enhanced first-pass myocardial perfusion tracks the first minute of 
gadolinium arrival and distribution within the myocardium. This sequence should be 
the most sensitive technique for detecting MVO292,293 as it allows less time (than the 
other later imaged sequences) for diffusion of gadolinium to artefactually diminish 
MVO volume. The sequence does however afford only half the spatial resolution of 
the inversion recovery sequences and typically only covers three slices of the 
myocardium.294  
 
2. Late gadolinium enhancement imaging (LGE). As with standard LGE imaging, 
pictures are taken 10 - 15 minutes following administration of contrast using 
inversion recovery sequences. LGE technique offers information on a more 
equilibrated distribution of the contrast agent in the infarct area with high-resolution 
images but is limited by a longer examination time because it requires at least 10 
minutes after contrast agent injection to obtain equilibration. Multiple breath holds to 
fully cover the LV.293 Signal intensity in the area of hypoenhancement rises slowly in 
the first 5 to 10 minutes after contrast injection. The extent of hypoenhancement may 
vary with the time after injection, as it is unlikely that the degree of microvascular 
damage is identical throughout the entire infarct. Some areas may have only mild 
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damage and allow slow contrast wash-in by diffusion from surrounding regions with 
intact microcirculation. Other areas may have extensive microvascular damage, 
resulting in persistent hypoenhancement.295 In essence areas of MVO may be 
missed at differing times following contrast agent administration when using LGE 
imaging techniques are used to identify it. 
 
Figure 11  Figure showing Temporal changes in signal intensity after 0.2 mmol/kg gadolinium-
DTPA administered intravenously 
 
Temporal changes in signal intensity after 0.2 mmol/kg gadolinium-DTPA administered intravenously 
in the same patient as Figure 2. Magnified view of three-chamber view at 2 min (A), 15 min (B), and 
30 min (C). 
Reproduced with permission from: Beek et al. Delayed contrast-enhanced magnetic resonance 
imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am 
Coll Cardiol. 2003;42(5):895-901. doi:10.1016/S0735-1097(03)00835-0 
 
3. Early gadolinium enhancement imaging (EGE) Imaging within the few minutes 
after contrast injection and using similar inversion recovery sequences as for LGE 
imaging but with a fixed and long inversion time. Advantages include complete 
ventricular coverage, optimal signal-to-noise (SNR) and spatial resolution which 
combined may overcome the shortcomings mentioned above.296 Full coverage of the 
left ventricle means that EGE images can then be compared to late enhancement 
images.  
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Figure 12 Figure of a study patient showing two chamber images showing the different 
techniques available to image MVO and haemorrhage 
 
1.Two chamber Cine for reference, 2. T2 Gradient Echo 3. T2-weighted (TIRM) with increased signal 
in the inferior wall with an area of signal void in the subendocardium. 4. FFP, 5. EGE with fixed T1 
440 and 6. LGE 
 
As mentioned above the presence of MVO appears to be an independent predictor 
of major adverse cardiovascular events. It should be taken into account that for the 
studies investigating the relationship between MVO and clinical outcomes, significant 
variability exists between how the MVO is imaged and at what time point following 
infarction that the imaging takes place. 
 
Wu et al.297 demonstrated that the presence of MVO as assessed by gadolinium 
enhanced first-pass myocardial perfusion imaging at one minute post contrast was 
strongly correlated with increased major adverse cardiovascular events when 
compared to patients without MVO. The group also demonstrated the relationship 
between infarct size measured by CMR and the risk of adverse cardiac events post 
Page 107 of 261 
 
infarction - patients with larger infarcts having worse outcomes. Although the 
presence of MVO is related to larger areas of late enhancement, MVO is a strong 
(independent) predictor of adverse cardiovascular events, even after the extent of 
total myocardial damage is controlled for.297 The study by Wu et al. also cast doubt 
on the ability of LV indices (LV volumes, mass and ejection fraction) to predict 
outcome post infarction and at the same time highlighting the merits of methods that 
directly assess myocardial injury. The poor predictive value of ejection fraction 
following AMI has been attributed to a number of factors including; 
 
1. Myocardial stunning following AMI can lead to an initial underestimation of LVEF. 
Restoration of function cannot be expected to occur immediately when reperfusion or 
other protective interventions are applied after several hours of severe myocardial 
ischaemia. Therefore, evaluation of cardiac performance several hours or even days 
after relief of ischaemia will not provide an adequate assessment of eventual 
function.298 
 
2.  Hyperkinesis of remote non-infarcted myocardium may be present in the first 
hours after MI.299 This may in turn normalise the measured global ejection fraction 
despite dysfunction within the infarcted zone. This hyperkinesis of the remote 
myocardium will likely subside leading to a deterioration in the ejection fraction when 
measured at a later date possibly despite an improvement in function of the infarcted 
segment. 300 
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3. The ability of ejection fraction to accurately reflect the extent of myocardial 
damage early after acute infarction is limited by its dependence on global pre- and 
afterload conditions.169 
 
One potential mechanisms for the negative effect of the presence of MVO on 
outcomes is the adverse effect on LV remodeling 
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Summary of CMR studies which that have assessed the functional and clinical 
outcome of the presence of MVO 
Study Author, 
Journal 
Number 
(n) 
MVO 
assessment Quantification 
Time point 
post-MI Findings 
Functional outcome and LV remodelling 
Wu291 
 
44 EGE Present/absent 
4–16 days 
MVO predicted 
LV remodelling 16 months 
Hombach301 110 LGE Present/absent 
6–8 days 
 
Late MVO 
(PMO) and 
infarct size 
predicted LV 
remodelling 
7.5 months 
Nijveldt36 60 
FPP 
Present/absent 
2–9 days Late MVO 
strongest 
predictor of LV 
remodeling 
LGE 4 months 
Orn302 42 FPP Present/absent 
2 days 
MVO 
detectable at 
1 week 
predicted LV 
remodeling 
1 week  
2 months 
1 year 
Weir303 
 
100 
FPP 
Present/absent 
4 days Late MVO 
better 
predicted 
remodeling at 
6 months 
EGE 12 weeks 
LGE 24 weeks 
Wong304 
 
40 
FPP 
Present/absent 
3 days Late MVO 
strongest 
predictor of LV 
ejection 
fraction at 
90 days 
LGE 90 days 
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Clinical Outcome 
Wu291 44 EGE Present/absent 4–16 days 
MVO predicted 
MACE at 
16 months, 
independent of 
infarct size 
Hombach301 
 
110 LGE Present/absent 6–8 days 
MVO predicted 
MACE at 
7.5 months, 
independent of 
LVEF, LVEDV, 
or infarct size 
Bruder305 
 
67 
EGE (by 
SS SSFP-
IR) 
Quantified 5 days 
MVO >0.5 % 
independently 
predicted 
MACE at 
1 year 
Cochet306 184 
FPP  
Present/absent 3–7 days 
Late MVO 
predicted 
MACE at 
1 year 
LGE 
De Waha307 438 
EGE  
Quantified 3 days 
Presence and 
extent of late 
MVO are 
independent 
prognosticators 
and better 
predicted 
MACE at 
19 months 
LGE 
Note: FPP: first pass perfusion; EGE: early gadolinium enhancement technique; LGE: 
late gadolinium enhancement technique; MVO: microvascular obstruction; MACE: major 
adverse cardiovascular events; LVEDV: left ventricular end-diastolic volume. 
Late MVO describes MVO detectable by the LGE technique at a minimum of 10 mins 
post-gadolinium administration, and can be otherwise described as persistent MVO or 
‘PMO’ 
Table 4 Table showing the summary of CMR studies which have assessed the functional and 
clinical outcome of the presence of MVO 
Adapted from Wu, K.: ‘Functional and clinical impact of microvascular obstruction in 
acute MI’. Presented at the SCMR Scientific Sessions. Nice, France; 2011. 
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Further studies have confirmed that the presence of MVO, as assessed by CMR is a 
key determinant in prognosis following AMI. A large study on the impact of MVO on 
long term outcomes after STEMI followed up 438 patients over a median of nine 
months. de Waha et al. demonstrated that MVO on LGE (as opposed to EGE) MVO 
was independently associated with mortality and the occurrence of the combination 
of death, myocardial re-infarction, and congestive heart failure. The extent of MVO 
measured on LGE images showed a graded relationship with the occurrence of this 
composite endpoint and presence and extent of late MO provided an incremental 
prognostic value above the traditional prognostic markers.307 The same group went 
on to demonstrate that the analysis of a ratio of MVO to infarct size adds incremental 
prognostic value. The ratio was determined to be an even stronger predictor for long-
term prognosis after STEMI than either MVO or infarct size alone.308 Similar studies 
extended follow up out to five years (median 52 months) but with a much smaller 
sample size suggested that the ratio of infarct size to MVO measured on first pass 
(as opposed to LGE measured by de Waha’s group) imaging added superior 
prognostic value compared to the extent of MVO alone.309 Malek et al. in a small 
study postulated that the presence of MVO but not its extent corresponded to larger 
infarct size in STEMI. Disappointingly the method used to quantify the amount of 
MVO was an arbitrary allocation of ‘small’ or ‘large’.310  
 
Given its adverse effect on outcome, it is reasonable to try and direct 
cardioprotective strategies towards the treatment/prevention of MVO.  If we can 
attenuate MVO, or this form of reperfusion injury, then we can expect to improve 
clinical outcomes in our patients.  Treating MVO may allow better healing, less 
adverse ventricular remodeling, continued downstream access to drug levels and 
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allow for better collateral flow.311 Currently there is no effective therapy for doing this. 
Numerous pharmacological agents have been tried including adenosine, nitrates, 
calcium channel blockers and all of them may improve some of the perfusion indices 
but have not been shown to actually improve clinical outcomes. 
 
Clearly the presence of MVO pertains to a worse outcome in patients following 
STEMI being a marker of severe microvascular destruction. The presence of MVO 
has been shown to have incremental prognostic value above traditional prognostic 
markers including cardiac biomarkers and LV function. It is a promising marker to 
help evaluate new strategies to reduce reperfusion injury.312 Historically, clinical trials 
have used less sensitive surrogates for identifying MVO including ECG, angiographic 
measures and MCE. MVO may be missed unless more precise assessments (using 
CMR) are employed in clinical trials of cardioprotective agents in AMI. There are 
currently few human clinical trials in cardioprotection that have employed MVO, as 
assessed by CMR, as an endpoint, but they are beginning to increase in number.313 
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Study N Intervention MVO 
Assessment 
Quantification Time 
Point 
Post 
MI  
days 
Conclusion 
Thiele314 154  IV vs. IC 
Abciximab  
EGE  
LGE 
Quantified 
%LV Mass 
2 IC reduced 
IS and 
MVO 
Atar315 234 FX06 LGE Quantified 
%LV Mass 
5 Reduced 
necrotic 
core zone 
Ludman316 51 Erythropoietin EGE or  
LGE 
Presence or 
Absence 
2 Increased  
incidence 
MVO 
Zia317 60 Thrombectomy LGE Quantified 
%LV Mass 
2 Reduction 
in degree  
MVO 
Prunier 318 110 Erythropoietin LGE Presence or 
Absence 
5 Reduced 
incidence  
MVO 
Wöhrle319 51 Bivalirudin vs 
unfractionated 
heparin plus 
abciximab 
LGE Quantified 2 No 
difference 
in MVO 
Desmet320 112 Adenosine LGE Quantified 2-3 No 
difference 
in MVO 
Table 5 Table showing clinical studies that have assessed MVO as a secondary endpoint  
 
Further validation and prognostic studies would help deﬁne the role of MVO in future 
CMR endpoint clinical trials and help answer the numerous unresolved including (i) 
at which time point post STEMI is best to image for MVO, (ii) which CMR sequence 
(and hence what time point post contrast administration) provides the primary 
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prognostic information and (iii) does the amount/extent of MVO impact on prognosis 
or is the poor prognostication derived solely from it’s presence irrelevant of size.  
 
1.5.5 Intramyocardial Haemorrhage assessed by CMR 
 
Intramyocardial haemorrhage (IMH) is by no means a new concept in the setting of 
acute myocardial infarction. Haemorrhagic infarction has been demonstrated both in 
infarcts treated by mechanical and pharmacological therapy (with the extent of the 
haemorrhage not increased by the lytic state).321  However, IMH occurs frequently in 
a reperfused infarct but only rarely in the case of a non-reperfused infarction.322 
Passoti et al. describe haemorrhagic infarction as a reperfusion-associated 
pathology in that it was rarely documented in the pre-reperfusion era, but its reported 
incidence markedly increased after the start of the thrombolytic era and it continues 
to be seen with mechanical intervention.323   
Previously IMH could only be identified in-vitro in experimental studies or post 
mortem. CMR has allowed for the in-vivo identification of IMH, therefore 
reawakening interest in this phenomenon. The inability to image IMH has meant that 
the clinical implications were generally unknown. The interplay between 
haemorrhage and other components of infarction (e.g. oedema, MVO etc.) also 
remains unclear. Reperfused acute infarctions have been noted macroscopically to 
have a reddish appearance. IMH is thought to be due to vascular cell damage and 
leakage of erythrocytes out of the injured vessels and into the extravascular 
space.324 IMH is imaged by CMR by the use of two different sequences: 
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(i) T2-weighted Imaging of cerebral haemorrhage over time has shown that its 
appearance on MRI depends on the age of the haemorrhage and whether T1 or T2 
weighted imaging is used. The effects of haemorrhage on T2 relaxation are complex 
and depend on the presence of blood degradation products (ferritin and 
haemosiderin), the effects of cellular compartmentalisation and the form of 
hemoglobin present.  As a hematoma ages, the haemoglobin passes through 
several forms (oxyhaemoglobin, deoxyhaemoglobin, and methaemoglobin) prior to 
red cell lysis and breakdown into ferritin and haemosiderin.325,326  Early imaging of 
haemorrhage causes a shortening of T2 consistent with the paramagnetic effects of 
deoxyhaemoglobin associated with IMH. This manifests itself as a signal void (or 
hypointense region) within an area of high signal intensity that represents 
oedema.327 In an observational study of only two patients Basso et al. showed 
excellent overlap among the location, spatial extent, and shape of the hypointense 
regions by ex vivo T2 CMR images and haemorrhage by pathologic investigation.328 
 
Early studies showed that the presence of IMH was associated with severe 
microvascular injury.329 There is however some disagreement as to the prognostic 
significance of IMH beyond that of MVO. Using T2-weighted MRI to image 
myocardial haemorrhage, a recent study by Ganame et al.  demonstrated that in the 
acute phase, the presence of IMH was associated with larger infarct size and 
transmurality, larger LV volumes and lower LV ejection fraction, and more impaired 
contractility in the infarcted and peri-infarct territory. Evidence of adverse remodelling 
was shown at four months with haemorrhagic infarcts showing pronounced increase 
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in end-diastolic and end-systolic LV volumes with lack of functional recovery (globally 
and regionally in the infarcted area), and significant wall thinning in the infarcted, 
adjacent, and remote areas.330 Beek et al. studied 45 patients with T2 weighted 
imaging and similarly found that the presence of IMH to be associated with larger 
infarcts, presence of MVO, higher left ventricular volumes and lower ejection fraction, 
and the lack of improvement at follow-up.331 Their findings differed from Ganame’s 
group in that they were unable to demonstrate that haemorrhage was an 
independent predictor of functional change at follow up and essentially showed that 
IMH had no prognostic significance beyond MVO. Bekkers et al. undertook a similar 
study and found that IMH and MVO were strongly related yet only infarct size was an 
independent predictor of LV remodelling.332 
 
As with T2-weighted imaging for oedema, studies on IMH are limited by differences 
in protocol used to investigate the phenomenon. Such alternatives in protocols may 
account for some of the differences in outcomes. The approach of Beek et al. was 
slightly atypical in that they imaged in the long axis and one short axis view at what 
is described at the core of the infarct (short axis slice noted to have the most 
significant regional wall motion abnormality on cine imaging). In all three studies, 
although MVO was observed in all patients found to have IMH, the converse was not 
shown - with IMH not occurring in the absence of MVO. Also when IMH was absent, 
the degree of MVO was noted to be significantly smaller. 
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Study N Patients 
IMH 
CMR 
Platform 
Day T2W Sequence 
(Thickness,TE) 
IMH 
without 
MVO 
Outcome 
Ganame 
330 
98 25% Philips 2 STIR 
(8mm,100ms) 
 
No IMH 
independent 
predictor 
adverse 
remodelling 
Beek311 45 49% Siemens 5 STIR 
(7mm, 64ms) 
 
No IMH related 
to infarct 
size, MVO 
and function 
Bekkers 
332 
90 43% Siemens 5 STIR 
(8mm, 100ms) 
 
No Infarct size 
independent 
predictor of 
adverse 
remodelling. 
Amabile
333 
114 11% Siemens 5 TSE 
(8mm, 52ms) 
No Independent 
predictor 
of adverse 
clinical 
events 
Eitel334 346 35% Philips 
Siemens 
3 STIR 
(8mm, 80ms) 
 
(10mm, 61ms) 
No IMH predicts 
MACE 
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Husser335 304 34% Siemens 6 STIR 
(8mm, 33ms) 
 
TSE 
(8mm, 100ms) 
Yes IMH predicts 
MACE and 
adverse 
Remodelling 
Mather294 53 33% 
 
25% 
Philips 2 STIR 
(10mm, 
100ms) 
 
 
T2* 
No IMH 
independent 
predictor 
adverse 
remodelling 
O’Regan 
326 
15 40% Philips 3 STIR 
(10mm, 
100ms) 
 
T2* 
No IMH 
indicates 
reduced 
salvage 
Table 6 List of studies assessing IMH and it's relationship to outcomes 
 
Eitel et al. demonstrated that the presence of a hypointense core within areas of 
oedema carried independent prognostic value being a strong indicator of MACE at 6 
months. The occurrence of IMH was found to be associated with the presence and 
extent of late MVO, larger infarct size and LV dysfunction.334 A similarly sized trial by 
Husser et al. suggested the presence of IMH is a small proportion of their cohort who 
displayed no MVO. The group found that although the presence of IMH was an 
independent prognosticator of adverse prognosis and remodelling, the addition of 
information from T2-weighted information did not improve predictive value beyond 
infarct size and cardiac volumes.335  
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(ii) T2* sequence is a well used and validated sequence in the clinical context to 
quantify the severity of myocardial (and hepatic) iron loading in patients with 
thalassaemia major.336 O’Regan et al. applied the T2* sequence in the setting of 
reperfused AMI to image IMH. The group also showed the possible effect of IMH on 
the AAR measured with T2-weighted imaging. At higher threshold levels, signal from 
oedema can be masked by presence of haemorrhage in infarct core leading to 
underestimation of AAR. Pedersen et al.  assessed the T1 and two T2 techniques 
(T2-STIR and T2*) for the assessment of IMH and compared them to ex-vivo 
pathological samples. The T1 weighted imaging yielded a higher sensitivity and 
specificity for IMH as well as a better agreement with pathology compared to T2-
STIR and T2* imaging. In a limited number of pigs T2 weighted imaging was either 
unable to delineate haemorrhage or demonstrated an area of hypo-enhancement on 
T2-weighted images that was not present on the corresponding pathological 
slices.337 
1.5.6 Diffuse fibrosis 
 
There is a significant structural component in the gaps between the cells. The ratio of 
cells to interstitium is important and will vary dependent on different disease 
processes. The importance of the interstitium was noted in 1854 by Claude Bernard 
when he described the “Le Milieu intérieur” or ‘the environment within’.338 This refers 
to the extracellular environment, and its physiological capacity to ensure protective 
stability for the tissues and organs of multicellular living organisms.339 In essence the 
interstitium provides the myocardium with its architectural structure. Disease 
processes lead to disruption of this architectural structure with expansion of the 
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interstitial space usually through the development of fibrosis (excessive deposition of 
extracellular matrix material in addition to myocyte degeneration leads to expansion 
of the interstitial space).340 This is strongly associated with left ventricular 
remodelling and adverse outcomes such as heart failure, arrhythmia and death.341 
The pathophysiology interstitial expansion varies with different disease process with 
different subtypes of fibrosis being described. The final common pathway is the 
formation of focal fibrosis which is usually irreversible. Diffuse (interstitial) fibrosis 
which has been described in a number of disease states (present in the aging heart, 
diabetes, systemic hypertension, in idiopathic dilated cardiomyopathy, and in left 
ventricular (LV) pressure-overload and volume-overload states induced by chronic 
aortic valve regurgitation and stenosis.) and has shown to be reversible with specific 
therapies.342 
 
Assessment and quantification of fibrosis has generally been achieved through 
endomyocardial biopsy. Biopsy constitutes an invasive procedure with a low but 
definite risk of complications and is prone to sampling error especially in the setting 
of diseases with patchy myocardial involvement.343 
 
Figure 13 Three Dimensional remodelling of Cardiomyocytes in a patient with Aortic Stenosis 
From Kanzaki, Y., et al., Three-Dimensional Remodeling of Cardiomyocytes in a Patient With Aortic 
Stenosis: Scanning Electron Microscopy. Circulation, 2009. 119(2): p. e10-e10. 
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Gaps between the cells are imaged using CMR with contrast agents. Late 
gadolinium enhancement imaging enables us to image the gaps between cells. We 
are therefore able to identify focal fibrosis using inversion recovery (IR) sequences 
following a bolus of contrast. The IR technique results in a high sensitivity to regional 
T1 variation but sacrifices absolute quantification meaning that differing degrees of 
focal interstitial expansion will look the same (bright).344 The LGE technique cannot 
be used to visualize diffuse fibrosis because “normal” myocardium with diffuse 
fibrosis is “nulled” to highlight focal scar, thereby losing all information of any 
background interstitial expansion.345 Newer CMR imaging techniques, where a 
primed contrast infusion is used to eliminate contrast kinetic effects offer the ability to 
non-invasively measure the myocardial extracellular volume.346 T1 mapping 
measures myocardial longitudinal magnetic relaxation. Measurements can be 
performed before and after contrast administration. Chelated gadolinium contrast 
distributes between cells embedded in the interstitium between cells (extracellular 
space) and blood plasma such that the relative pre- and post-contrast signal 
changes measure the myocardial extracellular volume fraction (ECV).347 These 
techniques have been shown to correlate with histological techniques. Such changes 
in the extracellular volume (as measured by the volume of distribution of gadolinium) 
have shown to with markers of disease severity.  
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1.6 AIMS AND OBJECTIVES 
 
In this thesis we have investigated the role of CMR in STEMI patients treated by 
PPCI. Specifically, we have investigated its role in assessing the cardioprotective 
efficacy of remote ischaemic preconditioning in this patient group. 
 
1.6.1 Hypothesis 
 
Cardiac MRI can be used to assess whether Remote Ischaemic Perconditioning has 
any beneficial effect in patients undergoing PPCI for STEMI. 
 
1. To determine the most reliable and robust CMR method for quantifying 
myocardial infarction in STEMI patients undergoing PPCI (chapter 3). 
2. To investigate the beneficial effects of remote ischaemic preconditioning in 
STEMI patients undergoing PPCI as assessed by CMR (chapter 4) 
3. To investigate the use of CMR for tissue characterising the myocardial 
infarction in terms of myocardial oedema, diffuse interstitial volume, and intra-
myocardial haemorrhage (chapter 5)   
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2 Methods 
 
2.1 Overview 
 
We conducted a two centre, open label randomised control study to assess the 
effect of remote ischaemic perconditioning induced by transient upper limb 
ischaemia on myocardial injury in consecutive patients presenting with STEMI who 
subsequently underwent PPCI. 
 
2.2 Ethical Approval and Informed Consent. 
 
The protocol for this study was written in accordance with the International 
Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidance, and the 
study was subject to approval by the joint University College London 
(UCL)/University College London Hospitals (UCLH) committees for the ethics of 
human research. Approval for the study was sought on the standard application form 
initially provided by the NHS COREC (Central office for the Research Ethics 
Committees), and subsequently integrated with the National Research Ethics 
Service (NRES), affiliated to the National Patient Safety Agency (NPSA). In addition 
to the study protocol, the patient information sheet, consent form, and a letter to the 
patient’s general practitioner, were also approved by the ethical committee. 
  
Once ethical approval was obtained, a separate application was made to the 
research and development (R&D) department UCLH, who also acted as sponsors of 
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the study. Any amendments to the protocol were classed as major or minor, as per 
advice from the ethical committee. I made the amendments and submitted the 
documents, annotated with appropriate dates and version numbers for approval for 
each amendment. 
  
Any serious adverse event or reaction during the course of the study had to be 
reported to the R&D department as per guidelines. No serious adverse events or 
reactions occurred during the course of the study. 
  
  
2.3 Patient Selection 
 
Patients admitted to either of the two centres with a STEMI and a plan to undergo 
PPCI were approached with regard to taking part in the study. An abbreviated form 
of written consent was taken from the patient. The patient was then revisited 
following PPCI and full informed consent was taken. 
  
2.3.1 Inclusion Criteria 
 
Patients were included if they were aged over 18 years and presented to one of the 
two centres within 12 hours of onset of symptoms, fulfilled ECG criteria for STEMI 
(>2mm ST-elevation in chest leads, >1mm ST elevation in contiguous limb leads or 
new onset left bundle branch block) with a plan to undergo PPCI. Other inclusion 
criteria were the finding of a single vessel culprit lesion, Thrombolysis in Myocardial 
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Infarction (TIMI) grade of 0-1 and Rentrop collateral grade of 0 on coronary 
angiography. 
 
2.3.2 Exclusion Criteria 
 
Exclusion criteria included abnormal renal function (eGFR <35 ml/min/1.73m2), 
known thromboembolic disease, peripheral vascular disease affecting the upper 
limbs, malignancy, multi-vessel coronary artery disease, cardiogenic shock and 
cardiac arrest. Patients who were claustrophobic or had metal implants which meant 
they could not enter an MRI scanner were excluded from the CMR scan. Patients 
with pre-infarct angina or known to be taking pre-conditioning mimetics were also 
excluded. 
 
2.3.3 Randomisation 
 
Patients were randomised to either the control group or the Remote ischaemic 
Perconditioniing (RIPerC) group, using electronic randomisation methods of random 
sequence generation for the two treatments. A simple randomisation method was 
used to allocate patients to receive either RIPerC or a placebo. 
(http://www.random.org/sequences/) 
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2.4 Remote ischaemic Perconditioning (RIPerC) 
 
2.4.1 Control group   
 
These patients had an un-inflated blood pressure cuff placed on the arm for 20 
minutes prior to myocardial reperfusion. 
 
2.4.2 RIPerC group  
 
RIPerC was induced by transient upper limb ischaemia using a standard 9 inch 
blood pressure cuff. Patients received 2 cycles of 5 minutes of upper limb ischaemia 
(with the cuff inflated to 200 mmHg), separated by 5 minutes of reperfusion between 
each cuff inflation prior to myocardial reperfusion. A similar protocol of three cycles 
was first used by Kharbanda et al.,123 to induce RIPC and was shown to protect 
against endothelial IRI of an opposite limb in normal human volunteers. 
 
 2.5 Primary Percutaneous Coronary Intervention (PPCI) 
 
Patients were taken directly for PPCI. The procedure was carried out according to 
the interventional consultants preference with no restriction placed on vascular 
access site, choice of stent or method of stenting (Direct/Predilatation/Post 
dilatation). Any patients who following angiography did not undergo primary 
angioplasty were excluded from continuation in the study. Patients who underwent 
intervention to a non-culprit vessel (following angioplasty to the culprit artery) were 
also excluded. The use of medication including glycoprotein IIb/IIIa inhibitors was 
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also left to the interventional consultant’s discretion but patients receiving 
thrombolytics or adenosine were excluded. 
 
2. 6 Study Endpoints 
 
2.5.1 Blood Tests 
Blood samples were taken for TnT, CK-MB and CK levels at the time of arterial 
sheath insertion (0 hour), and at 6 hours, 12 hours, and 24 hours post PCI 
procedure. Full blood count, renal function and glucose levels were also checked at 
baseline. 
 
In both recruiting Centres, TnT was measured quantitatively by a one-step enzyme 
immunoassay based on electrochemiluminescence technology (Elecsys 2010; 
Roche). The Elecsys troponin T assay consists of two monoclonal antibodies 
specifically directed against human cardiac troponin T, and detects free cardiac 
troponin T, as well as its binary and ternary complexes. The lower detection limit of 
troponin T concentration that can be distinguished from zero is 0.01 µg/l, and the 
lowest troponin T concentration that meets a 10% coefficient of variation requirement 
is 0.03 µg/l.348,349,350  
 
CK-MB mass assay in both the recruitment centres were measured using Elecsys 
2010 CKMB STAT assay (Roche Diagnostics). The Elecsys CK-MB STAT assay351 
employs two different monoclonal antibodies directed against human CK-MB. 
Increased CKMB value is deﬁned as a measurement above the 99th percentile URL, 
which is designated as the decision level for the diagnosis of MI. Sex-speciﬁc values 
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should be employed are recommended to be used in clinical practice.13 The lower 
detection limit of this assay is 0.1µg/L with the 99th percentile limit varying between 
3.7-6.7µg/L dependent on gender.352,353 
 
2.5.2 Cardiac MRI 
 
Cardiac MRI was carried out prior to discharge. Patients were scanned on one of two 
1.5 Tesla Siemens AVANTO scanner (Erlangen, Germany) either at The Heart 
Hospital or Great Ormond Street Hospitals, London, UK. Patients were transferred 
using a critical ambulance and medical escort. Prospective ECG gating was using 
along with standard imaging acquisition.354 Free breathing pilot scout images were 
obtained in three orthogonal planes - transaxial, coronal and sagittal - to align the 
true long axis of the left ventricle. Typical imaging parameters were as follows: 
repeat time (TR) = 3.39ms, echo time (TE) 1.7ms, slice thickness, 5mm, field of view 
360 x 360mm, read matrix 256, flip angle 60º.  
 
To enable analysis of cardiac volumes, SSFP cine images were obtained with breath 
holding at end expiration. A perpendicular two chamber pilot view (Horizontal long 
axis/HLA) was obtained through a perpendicular plane passing through the apex and 
centre of the mitral valve. Four perpendicular short axis pilot views were then 
acquired either side of the atrioventricular groove. The four chamber SSFP cine was 
obtained from the four short axis pilot views by cutting through the centre of the left 
ventricle below the aorta. Using the two chamber pilot view and the four chamber 
cine, a two chamber long axis SSFP cine is obtained. Left ventricular short axis 
SSFP cines were obtained using the two and four chamber cines. Initial 
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perpendicular short-axis slice is placed on the atrioventricular groove through the 
back of the left and right ventricles.354,355 A short axis stack of slices from the 
atrioventricular ring to apex was then acquired with a slice thickness of 7mm and a 
3mm gap between each slice. The number of cardiac phases per acquisition was 80-
90% of the RR interval divided by the temporal resolution (typically 48ms) with 8 to 
12 slices to cover the whole LV. Typical FISP imaging parameters were TE 1.6ms, 
TR 3.2 ms, in plane pixel size 2.3 x 1.4mm, slice thickness 7mm, flip angle 60º, 
acquired in 12 heart beats, with 15 to 20 phases. Parameters were optimised to take 
into consideration arrhythmias and inability of the patient to hold their breath. 
 
 
 
Figure 14 Schematic to demonstrate Piloting and Acquisition of a Short Axis Stack through the 
Myocardium 
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The ventricular volume is the sum of the endocardial areas multiplied by the 
interslice distance, and ventricular mass is the area occupied between the 
endocardial and epicardial border multiplied by the interslice distance.189 Analysis of 
cardiac volumes was performed on a personal computer using the software package 
CMRtools (Imperial College©) and the plug-in LV tools (an automatic algorithm that 
allows for user-independent myocardial border delineation). First the short axis stack 
and two long axis perpendicular slices that pass through the centre of the mitral 
valve (four chamber and two chamber) are selected along with the short axis stack. 
The apex is then manually selected and the axis of the LV manually adjusted so that 
slices are aligned correctly. The endocardial and epicardial borders are semi 
automatically segmented in both systole and diastole and a thresholding tool is used 
to differentiate blood pool from myocardium (to include papillary muscle) enabling 
the calculation of the LV mass. The long axis images are then used to identify the 
position and orientation of the mitral valve leaflets at end-diastole and end-systole to 
exclude regions that belong to the left atrium. The stroke volume (SV) is calculated 
from the difference between the end diastolic volume (EDV) and the end systolic 
volume (ESV). 
Stroke Volume (SV) = EDV – ESV 
 
The ejection fraction can then also be calculated using the following equation: 
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The calculation of LV mass can be calculated manually, after planimetry of the 
epicardial and endocardial borders in end-diastole, by a summation of the discs 
technique and multiplying the myocardial muscle volume by the density of 
myocardial tissue (1.05 g/cm3).356 
 
0.1mmol/kg Gadoteric acid/gadolinium (Dotarem®; Guerbet SA, Paris, France) was 
administered via an antecubital vein followed by a 20ml of saline. Early gadolinium 
enhancement images were obtained early after administration gadolinium (1-2 
minutes) with coverage of the left ventricle in the short axis with slices matching 
those of the original SSFP short axis stack with no interslice gap. A fixed inversion 
time (TI) of 440ms was used. Other imaging parameters were TR 7.0ms, TE 4.9ms, 
flip-angle 23°. 
 
Late gadolinium images were taken ten minutes following administration of contrast. 
Standard breath-hold, segmented inversion recovery gradient echo sequences were 
used with image parameters : slice thickness 8 mm, TR 9.8 ms, TE 4.6ms, Flip angle 
21º, field of view 340 x 220 mm (transverse plane), sampled matrix size 256 x 115-
135, 21 k–space lines acquired every other RR interval (21 segments with linear 
reordered phase encoding), spatial resolution 1.3 x 2.1 x 8 mm, no parallel imaging. 
Images were obtained in the same planes as SSFP cine images. The inversion time 
was adjusted to null the myocardium. To avoid cerebrospinal fluid (CSF - normal 
CSF has long T1 and long T2 times that manifest as dark signal on T1-weighted 
images and bright signal on T2-weighted images.)357 Ghosting a presaturation band 
was placed over the CSF. In the event of arrhythmias or the patient having difficulty 
with breath holding, sequences were optimised to obtain the best images including 
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the use of prospective gating or single shot multi-slice non breath hold imaging 
respectively.358  
 
The extent of infarction/infarct size was then calculated. In order to determine the 
optimal method to quantify infarction using LGE images a study was carried out 
comparing the different techniques described to assess infarct size. SNR and CNR 
are assessments of image quality.359 SNR was calculated as mean signal intensity of 
enhanced area/SD of noise. CNR was calculated as (mean signal intensity of 
enhanced area − mean signal intensity of unenhanced area)/1.5 × SD air. 
Myocardial volume and mass analysis were carried out on cine images using 
standard techniques.354 Short-axis images were manually segmented for epicardial 
and endocardial borders (excluding papillary muscles) to obtain the myocardial 
volume. Where more than one image of the same slice position was present, the 
optimal image was selected for analysis. All further quantification occurred on the 
presegmented images. LGE was quantified manually by tracing around the borders 
of infarction or fibrosis. Semi automated analysis were then carried out using 
purpose-written ImageJ (National Institutes of Health, Bethesda, MD) macros to 
determine FWHM and 6-, 5-, 4-, 3-, and 2-SD (above the mean remote myocardial 
signal) derived volumes. This involved the manual delineation of ROIs, firstly in the 
remote myocardium used to generate mean and SD for 6-, 5-, 4-, 3-, and 2-SD 
thresholds. Secondly, an ROI was drawn around hyperintense myocardium and used 
to define maximal signal for the FWHM threshold. Manual corrections were then 
required and done twice for all automated ROIs: first, MVO (defined as a 
hypointense core within a hyperintense region in patients with acute myocardial 
infarction337) was manually adjusted to be included as LGE. Second, any blood pool 
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or pericardial partial voluming and artifact (which occurred only rarely) were manually 
removed from the ROI. LGE volume as a percent of myocardium was quantified per 
slice, twice by 2 readers (J.H. and A.S.F., analysis blinded with 1-month temporal 
separation between repeat analyses) in all patients, with interobserver and 
intraobserver reproducibility and LGE volume assessed.360 
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3     Quantification of Myocardial Infarct Size Using 
Late Gadolinium Enhancement CMR 
 
3.1 Preface 
 
A version of this chapter was written with Dr Andrew Flett and published in Journal of 
the American College of Cardiology: Cardiovascular Imaging 2011.360 
 
3.2 Introduction 
 
The Objective of this sub-study was to determine the most reproducible technique to 
measure focal fibrosis using CMR that could be translated into a research tool for our 
subsequent study. Myocardial scar represents the replacement of ‘normal’ 
cardiomyocytes with those injured or destroyed by varying disease processes that 
affect the myocardium. Late gadolinium enhancement (LGE) imaging by CMR has 
become the reference standard for imaging myocardial scar. Following contrast 
administration and with the correct settings during an inversion recovery sequence, 
normal myocardium will appear black (nulled) whilst damaged myocardium will 
appear bright (‘enhancement’). The use of LGE imaging to identify myocardial scar 
has been validated in both animals and humans. In animal models LGE has been 
shown to distinguish between reversible and irreversible ischaemic injury. Whilst with 
ex-vivo imaging in models of acute and chronic infarction, the location, spatial extent, 
and 3D shape of the regions of increased signal intensity have been shown to 
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correlate with those of the irreversibly injured regions defined by TTC.235 CMR 
techniques are able to identify tiny areas of infarction. Assuming a myocardial 
specific gravity of 1.05 g/cm3, CMR has been able to visualise discrete areas of 
infarction with measured volumes of <1g.361 The extent and degree of myocardial 
injury after an acute ischaemic event are strong predictors of patient outcome, and 
interventions that reduce injury significantly improve prognosis.235 In a recent meta-
analysis of 4,438 patients, the overall hazard ratio for MACE was 2.65 for the 
presence of any LGE. Furthermore, there was a continuous relationship between risk 
and the amount of LGE detected - for every 10% of the left ventricular mass with 
LGE, the risk of MACE increased by 56%.362 Therefore the quantification of LGE 
offers further prognostic information beyond the simple presence of infarction. The 
ability to accurately prognosticate in the setting of AMI allows for the tailoring of 
therapy to the patients who are most likely benefit from it the most such as the 
implantation of implantable cardiac defibrillators.363 Different groups have used 
varying amounts of LGE as cut-offs for predicting adverse outcomes in patients 
suffering AMI. Given the effectiveness of PPCI and current anti-platelet therapy, the 
ability to demonstrate incremental reductions in mortality in the setting of AMI is 
increasingly difficult and necessitates studies with larger sample size.  This forces 
logistical and financial barriers on the testing of novel therapeutic strategies, and 
also limits the number of treatments that can be evaluated.248 Given the high 
sensitivity of LGE and the reproducibility of measurements of infarct size, the use of 
LGE imaging as a surrogate endpoint in clinical trials has become increasingly 
appealing. CMR provides the possibility of the detection of smaller changes in infarct 
size and therefore the possibility of a reduction of sample size populations required 
to demonstrate benefit (or otherwise) from therapy. Sample size is dependent on 
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estimated measurement variability. This parameter is represented by the expected 
SD in the measurements made within a cohort. As statistical variability increases, the 
sample size needed to detect the minimum difference increases. Visa-versa, as 
measurement variability decreases, the sample size needed to detect a minimum 
difference decreases.364 
 
The accuracy of a measurement system is the degree of closeness of 
measurements of a quantity to that quantity's actual (true) value. The precision of a 
measurement system, also called reproducibility or repeatability, is the degree to 
which repeated measurements under unchanged conditions show the same 
results.365 Ideally, quantification of infarction should be accurate and precise with 
measurements close to and tightly clustered around a known value or reference 
standard. 
 
A number of different techniques exist for the quantification of myocardial scar from 
LGE images. The gold standard quantification technique is not clear. Current 
techniques rely on the fact that LGE imaging makes scarred myocardium appear 
brighter than normal myocardium and as such can be defined as a specific signal 
intensity above normal myocardium. Regions of hyperenhancement have been 
described when the signal intensity is higher than the mean signal intensity plus 2 
standard deviations (SD) of the signal intensity of the remote myocardium. 
 
Previous SCMR reporting guidelines recommended a threshold of more than 2SD as 
a cut off to report scar area on LGE images.354 More recent guidance confirms the 
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controversy and uncertainty around the most accurate way to quantify myocardial 
scar. The task force for the standardisation of post processing in CMR refrained from 
making a dedicated statement regarding the optimal method for the quantitative 
assessment of scar.366 Different groups have used different techniques including; 
 
(i) Manual planimetry - drawing round the region of scar as perceived by the 
operator. The size of the hyperenhanced regions is influenced by the image window 
settings (centre and width), that reflect the personal preference of the person 
undertaking the analysis.367  
 
(ii) Standard deviations of differing signal intensities - Mean signal intensities plus 
2,3,4,5 and 6 SD above the remote myocardium have been used with semi-
automated algorithms to threshold out the hyperenhanced segment. Obviously the 
potential exists for lower signal intensity cut offs to overestimate infarct size and 
higher cut offs to underestimate in the same way.  
 
(iii) Full width half maximum - an initial region is determined to grow to include all 
pixels with SI >50% of a selected point. The maximum Si inside this initial region is 
then determined, and the final MI extent is defined as the area presenting with a 
signal intensity 50% above the maximum of the initial region. In the canine model 
Amado et al. demonstrated that the FWHM technique was able to accurately and 
reproducibly quantify the amount of infarction that correlated with post mortem infarct 
size measured by TTC staining.368  
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Our objective was to compare the seven quantification techniques across the 
spectrum of disease in which LGE has been linked to outcome: AMI, CMI and 
hypertrophic cardiomyopathy (HCM), assessing the LGE volumes obtained, the 
reproducibility of each method and any associated effects on future study design. 
We hypothesised that the techniques would yield significantly different LGE volumes; 
that LGE quantification would vary with LGE aetiology; and that the 7 techniques 
would have statistically different reproducibility. 
 
3.3 Methods 
 
The 7 techniques (thresholding at 2, 3, 4, 5, 6 SD from remote, FWHM and manual 
quantification, see general methods section) were compared in a retrospective 
manner in 60 consecutive patients referred for CMR with the confirmed clinical 
diagnosis of AMI (n=20,), CMI (n=20) and HCM (from a tertiary referral 
cardiomyopathy clinic n=20,),  who had evidence of LGE. MI was defined by clinical 
presentation compatible with a STEMI, angiographic confirmation of coronary artery 
disease in the appropriate territory and a raised troponin. In AMI CMR was 
performed within one week and in CMI the scan was performed no less than 3 
months from the AMI. No other inclusion/exclusion criteria were used. Mean LGE 
volume, intra- and inter-observer variability were assessed and implications for 
sample size calculations derived.  CMR protocol and analysis was carried out as 
previously described in the methods section.  
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3.3.1 Statistical Methods 
 
LGE volume by each method was compared using a one-way repeated measure 
ANOVA with Bonferroni post-hoc analysis; reproducibility by intra-class correlation 
coefficient369 (ICC) and the significance of reproducibility differences using a 
Wilcoxon Rank comparison of the squared differences.370 Bland-Altman371 testing 
was performed in order to assess systematic offsets and the relation of observed 
differences to LGE extent. In addition, the reproducibility data was graphically 
displayed showing the variability attributed to intra and inter-observer effects as a 
proportion of total variability for each method (1-ICC).194 The sample size required to 
detect a clinically important change in LGE (5% was used illustratively) was 
calculated for each method for both paired and unpaired data by estimating the total 
patient level variability using standard variance components analysis.372  This 
modelling technique includes as variables both intra-observer and inter-observer 
effects which accounts for any observed systematic differences in the LGE.  
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3.4 Results 
Patient demographics and CMR data are shown in the table below (table 7 and table 
8 for each of the individual conditions studied.  
 Patient Characteristics by disease 
 AMI CMI HCM 
N 20 20 20 
Age (median, IQR) 58, 48-61 60, 52-66 50, 37-57 
Gender (M:F) 16:4 17:3 14:6 
Peak Troponin 7.5±5.2 7.0±4.7 - 
Infarct LAD:RCA:Cx* 10:7:3 10:5:5 - 
MI to scan time (days) 2.1±1.2 132±14.1 - 
* LAD – Left anterior descending, RCA – Right coronary artery, Cx – Circumflex 
Table 7 Patient Characteristics by Disease 
 
CMR Characteristics by Disease 
 AMI CMI HCM 
EDV (mls)$ 147±27 172±51 136±33 
ESV (mls)$ 67±19 82±41 34±13 
SV (mls)$ 80±2 90±25 102±27 
EF %$ 55±10 54±13 76 ±9 
Mass (g) 175±35 175±46 236 ±74 
Mean TI Range 359-384 355-405 333-411 
SNR (mean±SD)Ŧ 22±10 31±21 27±14 
CNR (mean±SD) Ŧ 12±6 16±11 12±7 
Max WT (mm) - - 19±4 
$ EDV – End diastolic volume, ESV – End systolic volume, EF – Ejection Fraction 
Ŧ SNR – Signal to Noise Ratio, CNR – Contrast to Noise Ratio* 
Table 8 CMR Characteristics by Disease 
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3.4.1 LGE Extent 
 
Calculated LGE volume varied substantially dependent on the quantification method 
used (Figure 15). Comparing all methods against the manual technique, there was 
no significant difference between manual and 6SD in the three conditions. There was 
no significant difference between manual and FWHM in HCM and between manual 
and 6 or 5SD in CMI. The 2SD technique generated LGE volumes up to 2x as high 
as FWHM, 6SD and manual techniques (p<0.001). The difference was most marked 
in HCM (Figure 15). The most extreme mean LGE difference in each disease was 
from 22% to 30% (AMI); 14% to 23% (CMI) and 11% to 29% (HCM). 
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Acute Myocardial Infarction 
 
Chronic Myocardial Infarction 
 
Hypertrophic Cardiomyopathy  
 
Figure 15 LGE Quantification using Seven Techniques 
 
Late gadolinium enhancement quantification using seven techniques in hypertrophic 
cardiomyopathy, chronic and acute myocardial infarction and: Example analysis of a 
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single short axis LGE slice in hypertrophic cardiomyopathy, chronic and acute 
myocardial infarction using the 7 quantification techniques. 
 
 
Figure 16 Mean LGE Volume By the seven Techniques 
  
 
3.4.2 Bland-Altman Analysis 
 
Bland-Altman analysis (see supplemental data for the 42 Bland-Altman plots 
performed) confirmed minimal inter/intra-observer bias (offset) for all methods except 
in 5 HCM assessments (SD2 through 6) where a small systematic offset appears to 
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have arisen from the 2 observers drawing their remote myocardium ROIs differently. 
Additionally, it was confirmed that observed differences in LGE were not related to 
the mean. 
 
3.4.3 Reproducibility in LGE measurements. 
 
For both intra- and inter-observer, the FWHM technique was the most reproducible 
in all 3 conditions (p<0.001) when compared to the other techniques studied. Inter- 
and intra-observer reproducibility of all LGE techniques were worse in HCM than 
AMI and CMI. In CMI and HCM, manual quantification was the least reproducible 
technique. For HCM, the FWHM technique was the only statistically acceptable 
quantification method (ICC >0.7)373 (Figure 17). 
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Figure 17 Intra And Interobserver variability by LGE quantification technique 
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3.4.4 Impact of Reproducibility on Sample Size Calculations 
 
The improved reproducibility of the FWHM technique has a significant impact on 
sample sizes needed to demonstrate a change in the number of patients required for 
a trial with the same power. On the basis of a difference in paired comparisons of 
slices between two observers, the FWHM technique inter-observer reproducibility 
compared to the next best method reduces required sample size by 69% (CMI), 60% 
(AMI) and 91% (HCM) for equivalent power. On the basis of unpaired analysis, 
taking into account an estimate of the total variability of each method on a patient 
basis, the calculated sample sizes using the FWHM compared to the next best 
method is reduced by 17%(AMI), 7% (CMI), and 56% (HCM).  
 
3.5 Discussion 
 
Quantification of LGE has important implications for cardiovascular research and 
also clinical practice across a spectrum of cardiovascular disease. Our study 
demonstrates how in three cardiovascular disease processes, 7 different techniques 
used to quantify LGE can provide significantly different results. The FWHM 
technique provided the most reproducible method across all three conditions 
proposing the ability to significantly reduce sample size in clinical trials that use LGE 
as a surrogate endpoint. Uses of alternative techniques to quantify LGE have the 
potential to more than double the size of a given clinical trial with ensuing cost and 
time implications.  
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Our study confirms the findings of Amado et al. that the FWHM criterion is a 
reproducible segmentation method to define infarct size when they compared it to 
TTC stained segments. Speiwak et al.374 compared differing quantification 
techniques but just in patients with HCM. Although their group found as we did 
(albeit in a smaller sample) that the FWHM technique was the most reproducible, 
they rejected it on the basis that results of FWHM technique did not correlate with 
visual analysis. The group concluded that 6SD above the mean SI of the remote 
myocardium provided the best agreement with visual assessment in patients with 
HCM. The assumption being that visual assessment and manual planimetry provide 
a gold standard for quantification of LGE when we have demonstrated that the 
manual technique is not reproducible, especially in HCM, where it is statistically 
unacceptable (ICC <0.7). Bondarenko et al. in 2005 showed significant 
overestimation of LGE with 2–4SD techniques in CMI. The same group in 2009 
demonstrated the ability of 6SD to predict segmental functional improvement after 
revascularization over 2-5SD and FWHM.375,367 The difference between the other 
techniques was, however, small and non significant. No reproducibility assessments 
were provided by the group for their second study.  
 
A number of limitations exist within the different thresholding techniques. Firstly, no 
real gold standard exists to compare these techniques with. TTC staining is the most 
popular method for measuring infarct size ex-vivo. TTC staining in itself has been 
shown to underestimate infarct size in certain scenarios.376 It cannot be used in-vivo 
and therefore is only of use in post-mortem human studies. Although TTC staining is 
common place in animal studies, the histological approach is strongly affected by the 
precise sequence and conditions in which the individual steps are carried out. 
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Therefore, the quality of histological images varies widely and is often poor in terms 
of contrast and border delineation introducing significant variability to 
quantification.377 Dehydration of myocardial tissue may also lead to variability 
between LGE extent (expanded by myocardial oedema) and ex-vivo sizing. It is also 
important to note that the pathophysiology underlying infarct measurement using 
TTC staining and LGE are different with the techniques being reliant on the release 
of NADH or increased volume of distribution respectively.   
 
Secondly, for the thresholding techniques, the signal intensity is highly dependent on 
the selected area of the remote myocardium used to calculate the threshold. In turn, 
each of the above techniques requires the operator to select a region of interest 
(whether it be remote myocardium, LGE or both), which adds subjectivity to the 
approach and may affect sizing. The standard deviation in remote myocardium 
primarily depends on the signal-to-noise ratio of the acquisition, which is influenced 
by imaging protocol, contrast media, time from administration to imaging, contrast 
dose, RF receiver coil setup and aetiology of scar. 366,367 
 
Thirdly, thresholding techniques are only semi-automated, relying on the user to 
accurately trace the myocardial borders (Epicardial and Endocardial) and exclude 
artefact. Artefact can be found both within the myocardium or more importantly at the 
subendocardium from where the infarction is likely to spread. It is at the interface 
between the subendocardium and blood pool that it becomes difficult to distinguish 
artefact from infarction as there may be minimal difference in the signal intensity 
between the two regions. Regional wall motion abnormalities can lead to stasis of 
blood which in turn can cause increased signal intensity at the subendocardial 
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border,378 further confounding the quantification of the infarction.  In addition, in vivo 
imaging is complicated by blurring from associated cardiac motion. This results in 
significantly more partial volume effects compared with ex vivo imaging, creating 
voxels with intermediate (gray) signal intensity containing an admixture of viable and 
nonviable myocytes—particularly at the infarct boundary.379 
 
With regards to the FWHM technique, authors have raised concerns that the method 
assumes a bright infarct core and may not be accurate in homogeneously gray 
scars. In addition, multiple separate islands of scar may cause difficulties with this 
analysis method.248 In our experience however, cases like this were rare and when 
they did occur, all methods, rather than the FWHM alone, were more prone to errors. 
LGE is frequently less well defined in HCM than in infarction and as such the 
identification of myocardium with normal signal (for use in the thresholding 
techniques based on mean and SD of signal intensity) is often difficult. The 
identification of an area of high signal however for the FWHM technique is more 
straightforward. This is reflected in our results with impaired reproducibility of all 
techniques in HCM compared to infarcts, but the FWHM relatively preserved. 
 
Assessment was made of intraobserver and interobserver reproducibility but our 
study is limited by lack of assessment of interstudy reproducibility (the SD of the 
mean difference between 2 repeated studies). Inter-study reproducibility of a 
technique is important where repeated examinations are required such as to assess 
the effect of a therapy over time. The absence of ionising radiation means that CMR 
lends itself well to repeated testing.380 High interstudy reproducibility (low SD) leads 
to greater reliability of observed changes in a parameter under measure, and smaller 
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sample sizes. The ratio of the SD of interstudy reproducibility between techniques is 
related to sample size by a square function, therefore small improvements in 
reproducibility magnify effects on sample size.381, 382 Little data exists on the 
interstudy reproducibility of LGE in patients with IHD or HCM. Analysis of interstudy 
reproducibility may have demonstrated lower ICCs and decrease the sample size 
reduction suggested above. Yet the FWHM method would likely retain the optimal 
reproducibility of quantification techniques. At the same time lack of interstudy 
variability limits the extension of our findings to paired studies. Our study of RIC in 
acute infarction is, however, an unpaired study with one CMR scan being performed 
following randomisation to treatment.379  
 
As mentioned above, the relative SNR of scar tissue versus normal myocardium can 
vary dependent on the dose of the contrast media used. We used a single dose of 
gadolinium at 0.1 mmol/kg. Other groups have used 0.2 mmol/kg as well as differing 
time points after contrast to image acquisition. There is the potential for these issues 
to affect reproducibility.  From a practical point of view this lower dose might 
underestimate the presence of LGE especially in patients with HCM or myocarditis. 
This would be an issue of CNR and SNR, which was felt to be outside of the remit of 
a study based on post-processing techniques. All the LGE images used in this study 
were optimised, but our consecutive patient recruitment still reflects real-world 
scanning. 
 
New methods for thresholding and quantification continue to be developed. The 
Otsu-Auto-Threshold (OAT) method is an automatic method for the calculation of an 
optimal threshold for quantifying tissue characteristics in CMR. The algorithm 
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automatically divides an SI histogram into two classes: normal and enhanced. The 
threshold is determined using an exhaustive search for values that minimize the 
intra-class variance between two populations of signal intensities.383 OTSU is an 
automated technique requiring no user defined ROI - unlike FWHM and SD 
techniques. OTSU overcomes the limitation of an observer wrongly defining the 
abnormal tissue as normal (or visa-versa) as only epicardial and endocardial borders 
have to be defined. 
 
3.6 Conclusion 
 
The FWHM technique for LGE quantification is the most reproducible, regardless of 
underlying aetiology, across the spectrum of cardiac disease in which LGE 
quantification is known to be important.  Reproducibility of the FWHM method allows 
for study sample size on the basis of scar as an end point to be reduced for 
equivalent power.  
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4 Effect of Remote Ischaemic Conditioning on 
Myocardial Infarct Size in STEMI patients 
 
4.1 Introduction 
 
Primary percutaneous coronary intervention is the treatment of choice in the setting 
of acute myocardial infarction.384 Despite prompt restoration of flow in the infarct 
related artery and continual improvements in anti-platelet385 and anticoagulant386 
therapy mortality remains high. Paradoxically the restoration of flow to the ischaemic 
myocardium can induce further damage through myocardial reperfusion injury.387 
The presence of reperfusion injury attenuates the benefits of angioplasty in patients 
suffering a myocardial infarction, yet there is currently no therapy to protect the heart 
against reperfusion injury. As such, novel therapeutic strategies for protecting the 
heart against ischaemia–reperfusion injury (IRI) are urgently needed to: reduce 
myocardial injury, preserve cardiac function, prevent the development of heart 
failure, and improve clinical outcomes in the setting of acute myocardial infarction.388 
 
Conditioning the heart is an endogenous protective strategy. Pre- and post-
conditioning have shown promise as strategies to minimise cardiac damage in 
settings where ischaemia can be anticipated.80,41 Acute myocardial infarction is 
however an unpredictable event which does not allow for the application of strategies 
to pre-empt the index ischaemic event.  
 
Remote Ischaemic Conditioning (RIC) describes the cardioprotective effect elicited 
by applying brief episodes of non-lethal ischaemia and reperfusion to an organ or 
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tissue remote from the heart.116 In the clinical setting, RIC has been be achieved 
using a non-invasive virtually cost-free protocol in which a blood pressure cuff to the 
upper arm or leg is inflated to supra-systolic pressures to induce one or more brief 
episodes of ischaemia and reperfusion124 In animal124 and human184 studies an RIC  
protocol has been applied following the onset of ischaemia (and prior to reperfusion) 
called Remote Ischaemic Perconditioning. Such a strategy has shown benefit in 
STEMI patients following the measurement of traditional surrogate markers of 
infarction.  
 
We aimed to investigate whether RIC reduces infarct size in the setting of an acute 
myocardial infarction using cardiac MRI indices as surrogate endpoints.  
 
 
4.2 Methods 
 
The study methodology is described in the general methods chapter earlier 
 
4.3 Statistical Methods 
 
Patient demographics were compared between the two groups. Fisher's exact test 
was used for the analysis of demographics measured on a categorical scale. The 
unpaired t-test was used for continuous variables found to be normally distributed, 
whilst the Mann-Whitney test was used for continuous variables not found to be 
normally distributed. 
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Primary outcomes were measures obtained from the cardiac MRI scans. These 
outcomes were all measured on a continuous scale, and an examination of the 
distribution of these variables, suggested that all were approximately normally 
distributed. As a result, the unpaired t-test was used to compare between groups. 
Further analyses of CMR indices are described below. 
 
The secondary outcomes were the three cardiac biomarkers, which were measured 
at baseline (0 hours), and then at three further time points. Data from all time points 
were included in single analysis for each outcome. To allow for the repeated 
measurements from each patient, the analysis was performed using multilevel linear 
regression. Two level models were used with individual measurements nested within 
patients. The 6, 12 and 24 hour time points were considered as outcomes, with the 
baseline values a covariate in the analyses. An examination of the data indicated 
that all three biomarker outcomes had positively skewed distributions, and thus the 
outcomes were given a log transformation before analysis. The interaction between 
time and treatment group was examined. A significant interaction would indicate that 
the differences between groups varied at the different time points. If no significant 
interaction was found, this term was omitted from the analysis, and a constant 
difference between groups at all time points was assumed. 
Further analyses of the biomarkers, calculated the area under the curve (AUC) for 
each patient. The AUC values were found to have skewed distributions, and so the 
Mann-Whitney test was used to compare between the two groups. This analysis was 
restricted only to patients who provided data at all four time points, as the AUC could 
not be reliably calculated for patients with missing data (e.g. patients with CMR 
indices but not complete biomarker data). 
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4.4 Results  
 
Patients were screened for inclusion in the study with patients immediately 
recognised as ineligible. At this stage patients were consented for the study prior to 
coronary angiography. Following angiography a further patients were excluded due 
to further exclusion criteria. 19 patients were excluded following initial angiography in 
view of TIMI flow >1(n=10), angiographically normal coronary arteries (n=4), three 
vessel coronary artery disease (n=2) and significant collateralisation (n=5). Two 
patients had angioplasty to more than one vessel and were therefore excluded. In 
view of pre-infarct angina and also patients taking either Nicorandil or Glibenclamide, 
6 further patients were excluded. 1 patient withdrew consent following PPCI. 
Therefore 61 patients were successfully randomised, to receive either placebo 
(n=33) or RIC (n=28).  
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Figure 18 Schematic of Recruitment for RIC Trial 
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4.4.1 Patient Demographics 
 
The groups were all well balanced with regards to demographic and angiographic 
variables. Comparisons of patient demographics between groups were made, and 
the results are summarised in the following table. Categorical variables are 
summarised by the percentage in each category. Continuous variables found to be 
normally distributed are summarised by the mean and standard deviation, whilst 
continuous variables not found to be normally distributed are summarised by the 
median and inter-quartile range. P-values indicating the significance of the results 
are also reported. None of the patient demographics were found to vary significantly 
between the two study groups.  
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Variable 
Control 
(n=33) 
RIPC 
(n=28) 
P-value 
    
Age - Mean (SD) 57.3 (9.9) 57.7 (10.4) 0.88 
Weight - Mean (SD) 86.5 (21.6) 83.0 (16.7) 0.53 
Vessel:  LAD (%) 47 32 0.50 
Circumflex (%) 16 14  
RCA (%) 38 54  
TIMI flow:  TIMI 0 (%) 82 85 1.00 
                  TIMI 1(%) 18 15  
No. balloon inflations 
- Median (IQR) 
3 (2, 5) 4 (3, 6) 0.20 
Duration balloon inflations 
- Median (IQR) 
60 (35, 110) 76 (42, 109) 0.53 
Drug eluting stent (%) 53 48 0.80 
Bare Metal stent:(%) 47 52 1.00 
Diabetes:  (%) 25 11 0.19 
Metformin:  (%) 12 0 0.12 
Hypertension: (%) 38 46 0.60 
Hyperlipidaemia:  (%) 36 50 0.31 
Creatinine - Mean (SD) 79.5 (18.1) 85.4 (22.1) 0.27 
Ischaemia time - Median (IQR) 180 (141, 239) 181 (130, 344) 0.66 
Table 9 Table showing Patient Demographics 
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4.4.2 Cardiac MRI endpoints 
 
With regard to the primary outcome, myocardial infarct size assessed by late 
enhancement imaging on CMR showed no statistically significant difference between 
the RIC group and the placebo group. Findings were similar for all CMR indices 
measured and the results are summarised in Table 10 with no significant differences 
found been the groups. 
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4.4.2.1 Volumes and Infarct Size 
 
Outcome 
Control 
Mean (SD) 
(n=21) 
RIPC 
Mean (SD) 
(n=20) 
Difference 
Mean (95% CI) 
P-value 
 
Infarct size (g) 2.7 (1.9) 2.3 (1.7) -0.4 (-1.6, 0.8) 0.49 
EDV (mls) 69 (12) 72 (14) 3 (-5, 12) 0.39 
ESV (mls) 29 (12) 35 (14) 6 (-2, 14) 0.15 
SV (mls) 39 (8) 37 (7) -2 (-7, 2) 0.31 
EF (%) 59 (12) 53 (12) -6 (-13, 2) 0.12 
Mass 88 (15) 90 (20) 2 (-10, 13) 0.79 
EDV – End diastolic volume, ESV – End systolic volume, SV – Stroke volume,  
EF – Ejection fraction 
Table 10 Table showing Cardiac Volumes and Infarct Size 
 
4.4.2.2 Area at risk and Myocardial salvage 
 
The AAR (calculated by Infarct-ESA) was compared between the two study groups. 
This variable was found to be approximately normally distributed, and so the 
unpaired t-test was used for the analysis. Analyses were performed for all patients 
combined, and also for two of the vessel subgroups separately. Finally the 
association between the area at risk and infarct size was examined using Pearson 
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correlation. The analysis results are summarised in the next table. The figures 
presented are the mean and standard deviation in each group, along with the mean 
difference between groups, and confidence interval for this difference. The difference 
was calculated as value for RIPC group minus value for control group. 
 
Patient group 
Control 
Mean (SD) 
RIPC 
Mean (SD) 
Difference 
Mean (95% CI) 
P-value 
All patients 28.5 (13.8) 28.4 (14.5) -0.1 (-9.6, 9.3) 0.97 
LAD vessel only 37.3 (11.8) 39.2 (15.0) 1.9 (-13.1, 16.8) 0.79 
RCA vessel only 16.9 (7.4) 20.8 (9.4) 3.9 (-5.1, 13.0) 0.37 
Table 11 Table comparing the Area at Risk between groups and between IRA 
 
The results suggested no differences in AAR between the two groups, either for all 
patients, or when the groups were split into their component infarct related artery. 
 
The association between AAR and infarct size was also examined. Pearson 
correlation gave a correlation coefficient of 0.83, with an associated p-value of 
<0.001. This suggests strong evidence of a positive association between the two 
variables. In other words greater infarct sizes were associated with higher AAR 
values. 
 
We then calculated the extent of myocardial salvage and compared this between the 
two groups. The salvage Index (Area at risk – final infarct size / area at risk) was 
measured on a continuous scale, and was not found to be normally distributed. 
Therefore, the Mann-Whitney test was used to compare between groups. No 
difference was found in the degree of salvage between the two groups. 
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Variable 
Control 
(n=33) 
RIPC 
(n=28) 
P-value 
    
Salvage Index - Median (IQR) 0.24 (0.08, 0.53) 0.39 (0.10, 0.59) 0.39 
Table 12  Table demonstrating the salvage Index between study groups 
 
The association between the salvage index, ischaemia time and infarct as 
continuous parameters was examined using Spearman’s rank correlation. The 
correlation coefficients and associated p-values are summarised in the next table 
 
Variable 1 Variable 2 Correlation Coefficient P-value 
    
Salvage index Ischaemia time 0.04 0.83 
 Infarct size -0.59 <0.001 
    
Table 13 Table showing the association between the Salvage Index, Ischaemia time 
and Infarct 
 
There was no significant association between ischaemia time and infarct size. 
Ischaemia time was also not significantly associated with salvage index. However, 
there was a statistically significant association between salvage index and infarct 
size. There was, as expected, a negative correlation suggesting that the salvage 
index was lower for patients with a larger infarct size. 
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4.4.2.3 MVO  
 
The variables related to the incidence of MVO were measured on a categorical 
scale, and so Fisher's exact test was used for the analysis of these variables. The 
association between various continuous variables was also examined. However, due 
to the skewed distribution of these variables, Spearman's rank correlation was used 
for the analyses.  
Incidence of MVO per CMR 
technique applied 
Control  
(n=33) 
RIPC  
(n=28) 
P-value 
    
MVO (FPP): N (%) 13 (62%) 12 (63%) 1.00 
    
MVO (EGE): N (%) 11 (52%) 12 (57%) 1.00 
    
MVO (LGE): N (%) 11 (52%) 12 (57%) 1.00 
    
Table 14 Table showing the Incidence of MVO per CMR technique applied 
 
There was no significant difference in the incidence of MVO between the two study 
groups. Hence the treatment of two cycles of RIPC failed to reduce the incidence of 
MVO in STEMI patients having undergone PPCI. 
We examined the difference between the CMR methods to identify MVO in terms of 
the presence of MVO. As each method was assessed on the same patients, the 
paired exact test was used to compare between pairs of MVO methods. Patients in 
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whom all three techniques were not employed were excluded from the analysis. The 
results are presented in the following table.  
MVO Method MVO present  N (%) P-value 
   
FPP 25/40 (63%) 0.63 
EGE 23/40 (58%)  
   
FPP 25/40 (63%) 0.63 
LGE 23/40 (58%)  
   
EGE 23/42 (55%) 1.00 
LGE 23/42 (55%)  
Table 15 Table to compare Imaging methods to assess MVO 
 
 
Although slightly more patients with MVO were identified using the FPP perfusion 
technique there was no significant difference between the three techniques in their 
ability to detect MVO. This analysis will be open to bias in that the operator was not 
blinded between the individual techniques and will have identified MVO on the 
technique used which will have been the FPP in the majority of cases. 
Finally we examined how ischaemia time and infarct size varied between patients 
who displayed evidence of MVO on CMR. MVO was defined using the FPP method 
for these analyses. Although the previous analyses suggested no significant 
differences in the presence of MVO between techniques, this method had the 
highest occurrence of MVO.  
The results are summarised in the next table. 
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Variable MVO absent 
 
MVO present  P-value 
Ischaemia time  - Median 
(IQR) 
208 (124, 434) 192 (164, 296) 0.96 
Infarct size – Mean (SD) 0.98 (1.04) 3.52 (1.59) <0.001 
Table 16 Table to demonstrate how Ischaemia time and Infarct size varied between patients 
with MVO on CMR 
 
The results suggest that ischaemia time did not significantly affect the presence or 
absence of MVO. However, there was a large difference in infarct size between 
patients with MVO and those without. Infarct size was much larger in the presence of 
MVO, with a mean infarct size of 3.5g compared to a mean of infarct size of 1.0g 
when MVO was absent. 
 
4.4.3 Cardiac Biomarker Endpoints 
 
Analysis of the cardiac biomarkers also failed to show any significant difference 
between the two groups. A summary of the results of these outcomes at each point 
in the study are given in the next table. Due to the skewed distribution of the 
outcomes, the values were summarised by the median and inter-quartile range in 
each group. 
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Outcome 
  
Time point 
  
Control 
Median (IQR) 
RIPC 
Median (IQR) 
Troponin 0 hours 0.0 (0.0, 0.2) 0.2 (0.0, 0.9) 
  6 hours 4.7 (1.6, 6.4) 3.2 (1.0, 6.3) 
  12 hours 3.1 (1.6, 5.8) 3.2 (1.7, 5.0) 
  24 hours 2.6 (1.1, 3.4) 2.6 (1.7, 3.3) 
        
CK 0 hours 105 (81, 297) 169 (102, 505) 
  6 hours 1485 (470, 2764) 1280 (640, 2364) 
  12 hours 1225 (586, 1915) 1335 (880, 2223) 
  24 hours 751 (317, 1199) 885 (501, 1258) 
        
CK-MB 0 hours 
 
7 (3, 36) 21 (5, 42) 
  6 hours 143 (57, 257) 188 (99, 279) 
  12 hours 
 
102 (60, 195) 142 (80, 215) 
  24 hours 42 (21, 110) 67 (33, 97) 
Table 17 Table showing analysis of Cardiac Biomarkers between the two groups studied 
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The subsequent graphs demonstrate the differences between groups with regards to 
the different biomarkers measured. The graphs show the median and 95% 
confidence interval for the median at each time point for each of the two groups. 
Visually the graphs appear to show similar values in each of the two groups at each 
time point for all three outcomes. 
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Figure 19 Graph showing the difference between groups with regard to different biomarkers 
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Figure 20 Graph showing the difference between groups with regard to different biomarkers
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Figure 21 Graph showing the difference between groups with regard to different biomarkers 
 
Multilevel regression methods were then used to compare the difference in 
outcomes between the groups, and the results are summarised in the next table. The 
first column gives the p-value from the time by group interaction. This indicates if the 
differences between groups varied at the different post-baseline time points. The 
final two columns give the difference between groups assuming a constant group 
different at all time points. As the outcomes were analysed on the log scale, the size 
of difference between groups was reported as a ratio, along with corresponding 
confidence interval. This gives the ratio of outcome in the RIPC group relative to the 
control group. The final p-values give the significance of these group differences.  
Assuming a constant different between groups, the further analyses indicated no 
significant differences in any of the three outcomes between the two patient groups. 
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Outcome Interaction P-
value 
Ratio (RIPC/control) 
(95% CI) 
P-value 
    
Troponin 0.31 0.91 (0.66, 1.26) 0.57 
CK 0.58 1.26 (0.67, 1.97) 0.60 
CK-MB 0.61 1.32 (1.72, 2.43) 0.37 
Table 18 Table showing no significant differences in the outcome of the three biochemical 
biomarkers measured 
 
The results suggest that there is no significant interaction between groups and time 
for any of the three biomarkers. This suggests that the differences between groups 
were not statistically different at the post-baseline time points. It can therefore be 
assumed that there was a constant difference between biomarker groups at all three 
subsequent time points. 
Analyses calculated the area under the curve (AUC) for those patients with 
measurements at all four time points. A comparison of the AUC values between the 
two groups was made and the results are summarised in the next table. The figures 
reported are the median and inter-quartile range in each group, along with the 
median difference and confidence interval for this difference.  
Outcome Control Median (IQR) 
RIPC 
Median (IQR) 
Difference 
Median (95% 
CI) 
P-value 
     
Troponin 62 (34, 110) 82 (55, 110) 11 (-25, 46) 0.53 
CK (*) 15 (9, 33) 28 (15, 50) 9 (-6, 25) 0.23 
CK-MB (*) 2.2 (1.3, 3.6) 2.7 (1.6, 3.6) 0.4 (-1.1, 1.7) 0.54 
     
Table 19 Table showing the comparison of the AUC values between the two groups 
(*) AUC values recorded in 1000s 
The AUC analysis results suggest that the area under the curve values did not differ 
significantly between the two groups for any of the three biomarkers examined. 
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The association between the different biomarkers was examined, with analyses 
performed at each time point. The results are summarised in the next table. Due to 
the skewed distribution of the blood test results, Spearman's rank correlation was 
used for the analyses. The figures presented are the correlation coefficients, along 
with their corresponding p-values indicating the significance of the results.  
 
Timepoint Variable 1 Variable 2 Correlation 
Coefficient 
P-value 
     
0 hours Troponin CK 0.61 <0.001 
 Troponin CK- MB 0.64 <0.001 
 CK CK-MB 0.69 <0.001 
     
6 hours Troponin CK 0.83 <0.001 
 Troponin CK- MB 0.74 <0.001 
 CK CK-MB 0.73 <0.001 
     
12 hours Troponin CK 0.78 <0.001 
 Troponin CK- MB 0.66 <0.001 
 CK CK-MB 0.71 <0.001 
     
24 hours Troponin CK 0.82 <0.001 
 Troponin CK- MB 0.66 <0.001 
 CK CK-MB 0.86 <0.001 
Table 20 Table showing the association between the different biomarkers 
 
The analyses indicated that, as would be expected, there were strong correlations 
between each pair of biomarker outcomes at all the time points.  All correlations 
were positive in nature, suggesting that the different blood tests were all positively 
related. 
The association between the biomarker results and both infarct size and ischaemia 
time was examined using Spearman's rank correlation. The maximum blood test 
result from all time points was used in the analyses. The results are summarised in 
the following table. 
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Variable 1 Variable 2 Correlation Coefficient P-value 
    
Ischaemia time Troponin 0.15 0.27 
 CK 0.08 0.59 
 CK-MB 0.19 0.18 
    
Infarct size Troponin 0.72 <0.001 
 CK 0.73 <0.001 
 CK-MB 0.44 0.01 
    
Ischaemia time Infarct size -0.16 0.33 
Table 21 Table showing the association between the biomarker results and both infarct size 
and ischaemia time 
 
Interestingly the results suggested that there were no statistically significant 
association between ischaemia time and the biomarkers sampled. However, all three 
biomarkers were found to be significantly associated with infarct size with the 
positive correlations suggesting that a larger infarct size was associated with higher 
values for all three biomarkers.  
There was no significant association between ischaemia time and infarct size. 
Ischaemia time was also not significantly associated with salvage index. However, 
there was a statistically significant association between salvage index and infarct 
size. There was a negative correlation suggesting that, as expected, the salvage 
index was lower for patients with a larger infarct size. 
Page 174 of 261 
 
 
4.5 Discussion 
The main finding of this proof of concept study, is that the use of two cycles of RIC 
prior to PPCI failed to reduce infarct size in STEMI patients. These findings differ 
from those of Rentoukas et al.181 and Bøtker et al.184 who in larger studies with 
differing endpoints demonstrated the benefit of an RIC protocol prior to PPCI (with 
three and four cycles respectively). At the same time our findings are consistent with 
numerous other trials of cardioprotective strategies that have failed to show benefit in 
different clinical settings. A recent meta-analysis of 23 studies of the use of RIC in 
different clinical settings showed no evidence that RIC reduces mortality or MACE 
associated with ischaemic events, yet there was a reduction in peak troponin 
release. 389  
 
It is also important to comment on the yet unpublished work by Crimi et al. who used 
an RIC protocol of three cycles of 5 minute inflations up to 200mmHg. Interestingly 
the group applied the protocol to the lower limb and the intervention was begun at 
the point of reperfusion (first device time) making it a IPost protocol. The patient 
cohort was selected with the inclusion of patients with LAD infarcts with TIMI 0-1 flow 
on initial angiography without evidence of significant collateralisation. The study 
showed a 20% reduction in enzymatic infarct size as measured by CK-MB. Whilst 
there was a trend to improvement in infarct size when measured by late 
enhancement imaging on CMR, no statistically significant difference was found. 
Crimi’s hypothesis was that this may be due to the fact that only 80% underwent late 
enhancement imaging. Yet at the same time it should be noted that the AAR was not 
measured and manual planimetry was used to quantify the size of the infarction. The 
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other interesting aspect of the study is the use of myocardial oedema as a marker of 
reperfusion injury and were able to show the oedema as measured by T2-weighted 
imaging was significantly reduced in the RIC group. 
  
Our study differs from those of Rentoukas et al.181 and Bøtker et al.184 in a number of 
important aspects, which are reflective of the failure to translate cardioprotective 
strategies in pre-clinical work. 
 
Differences in the study protocols is likely to be reflected in the results. Differences in 
the protocols included the point at which the protocol was initiated, the number of 
cycles used and the length of each cycle 
 
(a) Number of Cycles: Each group (including our own) used a different study protocol 
varying from two to four cycles of upper limb ischaemia. Our study was limited by the 
inability to apply RIC prior to arrival at the cardiac centre, along with short door-to-
balloon times. This meant that only two cycles could be applied prior to the 
deployment of the first device leading to the advent of reperfusion. Bøtker’s group on 
the other hand had the benefit of longer transfer times (symptom to balloon times of 
>3hrs) with the protocol being initiated by the Paramedics. Given the simplicity and 
safety of the protocol, the recruitment of the ambulance service to instigate RIC is to 
be recommended. However, time for a longer protocol is a double edged sword as it 
will imply a longer ischaemic time for the patient. The protocol of Rentoukas et al. 
differs again. This group began the application of three cycles 10 minutes before the 
estimated time of first balloon inflation. Even if we use the inflation of the first balloon 
as the index of reperfusion, this would imply that the protocol continued well after 
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reperfusion given that three cycles of ischaemia and reperfusion will last 24 minutes. 
Yet reperfusion will often begin following the successful passing of the first wire 
down the occluded artery. This protocol is therefore more of a post-conditioning 
protocol rather than one of per-conditioning. 
 
Early studies of preconditioning revealed an ischaemic threshold below which 
preconditioning provides no protection and that increasing the ischaemic trigger 
increases the protection until the effect saturates.390 Loukogeorgakis et al391 
compared RIPC and RIPostC in an in-vivo model of endothelial IR injury. They were 
able to demonstrate that the degree of protection by RIPostC against endothelial IR 
injury in conduit vessels is similar to that achieved by RIPC. This experimental study 
also gives us a number of insights into the degree of stimulus required to cross the 
preconditioning threshold and provide protection. Three cycles of upper limb RIPC 
was shown to induce protection, yet shortening the stimulus to just two cycles failed 
to induce protection. At the same time the group demonstrated that the amount of 
tissue exposed to the preconditioning stimulus was a determinant of protection. 
Whereas two cycles of RIPC was ineffective against endothelial IR injury when 
applied to the upper limb, the same protocol applied to the leg was shown to induce 
protection. 
 
There is however divergent data with Li et al. demonstrating in a canine model that 
multiple cycles (six or twelve) offered no more protection than a single cycle.392  
 
Although there is no consensus on the number of cycles required to induce 
protection, it is conceivable that our protocol of just two cycles was below this 
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threshold and hence failed to provide protection. We may hypothesise that we been 
afforded more time to apply a longer protocol we may have seen a difference 
between the groups. At the same time, conclusions based on certain known data, 
when they are ampliative in nature, i.e. when they are extended to unknown areas, 
can have validity only on the assumption of everything else being equal.393 Further 
research in the clinical domain is clearly needed to define the optimum number of 
cycles needed to induce protection. 
 
(b) Cycle Length and Inflation: Cycle length also varied between the protocols and 
there remains no consensus as to how long a cuff should remain inflated for, nor to 
what pressure the cuff should be inflated to. Bøtker’s group protocol was similar to 
ours and cuff inflation was to 200mmHg for 5 minutes. Whereas with Rentoukas’s 
group the cuff was inflated to 20mmHg above systolic arterial pressure for 4 minute 
cycles. The group do not supply any data on the average BP of their different patient 
groups. Just as the volume of tissue to which the conditioning stimulus is exposed is 
a determinant of the degree of protection, so to the length of time to which it is 
exposed to the stimulus is also likely to influence the protective effect. In 
preconditioning the ischaemic time induced by the stimulus appears to be the 
determining factor of the conditioning effect.394 The period of reperfusion requires a 
minimum duration of between 30 seconds to one minute.395 Protection has been 
demonstrated when the period of reperfusion has been extended out to one hour.396 
It is unknown whether it is the ischaemic period, the reperfusion period, or the 
number of cycles that is the critical factor in postconditioning.390 
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(c) Patient Selection: Patient selection is obviously a significant determinant of 
outcome in any clinical trial. Randomised controlled trials (RCTs) have long been the 
gold standard research design because of their potential to offer unbiased estimates 
of an intervention's’ effectiveness. Evidence however suggests that trial participants 
are often unrepresentative of the target population, which can introduce bias in the 
measures of effect.397 Trials tend to recruit highly selected, unrepresentative 
populations; therefore the results cannot reliably be translated to real world 
scenarios. Multiple factors have been shown to affect IRI and the response of 
patients to cardioprotective strategies. These factors include; 
 
(i) Age where structural and functional changes during ageing render the heart more 
susceptible to cell death from ischaemia/reperfusion. Cardioprotective manoeuvres 
such as ischaemic pre and postconditioning appear to lose their effectiveness with 
ageing.398  
 
(ii) Gender. Both experimental and clinical studies have indicated that female gender 
influences favourably aids the remodeling and the adaptive response to myocardial 
infarction.399 In some studies, particularly in the rat, females show less IRI; however, 
in many animal studies no gender difference in IRI injury is observed.400  
 
Data on age and gender are easily collected and further work is needed to elucidate 
the actual effects of these aspects on cardioprotective strategies. 
 
Our own study (as with that of Bøtker and Rentoukas) excluded essentially the 
sickest patients who were deemed to be unstable (e.g. cardiac arrest prior to 
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admission or cardiogenic shock). Interestingly mechanical cardioprotective 
strategies, such as RIC, may be particularly beneficial in this patient group, as they 
have the potential to mediate multiorgan protection.112 
 
(d) Concomitant medication - A number of medications have been shown to either 
disrupt or augment cardioprotection. Nicornadil is thought to provide cardioprotection 
through inhibition of ROS formation.401  Controversy exists as to whether the diabetic 
heart is amenable to cardioprotective strategies.402 At the same time certain oral 
diabetic medication has been shown to lower the threshold required to protect the 
diabetic heart from IRI.403 Unfortunately different anti-diabetic agents appear to 
provide differing levels of protection. Whilst not all confounding variables can be 
controlled for, at the very least the pre-treatment of patients with such medication 
needs to be recorded. In an ideal scenario patients taking these medications would 
be excluded from clinical studies to ensure that any possible confounding effect is 
removed. 
 
In the same vein patients with IHD are likely to have multiple co-morbidities. How 
these co-morbidities either in isolation or indeed in combination may modify 
responses to IRI and the cardioprotection conferred by IPC and IPost is not clear.404 
 
(e) Endpoints. Different surrogate endpoints have been used for each of the three 
trials which will also influence outcomes. As therapy for acute MI advances, it 
becomes increasingly difficult to demonstrate incremental benefit of cardioprotective 
strategies. The selection of appropriate endpoints in clinical trials is of central 
importance in the assessment of the effects of cardioprotective interventions. 
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Meaningful end points should ideally (i) link the treatment effect to the underlying 
pathophysiology; (ii) be clinically relevant and provide prognostic information to 
subsequent patient outcome; and (iii) show high specificity and sensitivity, as well as 
high reproducibility.405,406 Imaging with cardiac MRI would appear to fulfil all three 
criteria, providing information on both infarct size and the AAR as well as ongoing 
insight into the pathophysiology of acute infarction through imaging of the different 
components of reperfusion injury. CMR is an almost ‘one-stop’ shop for the 
evaluation of patients post PPCI. However, variability in end point definitions, creates 
a significant barrier to the understanding of results across clinical trials407 or the 
pooling of results for the purpose of meta-analysis.  
 
In our study, the failure of RIC to reduce myocardial infarct size in PPCI patients is in 
conflict with the pre-clinical data reporting reductions in myocardial infarct size in a 
swine model of ischemia-reperfusion injury, with RIC applied prior to reperfusion.129 
The failure to translate cardioprotective strategies from animal models to human 
studies is discussed earlier on. 
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 Hasleton Bøtker Rentoukas Crimi 
N 61 251 96 96 
Ischaemic Time 
(min) 
180 189 194 180 
Diabetes (%) 18 9 31.5 12 
Pre Infarct 
Angina 
Excluded Not  
Excluded 
Not excluded Not excluded 
Conditioning 
Mimetics 
Excluded Not excluded Not excluded Not excluded 
Conditioning Prior  
to  
reperfusion 
Prior  
to  
reperfusion 
Protocol 
completed  
during  
reperfusion 
Post 
Reperfusion 
Limb Arm Arm Arm Leg 
Cycles 2 4 3 3 
Cycle Length  
(min) 
5 5 4 5 
Cuff Inflation  
(mmHg) 
200 200 20 above systolic 
pressure 
200 
Anterior MI only No No No Yes 
TIMI flow < 1 
only 
Yes No No Yes 
Collateral 
vessels 
Excluded Included Included Excluded 
AAR measured Yes  
(Infarct ESA) 
Yes 
(SPECT) 
No No 
Endpoint Infarct Size 
(CMR) 
Myocardial 
Salvage 
(SPECT) 
ST Segment 
Resolution 
(ECG) 
 
AUC CK-MB 
Table 22 Table of studies investigating the application of RIC in the setting of acute Myocardial 
Infarction 
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4.6 Conclusion 
 
In summary we have demonstrated that two cycles of remote ischaemic 
preconditioning failed to reduce myocardial infarct size or the incidence of MVO in 
the setting of PPCI for acute myocardial infarction. However, RIC remains a safe 
adjunct to PPCI and with additional cycles of ischaemia and reperfusion and larger 
sample sizes promises to show benefit in future studies. 
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5 Tissue Characterisation with Cardiovascular Magnetic 
Resonance 
 
Myocardial tissue composition holds important information regarding disease-specific 
patterns of injury, current activity of disease-related mechanisms, and the 
reversibility of changes.408 CMR provides information beyond simple geometry and 
functional indices of cardiovascular structure. By making use of the magnetic 
properties of H+ found in each cell, CMR allows for an almost in-vivo 
histopathological assessment of the myocardium. To this end CMR sequences are 
now available that enable the assessment of additional components of reperfusion 
injury and infarction including myocardial oedema, intramyocardial haemorrhage and 
diffuse (as opposed to focal) myocardial fibrosis. Additional indices allow for a more 
detailed profiling of individual patients as well as more accurate assessment of future 
risk. To this end treatment, in the form of pharmacotherapy, device-based therapy or 
surgery, can be tailored to individuals needs. Within the research arena, 
identification of further markers (beyond function and LGE) of adverse prognosis 
adds to surrogate endpoints for clinical trials. The use of ventricular volumes, 
contractility and even infarct size can be misleading in certain settings with the 
measurements of only complementary markers showing differences between trial 
groups. CMR is therefore unique in its ability to identify and assess numerous 
markers of disease that can be utilised for both patient and research benefit. 
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We aimed to characterise the myocardium in the setting of an acute myocardial 
infarction employing CMR sequences to identify myocardial oedema, intramyocardial 
haemorrhage and diffuse fibrosis. 
 
5.1 Myocardial Oedema 
  
Approximately 75% of the myocardium is water. This is mainly contained within the 
cells and to a lesser extent within the vasculature and depending on the disease 
state, the interstitium. A small amount of water is contained within the interstitial 
space.  Control of the amount of fluid within the interstitial space is governed by the 
hydrostatic pressures within the microvascular exchange vessels and within the 
interstitial space and colloid osmotic pressures within the microvessels and within 
the interstitium. Normally the same amount of water that enters the interstitial space 
would be removed from the interstitium via the myocardial lymphatic system409 
meaning that fluid does not build up within this compartment and it does not become 
oedematous. Myocardial oedema is therefore the accumulation of an excess of 
water within the interstitial space due to the disruption of water homeostasis within 
the myocardium. Myocardial oedema develops when the rate at which fluid entering 
the cardiac interstitium (microvascular filtration rate) is greater than the rate at which 
it is taken away.410 Myocytes themselves will swell with water during ischaemia as 
part of the process of necrosis. The massive inflow of water into the cell by the 
osmotic imbalance ultimately leads to cell swelling and rupture of the plasma 
membrane.411 This in turn leads to the release of cellular contents (including water) 
into the expanding extracellular space. Ischaemia with or without infarction can 
induce myocardial oedema. 
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Within the clinical arena, different imaging techniques have been employed for the 
assessment of myocardial oedema.  
 
Assessment of LV mass and ventricular wall measurements by echocardiography 
has been proposed as a surrogate for myocardial oedema. Whilst oedema will 
increase wall thickness and myocardial mass measurements, these indices are not 
specific to oedema. The application of echocardiography in this setting is therefore 
limited.  
 
CT has also been used to demonstrate myocardial oedema in canine and swine 
models.412 Early experiments were hampered by limited temporal and spatial 
resolution. Mahnken et al. reported good agreement between unenhanced CT and 
T2-weighted CMR. The pictures presented by the group in their paper show an area 
of enhancement on CT that appears to match and is certainly no bigger than the 
area of infarction on the LGE images. CT, as always, is limited by radiation. With 
unenhanced CT imaging for oedema, the difference in the CT values is low, resulting 
in the need to apply high tube-current time products to keep the image noise in 
acceptable ranges and to provide an acceptable CNR. This therefore results in the 
same radiation exposure as a coronary CT angiogram.413 Whilst dual source CT with 
ECG gating offers the potential to reduce radiation doses414, serious concerns 
continue to exist as to the use of even smaller doses of radiation and the causation 
of malignancy.415 
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CMR offers a more robust ability to image myocardial water content. A number of 
different sequences have been used to assess the myocardium for oedema. These 
sequences take advantage of the long T2 relaxation times of the water - logged 
myocardium. Long T2 values produce high signal and hence oedema appears as 
bright on T2 weighted sequences. Higgins et al. was the first to demonstrate the 
correlation between myocardial water content and increased T2 relaxation times in a 
canine model of acute infarction.260 The relationship between myocardial water 
content and relaxation times was, however, noted a decade earlier by Kiricuta et al. 
who documented that T2 relaxation times decreased as tissues (including the heart) 
matured and their water content decreased.416 T2 weighted sequences have 
therefore been employed across a range of cardiovascular pathologies to 
demonstrate acute and chronic myocardial oedema with the demonstration of a 
linear relationship between water content and T2 relaxation times. Settings include 
acute infarction (with studies demonstrating the lack of increased signal in chronic 
infarction), myocarditis417, pulmonary hypertension and transplant rejection.418 
 
A number of groups have suggested the use of T2 weighted imaging to elucidate the 
myocardium at risk in acute infarction. At the very least, T2 weighted imaging in the 
setting of AMI identifies oedema as a product of reperfusion injury.  
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Popular techniques include; 
 
1. Turbo Spin Echo (TSE) is a multi echo sequence using several phase encoded 
echoes 
2. Turbo Inversion Recovery Magnitude (TIRM) is the combination of a basic TSE 
and an inversion pulse for the preparation of longitudinal magnetisation. 
3. Short TI TAU Inversion Recovery (STIR) (Triple inversion recovery) is a TIRM 
sequence using a short inversion time suitable for suppressing the signal from fat. 
4. T2-SSFP is an alternative to TSE sequences. This is a bright blood sequence that 
helps eliminate bright endocardial surface artefacts. T2-prepared SSFP is reported 
to have higher diagnostic accuracy than T2-prepared dark-blood TSE with respect 
to determining the coronary artery distribution and determining whether a patient 
had an acute or chronic MI.283 
5. ACUT(2)E TSE-SSFP is a hybrid between steady state free precession (SSFP) 
and TSE for bright-blood T2-weighted imaging with signal-to-noise ratio (SNR) 
and contrast-to-noise ratio (CNR) similar to dark-blood TSE.284 
 
We aimed to apply T2-weighted sequences to a subgroup of patients with acute 
myocardial infarction who had been treated with PPCI who had enrolled in the RIC 
trial. Given that T2-weighted images have previously been used to calculate the 
AAR, we sought to compare the AAR as measured by the infarct-ESA and T2-
weighted CMR techniques. During our trial period a number of other sequences 
became available (ACUT(2)E TSE-SSFP and STIR) that we also applied in selected 
patients. 
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5.1.1 Methods 
 
Consecutive patients recruited to the RIC STEMI trial and without contraindication to 
CMR underwent standard scan as laid out in the protocol earlier. All scans were 
carried out within a week of PPCI. Oedema imaging was carried out prior to the 
administration of contrast. Following cine imaging, assessment was made of the 
short axis slice exhibiting the highest degree of regional wall motion abnormality. If 
no regional wall motion abnormality was detected then a mid-ventricular slice was 
selected. A Turbo Inversion Recovery Magnitude T2-weighted sequence was applied 
with typical parameters of TR 3.1ms, TE 67ms, slice thickness 8mm, field of view 
340×450mm and sampled matrix size 256×192. A short axis stack was then 
acquired with the application of the T2-weighted sequence matching the cine short 
axis stack slice positions.  
Patients who had difficulty tolerating the scan whether in view of ability to breath hold 
or lie in one position for a fixed time were excluded so as not to unnecessarily 
prolong their scan. Patients in whom we were unable to visually identify a region of 
raised signal intensity were excluded. 
Images were analysed as per the methods stated earlier. For this cohort of patients, 
the epicardial and endocardial surfaces were manually segmented. Using a visual 
assessment and windowing of the short axis T2-weighted images, the area of high 
signal was manually segmented and expressed as a percentage of the left ventricle. 
Artefact was noted within the blood pool in a number of patients. This was removed 
through comparison with cine images at the same level. Areas of hypointensity that 
corresponded with microvascular obstruction either on FPP, EGE or LGE was 
included in the segmented area of high signal intensity and classified as 
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intramyocardial haemorrhage. The infarct-ESA was calculated as previously 
described. 
 
Figure 22 Short axis section of the LV following PPCI for an anterior STEMI 
Short axis section of the LV from a study patient following PPCI for an anterior STEMI with 1. Cine 
SSFP for reference, 2. T2-weighted TIRM image demonstrating increased signal in the anterior and 
antero-septal wall and 3. is the corresponding LGE image.  
 
. 
 
 
Figure 23 Short Axis Section of the LV following PPCI for an Inferior Infarction 
Short axis section of the LV from a study patient following PPCI for an inferior infarction. Note that in 
panel 3 below there is extensive MVO but no signal void is appreciated on the T2-weighted image 
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5.1.2 Statistical Methods 
 
We compared two techniques (Infarct-ESA and T2-weighted oedema imaging) used 
to quantify the AAR. Initially Pearson correlation was used to examine if there was 
any agreement between the two methods. However, a high correlation does not 
necessarily imply good agreement between the two methods, and thus the 
agreement between the two methods was also assessed using the Bland-Altman 
limits of agreement method.  
 
5.1.3 Results 
 
Six patients were excluded in view of restlessness and difficulty with breath-holding. 
In two patients there was no discernable increased signal on T2-weighted images 
and in two separate patients there was no evidence of infarction on LGE imaging. 
Yet review of the clinical history, ECG, angiography and cardiac biomarkers all 
confirmed an AMI. The two patients without evidence of increased signal on T2-
weighted imaging had evidence of LGE in the territory of the infarct related artery 
without evidence of wall thinning in that area, also suggesting an acute event.  All 
patients who were included had evidence of increased signal within the myocardium. 
In one patient the identified area of increased signal did not fit with the territory 
supplied by the infarct related artery and did not match up with the area of infarction 
as identified on LGE. The patient was subsequently excluded.  
This gave a correlation coefficient of 0.85, with associated p-value of <0.001. This 
suggests a highly significant association between the two variables, and this 
association is shown in the next plot, along with the line of best fit. 
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Figure 24 Graph showing the Correlation and Line of best fit for Oedema and Infarct ESA 
measurements. 
 
As the two methods were measuring the same variable, it would be expected that 
there is a strong association between them. However, a high correlation does not 
necessarily imply good agreement between the two methods. 
As a result, the agreement between the two methods was assessed using the Bland-
Altman method. This analysis indicated that, considering the differences as oedema 
minus I-ESA, there was a mean difference of 6.7 between methods, with a 95% 
Bland-Altman limits of agreement of -7.3 to 20.6. This result firstly suggests that the 
oedema method gives slightly higher values, on average, than the I-ESA method. 
The key result for this method is the width of the limits of agreement. The limits 
suggested that the majority of differences between the two methods are between -7 
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to 21. A difference between measurement methods as extreme as this would likely 
introduce bias into any AAR or salvage calculations.  
 
A graphical illustration of the results is given in a Bland-Altman plot below, which 
plots the difference between methods against the average of the two methods. The 
lines presented are the mean difference between methods (in red) and the limits of 
agreement (in blue). 
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Figure 25 Bland-Altman plot comparing Oedema and Infarct ESA 
 
5.1.4 Discussion 
 
T2-weighted imaging is able to identify the territory subtended by the infarct - related 
artery through the presence of myocardial oedema. Oedema is a marker of acute 
injury and would not be expected to be seen in a healthy individual. We did however 
not scan any ‘normal’ patients to test for this. Oedema imaging although in theory is 
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simple to implement does not necessarily easily produce the desired results. Motion 
(cardiac and respiratory), patient compliance and arrhythmia all impact on image 
quality and signal intensity. Newer sequences continue to be developed which 
attempt to overcome these practical failings with signal drop off283 and motion.419  
The use of T2 weighted sequences has been limited by comparatively long sampling 
(and breath hold) times. Images are sensitive to cardiac motion (and to this end 
imaging is ideally done during mid-diastolic diastasis, the period of minimal wall 
motion)420 which can cause image degradation.  
 
Image quality (particularly with black blood imaging) is also impaired by insufficient 
through plane flow for the blood nulling preparation to be completely effective. This is 
compounded in the setting of stunning and regional wall impairment with complex 
myocardial mechanics, arrhythmias and blood flow patterns. The dark-blood 
techniques are therefore prone to residual high signal static blood artefacts next to 
the endocardial border due to inadequate suppression of the signal from the blood 
pool and are also limited by posterior wall signal losses associated with improper 
timing.284  
 
The choice of slice thickness varies between investigative groups. Thicker slices 
allow for a reduction in signal dropout and less artefact at the endocardial border. 
Increased slice thickness addresses some issues of image quality but comes at a 
cost. Ideally when one is calculating myocardial salvage between T2-weighted 
images and LGE images the slice thickness. Variation in slice thickness (sometimes 
up to 100%) will render salvage calculations void given that the extent of LGE can 
vary significantly between individual slices.  
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The reproducibility of T2-weighted imaging has been questioned. Our experience is 
similar to other groups in that we found it difficult to reproduce T2-weighted images 
not only between patients but also, more concerningly, in between individual scan 
sequences in the same myocardial slice with the application of the same sequence. 
Difficulties in obtaining consistent images have pushed users away from standard 
T2-weighted sequences in favour of quantitative T2 mapping, which offers precise 
cut offs for differentiating normal from abnormal myocardium.421  
 
Just as the question as to which is the ‘best’ sequence to image myocardial oedema 
is yet to be answered, so to the question as to how to best quantify the extent of 
oedema also is not clear. A number of groups have set out to evaluate the most 
appropriate technique to quantify oedema. The ability to delineate the extent of 
oedema will likely depend on the T2-weighted sequence used although no group has 
yet applied different quantification techniques to images produced by different 
sequences. McAlindon et al. evaluated the techniques we applied (with the addition 
of the OTSU method) in LGE imaging to STIR images. Importantly the group 
investigated the inter- and intra- observer and inter-scan reproducibility. They found 
that manual quantification provided the best inter-, intra- observer and best inter-
scan agreement, with the lowest variability.422 
 
The major limitation of T2 weighted imaging is the leap from being able to image 
myocardial oedema to the certainty that the area of increased signal intensity 
identified by CMR is a direct representation of the AAR. As we have noted earlier, a 
number of studies have set out as our own to correlate areas of increased signal on 
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T2 weighted images with other surrogates of the AAR including infarct-ESA. The 
correlation of one surrogate with another surrogate does not prove the actual 
relationship of the extent of oedema to the actual AAR. Pathological studies 
measures of the AAR via the measurement of oedema are also limited by techniques 
that involve removal and dehydration of myocardial tissue. Pre-clinical (and more 
recently clinical) studies have however provided the greatest threat to the idea that 
the extent of oedema is directly related to the AAR. The AAR is of a predefined, fixed 
size that can only be changed by the development of collateral vasculature and not 
by interventions introduced around the time of reperfusion. Findings that novel 
interventions are able to reduce the extent of oedema mean that it is unable to 
reliably serve as a surrogate for the AAR unless we are willing to undertake a non-
scientific approach of using the ‘best of a bad bunch’ in regard to available 
techniques. This does not infer the end for T2-weighted imaging in the setting of 
AMI, as oedema appears to be a product of the complex cascade of IRI. The 
assessment of myocardial oedema in the setting of AMI will help to further our 
knowledge of the pathophysiology of reperfusion injury and act as an endpoint in 
clinical studies alongside other indices including MVO and infarction. 
  
5.1.5 Study Limitations 
 
The small sample size is the most significant limiting factor of the study. There is 
also no assessment made of inter- or intra-observer variability. Calculating the extent 
of the area with increased signal intensity, involved the subjective process of 
manually segmenting out the epicardial and endocardial surface layers. This was 
followed by the operator driven manual delineation of the area of increased signal 
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intensity. Manual segmentation is a long and tedious task that is prone to intra- and 
inter-observer variability.423 The segmentation of abnormal myocardium on T2-
weighted images is technically more demanding, particularly because of the 
comparatively reduced signal to noise levels associated with this method. This 
involves adjustment of window and level settings and a threshold approach to 
delineate the area of increased signal intensity based on a difference in signal 
intensity (decided by the eye of the operator) from the mean signal intensity of an 
normal area of myocardium.424 Therefore to further manually delineate the area 
increased signal may serve only to introduce further variability. 
 
The assessment of myocardial oedema adds to the armamentarium of CMR. In the 
setting of acute myocardial infarction sheds light on the pathophysiology of IRI whilst 
enabling us to quantify the extent of the ischaemic phenomenon. Attenuation of 
myocardial oedema provides a further target for novel cardioprotective techniques. 
The ability of CMR to delineate the AAR needs to be judged against the pitfalls of the 
techniques that went before it.  
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5.2 Intramyocardial Haemorrhage (IMH) 
 
CMR also has the ability to delineate intramyocardial haemorrhage, another by 
product of IRI. IMH appears to be intrinsically linked with MVO. Studies investigating 
IMH are not clear whether it occurs as an independent phenomenon or whether IMH 
is only seen in the context of severe microvascular destruction. It is likely that the 
phenomenon of MVO occurs in a range of severity with those patients who exhibit 
haemorrhage lying at the more severe end of the spectrum carrying with them a 
worse prognosis. To this end the identification of IMH provides further prognostic 
information for patients who have suffered an AMI. A number of techniques exist to 
image IMH with both T2-weighted images and T2* imaging being employed in the 
identification of haemorrhage.  
 
In a small group (n=8) of patients we used both T2-weighted imaging (TIRM) and T2* 
techniques to assess IMH.  
 
5.2.1 Methods 
 
Patients were scanned as per the protocols described earlier for assessment of LV 
volumes, myocardial oedema and LGE. As previously short axis slice that was felt to 
have a significant area of regional wall motion abnormality was chosen. Prior to the 
administration of contrast, a T2* with typical parameters as follows; eight echoes 
obtained; change in echo time, 4.8 msec; voxel size, 1.7 × 3.7 × 10 mm; flip angle, 
20°; section thickness, 10 mm.  T2* analysis was performed with regions of interest 
drawn in the area of MVO and also separately in an area of remote myocardium. The 
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signal intensity of this region was measured for each image, and this was then 
plotted against the echo time to form an exponential decay curve as has been 
previously described.425 
 
 
Figure 26 T2* Images showing decay constant of less than 20ms with evidence of reperfusion 
haemorrhage 
 
5.2.2 Statistical Methods 
 
Analysis of the T2* variables between the area of infarction and the area of infarction 
was performed using the paired t-test. Additionally, Pearson correlation was used to 
examine the association between the two sets of measurements. 
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5.2.3 Results 
 
The mean T2* decay constant within the area of infarction was 16.9msec, as 
compared to 33.1msec within the area of remote myocardium. The results indicate 
that the T2* decay in the area of infarction were significantly different from the values, 
taken from the remote myocardium, a difference that was strongly statistically 
significant (p<0.001). The analysis results are summarised in the next table. 
Measurement N Mean (SD) 
(T2* decay constant -msec) 
P-value 
    
Remote 8 33.1 (6.1) <0.001 
Infarct 8 16.9 (4.9)  
    
Table 23 Mean T2* values in areas of IMH and Remote Myocardium 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 200 of 261 
 
The individual data values are shown graphically in the next plot. 
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Figure 27 Dot Plot showing T2* values  by Region of interest 
 
5.2.4 Discussion 
 
The results of this small study demonstrate the ability of CMR to assess reperfusion 
haemorrhage in the setting of AMI. All the patients with evidence of haemorrhage, 
had evidence of MVO (on all three imaging techniques – FPP, EGE and LGE), 
suggesting that MVO and haemorrhage are intrinsically linked. Our results are 
consistent with those of O’Regan326 showing that T2* decay measurements of less 
than 20msec appeared to correlate with areas of IMH. In all but one of the infarcts 
studied was the T2* decay constant < 20msec.  We were however not able to 
demonstrate any significant correlation (negative or otherwise) between the 
presence or degree of haemorrhage and other CMR indices including cardiac 
volumes and EF. Other studies have been able to demonstrate correlation between 
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the presence of IMH, as assessed by either T2* or T2-weighted images, and adverse 
outcomes (See table 6 in Introduction). Further studies are however necessary to 
assess the IMH to answer a number of uncertainties surrounding the assessment of 
IMH with CMR. The most robust technique to assess IMH is not yet clear with both 
T2* and T2-weighted imaging able to provide on IMH. The time course of the 
development and resolution of IMH in humans has yet to be elucidated and is 
necessary to guide appropriate imaging in clinical trials post AMI. Clinical studies are 
already listing IMH as a secondary endpoint in the assessment of novel 
cardioprotective agents (Study Evaluating the Use of Vasodilators to Reduce Infarct 
Size and Microvascular Obstruction in ST-elevation MI, NCT01747174). Such 
studies will be limited by the fact that the incremental value provided by IMH as 
assessed by CMR over and above traditional imaging biomarkers (infarction and 
MVO) is not yet clear and further validation is needed. However, IMH appears to 
represent a further imaging biomarker that is likely in the future to be of prognostic 
benefit and value as a clinical trial endpoint to aid the assessment of novel 
cardioprotective therapies.  
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5.3 Diffuse Fibrosis 
 
The myocardial extracellular matrix (ECM) is a complex microenvironment that plays 
a fundamental role in the myocardial remodelling process. The ECM however only 
takes up a small proportion of the cardiac structure in a healthy heart of 
approximately 6%.426 The ECM serves anchor cardiac myocytes and therefore 
determines the structural architecture of the heart. It therefore plays an integral role 
in the cardiovascular mechanics and electrical impulse propagation.427 With 
advancing age and as part of the pathophysiology of cardiovascular disease 
interstitial expansion takes place with an increase in ECM of up to 35%.426 Interstitial 
tissue volume is primarily determined by the amount of extracellular matrix.428 
Fibrosis invariably follows oedema, if long-standing. Fibrosis with interstitial 
expansion and increasing extracellular volume is end point of most processes that 
lead to irreversible or reversible tissue damage in the heart. With IHD, the extent of 
fibrosis is the most accurate marker of injury severity.408 The gold standard for the 
assessment of myocardial fibrosis is myocardial biopsy, which carries significant risk 
with the possibility of sampling an area of the myocardium that may not be 
representative of the disease state.429 A number of pharmacological agents having 
been investigated in animal models with the aim of reducing the degree of diffuse 
fibrosis. At present however there are no human studies aimed at reducing diffuse 
fibrosis that have been reported.430 
 
Imaging of focal fibrosis using late gadolinium enhancement imaging is now a well 
validated technique that equates closely to macroscopically identified scar on 
postmortem analysis. This has been shown to be the case across the spectrum of 
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cardiovascular diseases and has sparked interest in the effect of non-cardiovascular 
disease processes on the heart. Imaging of focal fibrosis, however, only takes us so 
far with regards to mechanistic insights into particular pathologies. Diffuse 
myocardial fibrosis is difficult to distinguish using LGE as the myocardial signal 
intensity is nulled to enhance to heterogeneity of abnormal myocardium. Therefore 
homogeneously diffuse tissue will be nearly isointense and therefore globally “nulled” 
becoming indistinguishable from normal tissue.431 Inversion recovery sequences 
utilised for LGE therefore delineate focal fibrosis but miss diffuse fibrosis. 
Measurement of the extracellular volume fraction using CMR offers the ability to 
identify and quantify the degree of extent fibrosis within the myocardium. Myocardial 
fibrosis has long been linked with adverse remodelling with the extrapolation that this 
translates to adverse outcomes in certain patient groups. Data is now emerging on 
the ability of ECV measurement by CMR to predict mortality as well as other 
cardiovascular composite end points.432,433 Quantification of the myocardial 
interstitial space may therefore represent an important diagnostic and prognostic 
biomarker as well as a possible further endpoint in clinical trials in cardiovascular 
disease.434 
 
The technique of T1-mapping in acute myocardial infarction was first described by 
Messroghli et al. in a small study of eight patients and reported focal changes in T1 
measurements. 
Given that in the setting of an MI the size of the extracellular space will be 
dependent on the amount of myocyte necrosis (myocyte wall rupture) one might 
hypothesise that the greater the degree of necrosis the larger the extracellular 
space. In acute infarction extracellular volume is increased by the presence of 
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myocardial oedema. Hence with the ‘resolution’ of myocardial oedema, the 
extracellular volume will shrink. Extracellular volume may reflect the extent of 
structural destruction of the myocardial architecture - the greater the extracellular 
volume the greater the degree of destruction. Imaging of the extracellular space and 
calculation of the extracellular volume therefore adds to our ability to characterise 
(anatomically and pathologically) the myocardium in vivo and enhances our 
understanding of the process of infarction and the differing degrees of disruption 
wrought by the different components of an MI and reperfusion injury.  
 
5.3.1 Methods 
 
We sought to characterise the myocardium in patients with an AMI who had 
undergone reperfusion with PPCI by calculating the degree of fibrosis within the 
reperfused myocardium. The research was granted approval from the local research 
ethics committee, and all participants provided written informed consent. Fifteen 
consecutive patients who had undergone successful PPCI and had no 
contraindication to CMR were recruited to the study. Patients had a full blood count 
taken at baseline for measurement of their haematocrit and subsequent calculation 
of the volume of distribution of contrast in the blood.  
 
An Equilibrium CMR technique was used as described by Flett et al. in validation 
studies in patients with aortic stenosis and hypertrophic cardiomyopathy.23 The 
equilibrium CMR technique is based on the concept that at a point of steady state 
the volume of distribution of contrast in the blood (Vd(b)) will equal the volume of 
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distribution of contrast in the myocardium (Vd(m)). The Vd(b) is calculated by the 
calculation of 1 - haematocrit.  
 
The Vd(m) can then be calculated with the formula:435 
 
 
  
 
                                       
The equilibrium technique removes uncertainties regarding contrast kinetics in heart 
failure or renal impairment and does not require an assumption of pseudo-
equilibrium.436 Patients were scanned according to standard protocols described 
above. Following cine imaging of the short axis stack, the slice felt to have the most 
marked region of wall motion abnormality was selected. Multiple T1 measurements 
were then made at this chosen short axis slice position using a multi–breath-hold, 
spoiled gradient echo inversion recovery (IR) sequence prior to the administration of 
contrast and following equilibrium with a primed infusion of contrast.  Typical 
parameters were: slice thickness 8 mm, TR 9.8 ms, TE=4.6 ms, field of view 
315×420 mm, sampled matrix size 256×130, 21 k–space lines acquired every other 
RR interval. T1 measurement were performed before and after equilibrium contrast 
in a single short axis slice in a single phase using increasing inversion times (TI) per 
breath-hold of 140 ms, then 200 to 800 ms in increments of 100-ms. Equilibrium was 
achieved through an initial bolus of Gadoteric acid (0.1 mmol/kg, Dotarem; Guerbet 
SA). After standard EGE and LGE imaging patients were commenced on a primed 
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infusion (0.0011 mmol/kg/min) for approximately 45 minutes (the majority of which 
the patient spent out of the scanner. Patients were then returned to the scanner and 
following re piloting further T1 measurements were performed in the same short axis 
slice. Three regions of interest were then drawn including the blood pool, the area of 
infarction (as noted on later LGE images) and remote myocardium. Mean signal 
intensities were plotted with restoration of phase and a curve-fitting technique was 
used to find the null point: TI′.345 
 
 
Figure 28 Figure showing an example of a post contrast T1 map (The last image is a standard 
LGE for reference). 
 
 
5.3.2 Statistical Methods 
 
The first set of analyses made comparisons between the various regions of interest 
/volume of distribution measurements. The paired t-test was used to compare 
between the measurements. These analyses were restricted only to patients with 
adequate pre and post contrast maps. Associations between the different volume 
distribution measurements and other study parameters were examined. All variables 
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were measured on continuous scales, and thus Pearson correlation was used for all 
analyses. 
 
 
5.3.3 Results 
 
The overwhelming majority of patients studied were male (92%). The median age 
was 57 years.  Three patients were excluded. The first refused to remain on the 
infusion. The second was excluded  in view of poor quality images that were felt to 
be un-interpretable. With the third the chosen slice for pre-contrast analysis 
subsequently turned out to have no evidence of LGE on later imaging and was 
subsequently excluded. In order to prevent this in future scans, further imaging in the 
form of T2* and T2-weighted imaging was applied to attempt to select an appropriate 
slice. Such a strategy is not full proof given the issues with T2-weighted imaging and 
the absence of MVO. The area of LGE correlated with the occluded artery at 
presentation. 6 patients presented with an occluded LAD, 6 with an occluded RCA 
and 1 with an occluded Circumflex. 7 patients had evidence of MVO and 6 patients 
with LGE without MVO (on either FPP, EGE or LGE images). The mean myocardial 
ECV in the remote myocardium was 0.26+/-0.08. This compares well with studies 
that have measured ECV in healthy patients.346 The mean ECV in the area of 
infarction was (0.585+/-0.079) significantly higher than the remote myocardium 
(p<0.001). This difference remained highly significant when comparing the remote 
myocardium separately with areas of MVO and regions of infarction without MVO.  
There was however no significant difference (p=0.3) between the ECV measured in 
areas of infarction without evidence of MVO (0.598+/-0.086) and areas of MVO 
Page 208 of 261 
 
(0.574+/-0.07). No correlation was found between the myocardial ECV and peak 
troponin or the other indices measured by CMR including ESV, EDV and EF.  
 
Graphical illustrations of the results are shown in the next graphs. The first graph 
shows the mean values, along with corresponding 95% confidence intervals, whilst 
the second graph shows the individual data values. 
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Figure 29 Box plot for measured ECV values 
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Figure 30 Dot Plot for Measured ECV values 
 
The next table shows the correlation analyses between the ECV measurement and 
the other CMR indices. The correlation coefficients and associated p-values from 
these analyses are summarised in the next table. 
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Volume of Distribution (Vd) Variable 2 Correlation Coefficient P-value 
    
Vd(M)/Remote Myocardium EDV -0.27 0.40 
 ESV -0.34 0.29 
 SV -0.06 0.86 
 EF 0.30 0.35 
    
Vd(MVO)/MVO EDV -0.54 0.5 
 ESV -0.41 0.49 
 SV -0.09 0.89 
 EF 0.37 0.54 
    
Vd(I)/ Infarct EDV -0.36 0.43 
 ESV -0.41 0.36 
 SV -0.24 0.60 
 EF 0.37 0.41 
    
ECV MVO & Infarct EDV -0.35 0.27 
 ESV -0.34 0.28 
 SV -0.20 0.53 
 EF 0.30 0.34 
    
Table 24 Table showing correlation between Vd measurements and cardiac volumes. 
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5.3.4 Discussion 
 
Our study points out the significant degree of interstitial expansion within an acute 
myocardial infarct as opposed to normal levels within the remote myocardium. ECV 
measurement furthers our ability to investigate infarction by CMR. Whilst the imaging 
of focal fibrosis with LGE enables the in vivo macroscopic identification of necrosis, it 
is clear that the visual (or even semi-automated) assessment of LGE is limited by the 
arbitrary use of thresholds. We are essentially assessing relatively crude 
macroscopic reflections of inherently minor microscopic pathological changes. Viable 
myocytes have been shown to be present within (and on the periphery of) infarct 
zones but may not be appreciated on clinical LGE images.437 ECV measurement 
allows for in vivo imaging of fibrosis (both diffuse and focal) at an almost microscopic 
level.  
The low measurements of ECV fit with those found in the hearts of otherwise healthy 
individuals. This is somewhat at odds with what we might have expected. It has 
previously been reported that compensatory contractile and structural changes take 
place in the remote uninvolved myocardial regions following myocardial infarction.438 
It would appear that increases in contractility in the remote myocardium is 
compensatory, possibly being triggered by the Frank-Starling mechanism439 rather 
than processes that we may expect to lead to an increase in the ECV. Although this 
adds to our understanding of the state of the myocardium in the acute phase it would 
be informative to collate information about the remote myocardium in the chronic 
phase following a period of remodelling when one may expect changes in the 
ultrastructural architecture of the remote myocardium. In the acute setting myocardial 
oedema will exacerbate extracellular expansion. In order to get a clear picture of the 
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remote myocardium we chose an area as far away from the infarct zone as possible. 
It would be interesting therefore to investigate areas of myocardium that have been 
salvaged or on the peripheries of the infarct, in that they show evidence of oedema 
without infarction. One may therefore be able to quantify the incremental contribution 
of oedema to the ECV on top of the infarction. Further work is clearly needed to 
assess the contribution of the different components of infarction / reperfusion injury 
to interstitial expansion. It is likely that as ischaemia, infarction and remodelling are 
dynamic processes and that the degree of interstitial expansion will change over time 
through to the stage of chronic infarction following the resolution of oedema, MVO 
and haemorrhage but with wall thinning. We were unable to demonstrate a 
difference in the ECV when comparing regions of infarction and regions of MVO. 
This is not necessarily the case with other groups who have noted differences in the 
nature of the different components of reperfusion using newer T1 mapping 
techniques. Azarisman et al. reported on a pre-contrast T1 mapping study of 23 
patients following AMI showing differences between infarction and MVO. They 
demonstrated that mean segmental T1 values differed significantly according to the 
extent of ischaemic injury.440 Ugander et al. showed in a canine model that the 
salvaged myocardium has a post-contrast T1 which is approximately 50 ms less than 
remote myocardium suggesting a higher ECV in the area of salvaged myocardium 
as compared to the remote myocardium.441 At 3T, Dall'Armellina noted how T1 
values could predict improvement of segmental function at six months following an 
acute coronary syndrome. In a subgroup of 7 patients they demonstrated that T1 
values in the MVO regions are significantly lower than in the surrounding LGE-
positive myocardium.442 
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Our study has a small sample size with a preponderance of male subjects. Sado et 
al. showed that healthy females have a higher myocardial ECV than male 
counterparts although the reason for this is not clear.346 The group also 
demonstrated in a larger cohort across the spectrum of cardiovascular disease the 
range of extracellular expansion with AMI showing the largest ECV. The group did 
not split their AMI patients into those with MVO and those without. 
 
The equilibrium technique is a robust way of assessing the ECV within the 
myocardium. It does however have limitations. From the point of view of running a 
clinical service, the technique adds on considerable time (in the form of the primed 
infusion) and is likely cumbersome for the patient. We applied the technique to only 
one chosen short axis slice. Whilst all the slices analysed had evidence of LGE – the 
quantification of one slice is unlikely to be representative of the whole myocardium. 
This may explain the lack of correlation between other CMR indices measured. 
 
Newer, faster sequences for T1 mapping techniques promise whole heart coverage 
and improved clinical utility over significantly fewer breath holds. ECV quantification 
by single breath-hold ShMOLLI T1 mapping can measure ECV across the spectrum 
of interstitial expansion. It appears to be better tolerated, more reproducible and 
better correlates with histology compared to the older multibreath-hold FLASH 
techniques.443 The use of a bolus of contrast rather than a prolonged infusion also 
appears to show promising results with regard to reducing the length of the scan 
although such a technique may overestimate the ECV in conditions of greater 
interstitial expansion.347 
 
Page 214 of 261 
 
The measurement of ECV by CMR shows significant differences in the myocardium 
beyond those detected by standard CMR technique. In the setting of AMI, the 
technique is able to distinguish between injured and normal myocardium with a high 
degree of accuracy. Further work, in larger groups is needed to further characterise 
the infarcted myocardium into the individual components of reperfusion injury to 
assess the additive value of each component. 
 
 
5.4 Conclusion 
 
We have a number of methods that we can use to detect the different components of 
reperfusion injury in both animals and humans. CMR stands out with its ability to 
assess numerous parameters with prognostic relevance in one sitting although some 
techniques are as yet less validated than others. The need to assess the AAR for 
clinical research in acute infarction is clear yet questions remain about the ability of 
different techniques to accurately do this. Oedema, haemorrhage and measurement 
of interstitial expansion measured by CMR as products of reperfusion injury and 
infarction offer exciting potential as imaging biomarkers in future clinical research. 
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6 Discussion and Conclusion 
 
 
Remote ischaemic conditioning has been shown to be a safe and effective form of 
cardioprotection across a number of clinical and preclinical cardiovascular settings. 
We specifically investigated the application of remote ischaemic perconditioning in 
the setting of AMI as an adjunct to PPCI.  PPCI remains the treatment of choice for 
patients with AMI. The availability of PPCI is increasing across the UK as regional 
programmes are rolled out to treat patients suffering with AMI as quickly as possible. 
The number of PPCI procedures in the UK continues to increase, yet the mortality 
and morbidity from AMI remains high. It is therefore clear that further measures are 
needed to improve patient outcome in this setting. Protection in the setting of AMI 
has always been more difficult to demonstrate given the inability to predict the onset 
of ischaemia, yet relatively small studies showing benefit (through reduction in 
different biochemical and imaging biomarkers) in this setting are beginning to 
emerge. 
 
 
Our study failed to demonstrate the benefit of a perconditioning protocol using two 
cycles of upper limb ischaemia prior to PPCI. The reason for the failure of this 
protocol to show protection has been discussed above. We were able to show that 
two cycles of upper limb ischaemia, although ineffective in inducing cardioprotection, 
is a safe, well tolerated and easy to apply protocol. There were no adverse events 
associated with the treatment protocol. The three other groups who have 
investigated cardioprotective strategies using limb ischaemia have used differing 
protocols. This emphasises the need for further studies into cardioprotective 
strategies in the setting of AMI. There is a need to clarify the most efficacious 
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method (whether upper or lower ischaemia) of applying the cardioprotective 
stimulus. In the same vein, given the time imperative associated with reperfusion, it 
is paramount to elucidate the threshold required to induce cardioprotection. Learning 
the lessons from our original study above, our institute therefore proposed further 
studies to elucidate the most effective protocol for inducing cardioprotection in the 
setting of AMI and these projects are now ongoing. Such studies will not only 
investigate the ideal number of cycles necessary to induce protection but also 
whether cardioprotection in the lower limb can be induced with fewer cycles than an 
upper limb protocol or visa-versa.  
 
 
Larger multicentre randomised controlled studies are necessary to determine the 
impact of RIC on short-term and long-term clinical outcomes in STEMI patients 
undergoing PPCI by assessing hard clinical endpoints such as cardiovascular death 
and hospitalisation for heart failure. The table below lists on going clinical trials (as 
searched for on http://clinicaltrials.gov/) that assess cardioprotective strategies in the 
setting of AMI using CMR endpoints. Only three trials employ RIC. Only two of the 
three RIC trials are using CMR endpoints. Interestingly two of the trials are adopting 
a novel approach of applying an RIC protocol daily for a month following PPCI. 
 
 
 
Our study has demonstrated the importance of the selection of biomarkers and 
measurement technique employed as endpoints in cardiovascular trials. We have 
shown how the use of differing measurement techniques can lead to statistically 
different results in endpoints. The standardisation of measurement techniques 
across different groups would be an important step in enabling the comparison of 
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results across experiments and hence the application to real world populations. It is 
possible that the demonstration of a statistically significant result with a ‘softer’ 
endpoint will not show the same significance with a ‘harder’ endpoint. Visa versa, 
negative studies utilising softer endpoints may later be found to be positive with the 
use of harder endpoints.  
 
 
Recent statements by both Working Group of Cellular Biology of the Heart of the 
European Society of Cardiology113 and the NIH Consortium for Preclinical 
Assessment of Cardioprotective Therapies (CAESAR)444 have emphasised the 
importance of study design including the choice of MI-limiting endpoint selection. 
 
 
We have shown how cardiovascular magnetic resonance imaging can be harnessed 
for a multi parametric approach to assessing the efficacy of novel cardioprotective 
therapies such as RIC. Our study has confirmed the safety of CMR in a cohort of 
patients soon after PPCI. There were no adverse events associated with the CMR 
studies in our trial and was well tolerated by the majority of patients. CMR offers the 
ability to assess traditional endpoints such as cardiac volumes, ejection fraction and 
infarct size with a high degree of accuracy and reproducibility. It also allows for the 
identification of a range of pathologies that were initially identified on microscopic 
examination in preclinical research such as oedema, haemorrhage, microvascular 
obstruction and diffuse interstitial fibrosis. Research in AMI has taken great strides 
with the use of CMR and forty years after seminal work by the likes of Krug, Kloner 
and Reimer and Jennings who identified the products of reperfusion injury, CMR has 
enabled the investigation of these phenomenon in-vivo that were previously limited 
to only in-vitro / post-mortem examination. Whilst these phenomena require further 
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validation they appear to offer exciting novel imaging biomarkers that not only add to 
our ability to understand the pathophysiology of reperfusion injury but can also act as 
robust endpoints for clinical cardiovascular research trials. 
Following on from these small studies our research institute is undertaking further 
research to optimise and develop CMR sequences for faster and more reproducible 
acquisition, determine interstitial volume in different components of reperfusion injury 
and remote myocardium whilst investigating the effects of RIC on the different 
components of the acute myocardial infarction treated with PPCI. 
 
 
Remote ischaemic conditioning offers the potential to provide protection in the 
setting of AMI in which attention is needed to improve outcomes. The use of CMR 
techniques to characterise the myocardium serves to complement and advance 
research into novel cardioprotective therapies. 
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Intervention Primary 
Endpoint 
CMR 
Endpoints 
T2W AAR 
CONDI2 
NCT01857414 
RIC 
(4 x 5min 
cycles) 
MACE Nil - - 
CRIC-RCT 
NCT01423929 
 
 
RIPerC 
(4 x 5min  
cycles) 
Repeated for 
28days 
Volumes by 
CMR 
Volumes No No 
DREAM 
NCT01664611 
Daily RIC EF by CMR Volumes 
IS 
No No 
ASSIST-MI 
NCT01818960 
 
Multivessel 
PCI 
vs 
Culprit  
vessel 
PCI  
IS by CMR 
 
 
Volumes 
IS 
No No 
Vasodilators 
NCT01747174 
 
 
IC Adenosine 
IC Sodium 
Nitroprusside 
IS by 3T 
CMR 
Volumes 
Salvage 
Haemorrhage 
MVO 
IS 
(48-72hrs) 
Yes 
STIR 
Yes 
NITRITE-AMI 
NCT01584453 
IC Sodium Nitrite CK 
(AUC/48hrs) 
Volumes 
Salvage 
MVO 
IS 
(48hrs & 
6months) 
Yes 
STIR  
 
 
Yes 
 
 
 
 
 
Allogeneic 
Mesenchymal Bone 
Marrow Cells 
NCT01770613 
IV Allogeneic 
Mesenchymal 
Bone Marrow Cells 
 
 
Safe 
Tolerability 
MACE 
IS by CMR No No 
MINIMISE STEMI 
NCT01882179 
 
 
MRA IS by CMR 
(12 weeks) 
Volumes 
Salvage 
MVO 
IS 
(3days & 
12wks)  
Yes 
 
 
Yes 
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PrepRAMSES 
NCT01493037 
Intermittent 
Coronary Sinus 
Occlusion 
(PICSO) 
Delivery 
Feasability 
IS 
(3 & 120days) 
No No 
EMBRACE 
NCT01572909 
Bendavia CK-MB 
(AUC/72hrs) 
Volumes 
Salvage 
IS (>2SD) 
(4 & 30days) 
Yes 
STIR 
Yes 
Postconditioning 
NCT01324453 
IPost 
4x30sec 
Inflation 
IS by CMR 
Volumes 
Salvage 
MVO 
(3 days)  
Volumes 
Salvage 
IS 
MVO 
(3days & 
12month)  
N/A N/A 
DANAMI-3 
NCT01435408 
IPost 
Deferred DES 
MACE IS 
Salvage 
(3 months) 
N/A Yes 
BB3 
NCT01539590 
BB3 IS by CMR 
(30 days) 
Volumes 
IS (1 & 6 
months) 
No No 
PRIME 
NCT01483755 
IPost  
4x60sec 
(Delayed) 
IS by CMR 
(5 days) 
IS No No 
MICROS 
NCT01382472 
 
 
Rosuvastatin 
 
 
IS by CMR 
(2 days) 
IS 
MVO 
(FPP,LGE) 
(2days & 
2months) 
No No 
GIPS-III 
NCT01217307 
 
Metformin EF by CMR 
(4 months) 
Volumes 
IS 
(4 months) 
No No 
DETO₂X-AMI 
NCT01787110 
Oxygen IS by CMR IS 
(3-5 days) 
No No 
ROSEMARY 
NCT01153334 
Rosuvastatin IS by CMR 
(3 - 7 days) 
IS 
(3 - 7 days) 
No No 
VELOCITY 
NCT01655433 
 
Hypothermia SAE Volumes 
Salvage 
IS 
(3 days) 
N/A Yes 
AVOID 
NCT01272713 
 
 
Oxygen TnI/CK Salvage 
IS 
(4days & 
6months) 
Yes Yes 
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SOCCER 
NCT01423929 
 
 
Oxygen Salvage by 
CMR 
(4 - 6 days) 
Volumes 
Salvage 
IS 
MVO 
(4 - 6 days) 
N/A Yes 
NOMI 
NCT01398384 
Nitric Oxide 
(Inhaled) 
IS by CMR 
(2 - 3 days) 
Volumes 
Salvage 
IS 
MVO 
N/A Yes 
NIAMI 
NCT01388504 
 
 
Sodium 
Nitrite 
IS by CMR 
(10 - 14 
days) 
Volumes 
IS 
(12days & 6 
months) 
N/A Yes 
DanShock 
NCT01633502 
 
 
VAD Death Volumes 
Salvage 
IS 
(6 months) 
No Yes 
ADVANCE 
NCT01216995 
Adipose- 
Derived 
Regenerative Cells 
IS by CMR 
(6 months) 
IS No No 
OPTIMA- 
STRATEGY 
NCT01462188 
Delayed stenting MBG IS 
MVO 
(6 months) 
No No 
THROMBUS 
ASPIRATION 
NCT01379248 
Export 
Catheter 
MVO by 
CMR 
(1 - 4 days) 
MVO No No 
Table 25 Table showing ongoing trials in acute coronary syndromes utilising CMR endpoints 
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Addendum 
 
 
 
1. Please include a description of the sample size calculation for chapter 4  
 
The primary endpoint of the study was MI size as measured by late 
gadolinium enhancement CMR. Sample size calculations were based on two 
previous studies that used CMR to assess the cardioprotective effect of 
different novel therapeutic agents. A sample size of at least 40 patients in 
total was determined based on the following assumptions: (a) a 20% 
reduction in mass of MI as measured on late enhancement imaging; (b) 
power of at least 80%; (c) significance declared at the two-sided 5% level.1,2  
  
 
2. Infarct size was assessed by a single scan. This needs to be justified, as it 
would have been usual to have a later scan to measure the mature infarct 
size.  
 
The primary outcome for our study was the measurement of infarct size by 
Cardiac MR (CMR). The scan was undertaken acutely within 72hrs of 
reperfusion by primary angioplasty. No follow up scan was undertaken. 
 
Controversy exists as to when is the ideal time to assess cardiac indices 
including the assessment of infarct size with late gadolinium enhancement 
(LGE) imaging following an acute myocardial infarction (AMI). Consistent with 
the original work of Reimer and Jennings, CMR studies have shown a 
reduction in infarct size within the first week following AMI. Contributory 
factors likely include the resorption of the products of reperfusion injury 
including myocardial oedema and haemorrhage which will cause an 
expansion in the interstitial volume of the myocardium and the over estimation 
of infarct size. On going remodelling with shrinkage and thinning of the 
infracted myocardium will lead to further changes in the infarct size. 
 
Given the change in infarct size over time the question remains of when to 
best utilise CMR following PPCI and how to interpret early measures of infarct 
size in the context of clinical trials. 
 
From a practical point of view the assessment of infarct size by CMR prior to 
discharge means the patient does not have to make a return visit. Early CMR 
will also allow for the visualisation of mechanical complications such as LV 
pseudoaneurysm, ventricular septal defect, mitral regurgitation, and 
ventricular thrombus. At the same time products of reperfusion injury such as 
myocardial oedema, microvascular obstruction and intra myocardial 
haemorrhage can be appreciated but are likely to have resolved at later time 
points when infarct size is thought to be stable. 
 
According to the definition published by a working group of the National 
Institutes of Health, a surrogate endpoint is ‘a biomarker that is intended to 
substitute for a clinical endpoint that is expected to predict clinical benefit, 
harm, or lack of benefit or harm.’ The group describe the a biomarker as ‘a 
characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenetic processes or pharmacological 
responses to a therapeutic intervention.3 According to the International 
Conference on Harmonisation (ICH) the strength of the evidence for 
surrogacy depends upon (i) the biological plausibility of the relationship, (ii) 
the demonstration in epidemiological studies of the prognostic value of the 
surrogate for the clinical outcome and (iii) evidence from clinical trials that 
treatment effects on the surrogate correspond to effects on the clinical 
outcome.4,5 
 
Whilst the use of LGE to measure infarct size late after AMI fulfils these 
criteria to harness it as a surrogate endpoint in clinical trials, evidence for the 
use of measurement of infarct size acutely has been lacking. 
 
Bodi et al.6 studied 214 patients with CMR within one week of STEMI with the 
aim to test the prognostic value of a comprehensive CMR assessment 
compared with known clinical risk profiles. Median follow up was 1.5 years. 
They concluded that the only variables that independently predicted outcome 
seemed to be the number of segments with wall motion abnormality and 
transmural necrosis. Larose et al.7 studied 103 patients following successfully 
reperfused acute STEMI with all patients undergoing CMR within 12 hours of 
PPCI. The amount of LGE was quantified using the FWHM technique. 
Patients were followed up for a median of 33 months and underwent repeat 
CMR at 6 months. The group demonstrated that quantification of LGE early 
after STEMI was able to predict late heart failure and adverse events beyond 
traditional risk factors. Eitel et al.8 studied 208 patients who underwent CMR 
early after successful PPCI (median 3 days). The group used T2 weighted 
imaging along with LGE to calculated the myocardial salvage index (MSI) and 
demonstrated that salvage index was able to predict major adverse cardiac 
events including death, reinfarction and heart failure at six months. The 
authors therefore suggest that the ability to quantify the extent of salvage 
after revascularisation might serve as a novel strong endpoint for clinical trials 
investigating the success of reperfusion strategies. Long term follow up 
(median 18.5 months) of the same cohort confirmed the use of salvage index 
to predict long-term clinical outcome in acute reperfused STEMI.9 
 
Hadamitzky et al.10 have recently shown the prognostic value of LGE and 
MVO early (median of 4.9 days) in 281 patients after reperfused STEMI. This 
retrospective observational study compared CMR indices to the current 
reference standard of SPECT with all patients having both scans. The group 
showed with follow up to three years that the best predictor of adverse 
outcomes (All cause mortality, recurrent MI and congestive cardiac failure 
requiring hospitalisation) was MVO followed by infarct size assessed by CMR. 
 
The largest body of evidence for the use of CMR early after PPCI comes from 
the CMR sub-study of the AIDA-STEMI trial. This sub study confirmed the 
findings of the main trial that there was no benefit of intracoronary versus 
intravenous abciximab administration on myocardial damage and/or 
reperfusion injury. At the same time the sub study demonstrated that infarct 
size determined by CMR was significantly associated with major adverse 
cardiac events at 12 months. CMR was carried out in 795 patients at a 
median of 3 days post PPCI.11 
Further long-term data is needed to cement the use of CMR indices early 
after reperfused STEMI as surrogate endpoints in clinical trials. There is, 
however, a growing body of evidence that infarct size assessed acutely by 
CMR carries important prognostic information and is likely to strengthen our 
understanding not only of reperfusion injury but also the therapeutic effect of 
novel cardioprotective agents. 
 
3. Please describe your contribution to chapter 3 in more detail  
 
Chapter 3 was written in collaboration with Dr Andrew Flett and a version of this 
chapter was published in JACC Cardiovascular Imaging in 2011.12 The macro 
used for analysis was created by Dr Flett. All analyses carried out using the 
Image J macro were carried out both by Dr Flett and myself with both readers 
independently analysing all scans. Statistical analysis was aided by Cono Ariti 
from the Department of Medical Statistics, London School of Hygiene and 
Tropical Medicine. I contributed towards the writing of the manuscript although 
the introduction, discussion and conclusions of Chapter 3 of this thesis vary from 
that published in JACC Cardiovascular Imaging whilst the methodology and 
results sections are similar. 
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